




- (51) International Patent Classification: Not classified
- (21) International Application Number:
PCT/US2017/014788
- (22) International Filing Date:
24 January 2017 (24.01.2017)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/286,947 25 January 2016 (25.01.2016) US
- (71) Applicant: **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; 1111 Franklin Street, 12th Floor, Oakland, CA 94607-5200 (US).
- (72) Inventors: **YOSHIKUNI, Yasuo**; 132 Glorietta Blvd., Orinda, CA 94563 (US). **WANG, Gaoyan**; 4894 Bernal Ave., Apt. M, Pleasanton, CA 94566 (US). **ZHAO, Zhiying**; 24 Stirling Dr., Danville, CA 94526 (US). **COATES, Robert, Cameron**; 3590 Walnut Street, Lafayette, CA 94549 (US). **CHENG, Jan-Fang**; 201 Moraga Way, Orinda, CA 94563 (US). **ROBINSON, David**; 2341 Yale St., Martinez, CA 94553 (US).
- (74) Agents: **JONES, Kevin et al.**; Morrison & Foerster LLP, 425 Market Street, San Francisco, CA 94105-2482 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: PATHWAY INTEGRATION AND EXPRESSION IN HOST CELLS

(57) **Abstract:** Provided herein are methods for integrating a gene of interest into a chromosome of a host cell. In some embodiments, the methods include introducing into a host cell a first plasmid comprising a transposase coding sequence and a donor sequence, which includes a selectable marker coding sequence flanked by a first and a second lox site and is itself flanked by inverted repeats recognized by the transposase. Following transposase-mediated chromosomal integration of the donor sequence into the host cell, a second plasmid is introduced, which comprises the gene of interest and a second selectable marker coding sequence, both flanked by a first and a second lox site. The gene of interest is chromosomally integrated into the host cell by recombinase-mediated cassette exchange (RMCE) between the donor sequence and the second plasmid via Cre/cuc recombination. Further provided herein are host cells, vectors, and methods of producing a product related thereto.

PATHWAY INTEGRATION AND EXPRESSION IN HOST CELLS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the priority benefit of U.S. Provisional Application No. 62/286,947, filed January 25, 2016, which is hereby incorporated by reference in its entirety.

STATEMENT OF GOVERNMENT SUPPORT

[0002] This invention was made with Government support under Grant No. DE-AC02-05CH11231 awarded by the Department of Energy. The Government has certain rights in this invention.

SUBMISSION OF SEQUENCE LISTING ON ASCII TEXT FILE

[0003] The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 220032001540SEQLIST.txt, date recorded: January 24, 2017, size: 89 KB).

FIELD

[0004] The present disclosure relates, *inter alia*, to methods for integrating a gene of interest into a host chromosome by integrating a donor sequence comprising two *lox* sites and a selectable marker flanked by inverted repeats into a host cell through transposase-mediated integration, followed by introducing a second plasmid comprising a gene or pathway of interest and a selectable marker flanked by two *lox* sites into the host cell, wherein the gene or pathway of interest is integrated into the chromosome of the host cell through recombinase mediated-cassette exchange. Further provided herein are vectors, cells, and methods related thereto.

BACKGROUND

[0005] Several decades have passed since microbes were first used as miniscule factories for antibiotics, vitamins and enzymes (Murphy, C.D., *Organic & Biomol. Chem*, 10(10): 1949-1957(2012)). Since then, genes, pathways, reporter constructions, and regulatory elements have been recombinantly engineered into bacteria, plant cells, yeasts, and mammalian cells for screening, bio-manufacturing, and even therapeutic applications (see, e.g., Nielsen, J. and Jewett, M.C. (2008) *FEMS Yeast Res.* 8:122-31; Kis, Z. *et al.* (2015) *J.*

R. Soc. Interface 12:20141000). Genetic engineering technologies have enabled scientists to manipulate host cells for desired products with optimized features, but only a small number of model eukaryotes and bacteria have been domesticated as hosts.

[0006] Three common techniques have been used to introduce and express genes in host cells (Ongley, S.E., et al., *Nat. Prod. Reports*, 30(8): 1121-1138 (2013). One such technique is plasmid based expression, but only a very few model host cells, particularly bacterial cells, have expression plasmids developed. A second technique is homologous recombination-based integration, but the efficiency is low in many host cells, and this method is limited to hosts that have relatively high recombination efficiency. A third technique is transposition-based chromosomal integration, but the efficiency decreases as the length of insert (*e.g.*, a pathway of interest) increases, and it is nearly impossible to insert different pathways into the same chromosomal location. In addition, with respect to bacterial host cells, those approaches mainly focus on manipulating a small range of domesticated model bacteria, and the expression of introduced genes or pathways is limited by the physiology of these strains (transcription, translation, post-translational modification, tolerance to products and availability of substrates and co-factors; see, *e.g.*, Kang, Y., et al., *Protein Expression and Purification*, 55(2):325-333 (2007).

[0007] Therefore, a highly efficient and universal technology to potentially integrate and express genes or pathways in any host cell would be very desirable, thereby providing a common tool box for genome engineering and other important applications (such as microbiome engineering for agriculture and renewable energy, pharmaceutical synthesis, commodity chemical and biofuel production, and the like).

SUMMARY

[0008] To meet these and other demands, provided herein are methods and compositions for pathway integration and expression in bacteria.

[0009] Accordingly, certain aspects of the present disclosure relate to a method for integrating a gene of interest into a chromosome of a host cell, the method including providing a bacterial host cell comprising a donor sequence comprising a first selectable marker coding sequence flanked by a first and a second *lox* site, wherein the first and the second *lox* sites are different, and wherein the donor sequence is integrated in a chromosome of the bacterial host cell; providing a plasmid comprising the gene of interest and a second selectable marker coding sequence, wherein the gene of interest and the second selectable marker are both flanked by a first and a second *lox* site, wherein the first

and the second *lox* sites are different; and introducing the plasmid into the bacterial host cell, wherein at least one of the plasmid and the donor sequence comprises a Cre recombinase coding sequence, and wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the gene of interest is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the second plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence. Further provided herein is a method for integrating a gene of interest into a chromosome of a host cell, the method including providing a host cell comprising a donor sequence comprising a first selectable marker coding sequence flanked by a first and a second *lox* site, wherein the first and the second *lox* sites are different, and wherein the donor sequence is integrated in a chromosome of the host cell; providing a plasmid comprising the gene of interest and a second selectable marker coding sequence, wherein the gene of interest and the second selectable marker are both flanked by a first and a second *lox* site, wherein the first and the second *lox* sites are different; and introducing the plasmid into the host cell, wherein at least one of the plasmid and the donor sequence comprises a Cre recombinase coding sequence, and wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the gene of interest is integrated into the chromosome of the host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the second plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence, wherein the host cell is a fungal, animal, or plant host cell. Further provided herein is a method for modulating expression of a gene of interest in a bacterial host cell, the method including: providing a bacterial host cell comprising a donor sequence comprising: (i) a Cre recombinase coding sequence, wherein the Cre recombinase coding sequence is flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; and (ii) a first selectable marker coding sequence flanked by the second *lox* site and a third *lox* site, wherein the third *lox* site is different from the first and second *lox* sites, and wherein the donor sequence is integrated in a chromosome of the bacterial host cell; providing a plasmid comprising a catalytically dead Cas9 protein coding sequence and a second selectable marker coding sequence, wherein the catalytically dead Cas9 protein coding sequence and the second selectable marker are both flanked by the second

lox site and the third *lox* site; introducing the plasmid into the bacterial host cell, wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the catalytically dead Cas9 protein coding sequence is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the second *lox* site of the plasmid and the second *lox* site of the donor sequence, and between the third *lox* site of the second plasmid and the third *lox* site of the donor sequence; providing a second plasmid comprising a guide RNA sequence that targets a guide RNA target sequence of the gene of interest and a third selectable marker coding sequence, wherein the guide RNA sequence and the third selectable marker are both flanked by the first *lox* site and the second *lox* site; and introducing the second plasmid into the bacterial host cell, wherein upon introduction of the second plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the guide RNA sequence is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the second plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence; wherein upon introduction of the second plasmid of the bacterial host cell, the catalytically dead Cas9 protein and guide RNA are expressed, form a complex, and bind the guide RNA target sequence of the gene of interest, thereby modulating expression of the gene of interest. Further provided herein is a method for modulating expression of a gene of interest in a bacterial host cell, the method including: providing a bacterial host cell comprising a donor sequence comprising: (i) a Cre recombinase coding sequence, wherein the Cre recombinase coding sequence is flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; and(ii) a first selectable marker coding sequence flanked by the second *lox* site and a third *lox* site, wherein the third *lox* site is different from the first and second *lox* sites, and wherein the donor sequence is integrated in a chromosome of the bacterial host cell; providing a first plasmid comprising a catalytically dead Cas9 protein coding sequence, a guide RNA sequence that targets a guide RNA target sequence of the gene of interest, and a second selectable marker coding sequence, wherein the catalytically dead Cas9 protein coding sequence, the guide RNA sequence, and the second selectable marker are flanked by the second *lox* site and the third *lox* site; introducing the first plasmid into the bacterial host cell, wherein upon introduction of the first plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre

recombinase coding sequence, and the catalytically dead Cas9 protein coding sequence and guide RNA sequence are integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the second *lox* site of the first plasmid and the second *lox* site of the donor sequence, and between the third *lox* site of the first plasmid and the third *lox* site of the donor sequence; providing a second plasmid comprising the gene of interest and a third selectable marker coding sequence, wherein the gene of interest and the third selectable marker are both flanked by the first *lox* site and the second *lox* site; and introducing the second plasmid into the bacterial host cell, wherein upon introduction of the second plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the gene of interest is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the second plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence; wherein upon introduction of the second plasmid of the bacterial host cell, the catalytically dead Cas9 protein and guide RNA are expressed, form a complex, and bind the guide RNA target sequence of the gene of interest, thereby modulating expression of the gene of interest. Further provided herein is a method for modulating expression of a gene of interest in a bacterial host cell, the method including: providing a bacterial host cell comprising a donor sequence comprising: (i) a Cre recombinase coding sequence, wherein the Cre recombinase coding sequence is flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; and (ii) a first selectable marker coding sequence flanked by the second *lox* site and a third *lox* site, wherein the third *lox* site is different from the first and second *lox* sites, and wherein the donor sequence is integrated in a chromosome of the bacterial host cell; providing a plasmid comprising a guide RNA sequence that targets a guide RNA target sequence of the gene of interest and a second selectable marker coding sequence, wherein the guide RNA sequence and the second selectable marker are both flanked by the first *lox* site and the second *lox* site; and introducing the plasmid into the bacterial host cell, wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the guide RNA sequence is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the second and the first *lox* site of the donor sequence, and between the second *lox* site of the second plasmid and the second *lox* site of the donor

sequence; providing a second plasmid comprising a catalytically dead Cas9 protein coding sequence and a third selectable marker coding sequence, wherein the catalytically dead Cas9 protein coding sequence and the third selectable marker are both flanked by the second *lox* site and the third *lox* site; introducing the second plasmid into the bacterial host cell, wherein upon introduction of the second plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the catalytically dead Cas9 protein coding sequence is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence, and between the third *lox* site of the second plasmid and the third *lox* site of the donor sequence; wherein upon introduction of the second plasmid of the bacterial host cell, the catalytically dead Cas9 protein and guide RNA are expressed, form a complex, and bind the guide RNA target sequence of the gene of interest, thereby modulating expression of the gene of interest. Further provided herein is a method for modulating expression of a gene of interest in a bacterial host cell, the method including: providing a bacterial host cell comprising a donor sequence comprising: (i) a Cre recombinase coding sequence, wherein the Cre recombinase coding sequence is flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; and (ii) a first selectable marker coding sequence flanked by the second *lox* site and a third *lox* site, wherein the third *lox* site is different from the first and second *lox* sites, and wherein the donor sequence is integrated in a chromosome of the bacterial host cell; providing a plasmid comprising the gene of interest and a second selectable marker coding sequence, wherein the gene of interest and the second selectable marker are both flanked by the first *lox* site and the second *lox* site; and introducing the plasmid into the bacterial host cell, wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the gene of interest is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the plasmid and the second *lox* site of the donor sequence; providing a second plasmid comprising a catalytically dead Cas9 protein coding sequence, a guide RNA sequence that targets a guide RNA target sequence of the gene of interest, and a third selectable marker coding sequence, wherein the catalytically dead Cas9 protein coding sequence, the guide RNA sequence, and the third selectable marker are flanked by the second *lox* site and the third *lox* site; introducing the second plasmid into the bacterial

host cell, wherein upon introduction of the second plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the catalytically dead Cas9 protein coding sequence and guide RNA sequence are integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence, and between the third *lox* site of the second plasmid and the third *lox* site of the donor sequence; wherein upon introduction of the second plasmid of the bacterial host cell, the catalytically dead Cas9 protein and guide RNA are expressed, form a complex, and bind the guide RNA target sequence of the gene of interest, thereby modulating expression of the gene of interest. Further provided herein is a method for modulating expression of a gene of interest in a bacterial host cell, the method including: providing a bacterial host cell comprising a donor sequence comprising: (i) a first landing pad comprising a Cre recombinase coding sequence, wherein the landing pad is flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; and (ii) a second landing pad, wherein the second landing pad comprises a first selectable marker coding sequence and is flanked by the second *lox* site and a third *lox* site, wherein the third *lox* site is different from the first and second *lox* sites, and wherein the donor sequence is integrated in a chromosome of the bacterial host cell; providing a plasmid comprising a catalytically dead Cas9 protein coding sequence and a second selectable marker coding sequence, wherein the catalytically dead Cas9 protein coding sequence and the second selectable marker are both flanked by the second *lox* site and the third *lox* site; introducing the plasmid into the bacterial host cell, wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the catalytically dead Cas9 protein coding sequence is integrated into the second landing pad by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the second *lox* site of the plasmid and the second *lox* site of the donor sequence, and between the third *lox* site of the plasmid and the third *lox* site of the donor sequence; providing a second plasmid comprising a guide RNA sequence that targets a guide RNA target sequence of the gene of interest and a third selectable marker coding sequence, wherein the guide RNA sequence and the third selectable marker are both flanked by the first *lox* site and the second *lox* site; and introducing the second plasmid into the bacterial host cell, wherein upon introduction of the second plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the guide RNA sequence is integrated into the first

landing pad by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the second plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence; wherein upon introduction of the second plasmid of the bacterial host cell, the catalytically dead Cas9 protein and guide RNA are expressed, form a complex, and bind the guide RNA target sequence of the gene of interest, thereby modulating expression of the gene of interest. Further provided herein is a method for modulating expression of a gene of interest in a bacterial host cell, the method including: providing a bacterial host cell comprising a donor sequence comprising: (i) a first landing pad comprising a Cre recombinase coding sequence, wherein the landing pad is flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; and (ii) a second landing pad, wherein the second landing pad comprises a first selectable marker coding sequence and is flanked by the second *lox* site and a third *lox* site, wherein the third *lox* site is different from the first and second *lox* sites, and wherein the donor sequence is integrated in a chromosome of the bacterial host cell; providing a first plasmid comprising a catalytically dead Cas9 protein coding sequence, a guide RNA sequence that targets a guide RNA target sequence of the gene of interest, and a second selectable marker coding sequence, wherein the catalytically dead Cas9 protein coding sequence, the guide RNA sequence, and the second selectable marker are flanked by the second *lox* site and the third *lox* site; introducing the first plasmid into the bacterial host cell, wherein upon introduction of the first plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the catalytically dead Cas9 protein coding sequence and guide RNA sequence are integrated into the second landing pad by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the second *lox* site of the first plasmid and the second *lox* site of the donor sequence, and between the third *lox* site of the first plasmid and the third *lox* site of the donor sequence; providing a second plasmid comprising the gene of interest and a third selectable marker coding sequence, wherein the gene of interest and the third selectable marker are both flanked by the first *lox* site and the second *lox* site; and introducing the second plasmid into the bacterial host cell, wherein upon introduction of the second plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the gene of interest is integrated into the first landing pad by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the second plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the

second plasmid and the second *lox* site of the donor sequence; wherein upon introduction of the second plasmid of the bacterial host cell, the catalytically dead Cas9 protein and guide RNA are expressed, form a complex, and bind the guide RNA target sequence of the gene of interest, thereby modulating expression of the gene of interest. Further provided herein is a method for modulating expression of a gene of interest in a bacterial host cell, the method including: providing a bacterial host cell comprising a donor sequence comprising: (i) a first landing pad comprising a Cre recombinase coding sequence, wherein the landing pad is flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; and (ii) a second landing pad, wherein the second landing pad comprises a first selectable marker coding sequence and is flanked by the second *lox* site and a third *lox* site, wherein the third *lox* site is different from the first and second *lox* sites, and wherein the donor sequence is integrated in a chromosome of the bacterial host cell; providing a plasmid comprising a guide RNA sequence that targets a guide RNA target sequence of the gene of interest and a second selectable marker coding sequence, wherein the guide RNA sequence and the second selectable marker are both flanked by the first *lox* site and the second *lox* site; and introducing the plasmid into the bacterial host cell, wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the guide RNA sequence is integrated into the first landing pad by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the plasmid and the second *lox* site of the donor sequence; providing a second plasmid comprising a catalytically dead Cas9 protein coding sequence and a third selectable marker coding sequence, wherein the catalytically dead Cas9 protein coding sequence and the third selectable marker are both flanked by the second *lox* site and the third *lox* site; introducing the second plasmid into the bacterial host cell, wherein upon introduction of the second plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the catalytically dead Cas9 protein coding sequence is integrated into the second landing pad by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence, and between the third *lox* site of the second plasmid and the third *lox* site of the donor sequence; wherein upon introduction of the second plasmid of the bacterial host cell, the catalytically dead Cas9 protein and guide RNA are expressed, form a complex, and bind the guide RNA target sequence of the gene of interest, thereby modulating expression of the gene of

interest. Further provided herein is a method for modulating expression of a gene of interest in a bacterial host cell, the method including: providing a bacterial host cell comprising a donor sequence comprising: (i) a first landing pad comprising a Cre recombinase coding sequence, wherein the landing pad is flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; and (ii) a second landing pad, wherein the second landing pad comprises a first selectable marker coding sequence and is flanked by the second *lox* site and a third *lox* site, wherein the third *lox* site is different from the first and second *lox* sites, and wherein the donor sequence is integrated in a chromosome of the bacterial host cell; providing a plasmid comprising the gene of interest and a second selectable marker coding sequence, wherein the gene of interest and the second selectable marker are both flanked by the first *lox* site and the second *lox* site; and introducing the plasmid into the bacterial host cell, wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the gene of interest is integrated into the first landing pad by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the plasmid and the second *lox* site of the donor sequence; providing a second plasmid comprising a catalytically dead Cas9 protein coding sequence, a guide RNA sequence that targets a guide RNA target sequence of the gene of interest, and a third selectable marker coding sequence, wherein the catalytically dead Cas9 protein coding sequence, the guide RNA sequence, and the third selectable marker are flanked by the second *lox* site and the third *lox* site; introducing the second plasmid into the bacterial host cell, wherein upon introduction of the second plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the catalytically dead Cas9 protein coding sequence and guide RNA sequence are integrated into the second landing pad by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence, and between the third *lox* site of the second plasmid and the third *lox* site of the donor sequence; wherein upon introduction of the second plasmid of the bacterial host cell, the catalytically dead Cas9 protein and guide RNA are expressed, form a complex, and bind the guide RNA target sequence of the gene of interest, thereby modulating expression of the gene of interest. Further provided herein is a kit comprising a first vector comprising: (i) a transposase coding sequence; and (ii) a donor sequence, wherein the donor sequence is flanked by inverted repeats recognized by the transposase,

wherein the donor sequence comprises a first selectable marker coding sequence flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; and a second vector comprising: (i) one or more restriction or targeted cloning sites suitable for recombining a gene of interest into the second vector; and (ii) a second selectable marker, wherein the second selectable marker and the one or more restriction or targeted cloning sites are flanked by the first and the second *lox* sites.

[0010] Accordingly, certain aspects of the present disclosure relate to a method for integrating a gene of interest into a chromosome of a host cell, the method including (a) providing a first plasmid including: (i) a transposase coding sequence; and (ii) a donor sequence, wherein the donor sequence is flanked by inverted repeats recognized by the transposase, wherein the donor sequence includes a first selectable marker coding sequence flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; (b) introducing the first plasmid into the host cell, wherein upon introduction of the first plasmid into the host cell, transposase is expressed from the transposase coding sequence, and the donor sequence is integrated into a chromosome of the host cell between the inverted repeats by the transposase; (c) providing a second plasmid comprising the gene of interest and a second selectable marker coding sequence, wherein the gene of interest and the second selectable marker are both flanked by a first and a second *lox* site, wherein the first and the second *lox* sites are different; and (d) introducing the second plasmid into the host cell, wherein at least one of the second plasmid and the donor sequence includes a Cre recombinase coding sequence, and wherein upon introduction of the second plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the gene of interest is integrated into the chromosome of the host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the second plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence. Further provided herein is a method for integrating a gene of interest into a chromosome of a bacterial host cell, the method including: providing a first bacterial donor cell comprising a first plasmid, the first plasmid comprising: (i) a transposase coding sequence; and (ii) a donor sequence, wherein the donor sequence is flanked by inverted repeats recognized by the transposase, wherein the donor sequence includes a first selectable marker coding sequence flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; (b) introducing the first plasmid into the bacterial host cell by conjugation with the first bacterial donor cell, wherein upon introduction of the first

plasmid into the bacterial host cell, transposase is expressed from the transposase coding sequence, and the donor sequence is integrated into the chromosome of the bacterial host cell between the inverted repeats by the transposase; (c) providing a second bacterial donor cell comprising a second plasmid, the second plasmid comprising the gene of interest and a second selectable marker coding sequence, wherein the gene of interest and the second selectable marker are both flanked by a first and a second lox site, wherein the first and the second lox sites are different; and (d) introducing the second plasmid into the bacterial host cell, wherein at least one of the second plasmid and the donor sequence includes a Cre recombinase coding sequence, and wherein upon introduction of the second plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the gene of interest is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first lox site of the second plasmid and the first lox site of the donor sequence, and between the second lox site of the second plasmid and the second lox site of the donor sequence. Also provided herein is a bacterial host cell including a chromosomally integrated donor sequence, wherein the donor sequence includes a selectable marker coding sequence flanked by a first and a second lox site, wherein the donor sequence is flanked in the chromosome of the bacterial host cell by inverted repeats recognized by a transposase, and wherein the first and the second lox sites are different. Also provided herein is a vector comprising: (a) a transposase coding sequence; and (b) a donor sequence, wherein the donor sequence is flanked by inverted repeats recognized by the transposase, wherein the donor sequence includes a selectable marker coding sequence flanked by a first and a second lox site, and wherein the first and the second lox sites are different. In some embodiments, the vector comprises the polynucleotide sequence of SEQ ID NO:4. Further provided herein is a vector comprising the polynucleotide sequence of SEQ ID NO:10. Further provided herein is a vector comprising the polynucleotide sequence of SEQ ID NO:11. Further provided herein is a method for producing a phenazine, including: (a) providing a bacterial host cell comprising a chromosomally integrated donor sequence, wherein the donor sequence includes a first selectable marker sequence flanked by a first and a second lox site, wherein the first and the second lox sites are different, and wherein the donor sequence is flanked by inverted repeats recognized by a transposase; (b) introducing a plasmid into the bacterial host cell, the plasmid including a phenazine biosynthesis pathway coding sequence and a second selectable marker coding sequence, wherein the phenazine biosynthesis pathway coding sequence and the second selectable marker coding sequence

are both flanked by a first and a second *lox* site, wherein at least one of the chromosomally integrated donor sequence and the plasmid includes a Cre recombinase coding sequence, and wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the phenazine biosynthesis pathway coding sequence is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the plasmid and the second *lox* site of the donor sequence; and (c) culturing the bacterial host cell comprising the chromosomally integrated phenazine biosynthesis pathway coding sequence in a culture medium under conditions whereby the phenazine biosynthesis pathway coding sequence is expressed in the cell, and whereby the phenazine biosynthesis pathway produces the phenazine. Further provided herein is a method for producing a class IIa bacteriocin, including: (a) providing a bacterial host cell including a chromosomally integrated donor sequence, wherein the donor sequence includes a first selectable marker sequence flanked by a first and a second *lox* site, wherein the first and the second *lox* sites are different, and wherein the donor sequence is flanked by inverted repeats recognized by a transposase; (b) introducing a plasmid into the bacterial host cell, the plasmid including a class IIa bacteriocin biosynthesis pathway coding sequence and a second selectable marker coding sequence, wherein the class IIa bacteriocin biosynthesis pathway coding sequence and the second selectable marker coding sequence are both flanked by a first and a second *lox* site, wherein at least one of the chromosomally integrated donor sequence and the plasmid includes a Cre recombinase coding sequence, and wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the class IIa bacteriocin biosynthesis pathway coding sequence is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the plasmid and the second *lox* site of the donor sequence; and (c) culturing the bacterial host cell including the chromosomally integrated class IIa bacteriocin biosynthesis pathway coding sequence in a culture medium under conditions whereby the class IIa bacteriocin biosynthesis pathway coding sequence is expressed in the cell, and whereby the class IIa bacteriocin biosynthesis pathway produces the class IIa bacteriocin.

[0011] In some embodiments, prior to providing the bacterial host cell, the donor sequence is integrated into the chromosome of the bacterial host cell by: providing a bacterial donor cell comprising a donor plasmid, the donor plasmid comprising: (i) a transposase coding sequence; and (ii) the donor sequence, wherein the donor sequence is flanked by inverted repeats recognized by the transposase; and introducing the donor plasmid into the bacterial host cell by conjugation with the bacterial donor cell, wherein upon introduction of the donor plasmid into the bacterial host cell, transposase is expressed from the transposase coding sequence, and the donor sequence is integrated into the chromosome of the bacterial host cell between the inverted repeats by the transposase. In some embodiments, prior to providing the bacterial host cell, the donor sequence is integrated into the chromosome of the bacterial host cell by: providing a bacterial donor cell comprising a donor plasmid, the donor plasmid comprising: (i) an integrase coding sequence; and (ii) the donor sequence, wherein the donor sequence contains an attP site; and introducing the donor plasmid into the bacterial host cell by conjugation with the bacterial donor cell, wherein upon introduction of the donor plasmid into the bacterial host cell, integrase is expressed from the integrase coding sequence, and the donor sequence is integrated into the chromosome of the bacterial host cell mediated through the recombination between the attP site and an attB site on the chromosome of the bacterial host cell. In some embodiments, prior to providing the bacterial host cell, the donor sequence is integrated into the chromosome of the bacterial host cell by homologous recombination. In some embodiments, prior to providing the bacterial host cell, the donor sequence is integrated into the chromosome of the bacterial host cell by: providing the donor sequence, wherein the donor sequence is flanked by inverted repeats recognized by a transposase; and introducing the donor sequence into the bacterial host cell in the presence of the transposase, wherein upon introduction of the donor sequence into the bacterial host cell, the donor sequence is integrated into the chromosome of the bacterial host cell between the inverted repeats by the transposase.

[0012] In some embodiments, the bacterial host cell is not an *E. coli* cell. In certain embodiments the host cell is a yeast, animal, or plant host cell. In certain embodiments the host cell is a fungal, animal, or plant host cell. In certain embodiments that may be combined with any of the preceding embodiments the host cell is a mammalian host cell. In certain embodiments that may be combined with any of the preceding embodiments, the host cell is a bacterial host cell. In certain embodiments that may be combined with any of the preceding embodiments, the host cell is a Proteobacteria cell. In certain embodiments

that may be combined with any of the preceding embodiments, the bacterial host cell is a cell selected from the group consisting of Alphaproteotacteria, Betaproteotacteria, Gammaproteobacteria, Deltaproteotacteria, Epsilonproteotacteria, and Zetaproteotacteria. In certain embodiments that may be combined with any of the preceding embodiments, the bacterial host cell is a cell of a genus selected from the group consisting of *Escherichia*, *Pseudomonas*, *Photorhabdus*, *Xenorhabdus*, *Serratia*, *Erwinia*, *Yersinia*, *Dickeya*, *Pectobacterium*, *Rhizobium*, *Brevundimonas*, *Ralstonia*, and *Aeromonas*. In certain embodiments that may be combined with any of the preceding embodiments, the bacterial host cell is a cell of a genus selected from the group consisting of *Pseudomonas*, *Photorhabdus*, *Xenorhabdus*, *Serratia*, *Erwinia*, *Yersinia*, *Dickeya*, *Pectobacterium*, *Rhizobium*, *Brevundimonas*, *Ralstonia*, and *Aeromonas*. In certain embodiments that may be combined with any of the preceding embodiments, the bacterial host cell is a cell selected from the group consisting of Bacteroidetes, Cyanobacteria, Firmicutes, and Actinobacteria. In certain embodiments, the bacterial host cell is a cell of the genus *Arthrobacter*. In certain embodiments that may be combined with any of the preceding embodiments, the first and the second bacterial donor cells are both Gammaproteobacteria or Firmicutes cells. In certain embodiments that may be combined with any of the preceding embodiments, the first and the second bacterial donor cells are both *E. coli* cells. In certain embodiments that may be combined with any of the preceding embodiments, the bacterial donor cell is an *E. coli* cell, and the bacterial host cell is not an *E. coli* cell. In certain embodiments that may be combined with any of the preceding embodiments, the first lox site of the second plasmid and the first lox site of the donor sequence are the same lox site selected from loxP, lox5171, lox2272, lox511, loxm2, loxm3, loxm7, loxm11, lox71, and lox66. In certain embodiments that may be combined with any of the preceding embodiments, the second lox site of the second plasmid and the second lox site of the donor sequence are heterospecific to the first lox site of the second plasmid and the first lox site of the donor sequence, and wherein the second lox site of the second plasmid and the second lox site of the donor sequence are the same lox site selected from loxP, lox5171, lox2272, lox511, loxm2, loxm3, loxm7, loxm11, lox71, and lox66. In certain embodiments that may be combined with any of the preceding embodiments, the transposase is a transposase selected from Mariner, Tn1, Tn2, Tn3, Tn4, Tn5, Tn6, Tn7, Tn8, Tn9, Tn10, and Tn917. In certain embodiments that may be combined with any of the preceding embodiments, the first selectable marker coding sequence encodes a first antibiotic resistance marker. In certain embodiments that may be combined with any of the preceding embodiments, the

method further comprises after step (b), growing the host cell under conditions in which the first antibiotic resistance marker is expressed, wherein the host cell is grown in the presence of a first antibiotic to which the first antibiotic resistance marker confers resistance, such that the host cell comprising the donor sequence is selected. In certain embodiments that may be combined with any of the preceding embodiments, the first selectable marker coding sequence encodes a first auxotrophic marker, and wherein the host cell lacks an endogenous ability to produce a compound generated by the first auxotrophic marker. In certain embodiments that may be combined with any of the preceding embodiments, after step (b), growing the host cell under conditions in which the first auxotrophic marker is expressed, wherein the host cell is grown in the absence of the compound generated by the first auxotrophic marker, such that the host cell that has the donor sequence is selected. In certain embodiments that may be combined with any of the preceding embodiments, the second selectable marker is different from the first selectable marker. In certain embodiments that may be combined with any of the preceding embodiments, the second selectable marker coding sequence encodes a second antibiotic resistance marker.

[0013] In certain embodiments that may be combined with any of the preceding embodiments, after step (d), growing the host cell under conditions in which the second antibiotic resistance marker is expressed, wherein the host cell is grown in the presence of a second antibiotic to which the second antibiotic resistance marker confers resistance, such that the host cell that has the gene of interest and the second selectable marker coding sequence is selected. In certain embodiments that may be combined with any of the preceding embodiments, the second selectable marker coding sequence encodes a second auxotrophic marker, and wherein the host cell lacks an endogenous ability to produce a second compound generated by the second auxotrophic marker. In certain embodiments that may be combined with any of the preceding embodiments, after step (d), growing the host cell under conditions in which the second auxotrophic marker is expressed, wherein the host cell is grown in the absence of the second compound generated by the second auxotrophic marker, such that the host cell that has the gene of interest and the second selectable marker coding sequence is selected. In certain embodiments that may be combined with any of the preceding embodiments, the donor sequence further comprises a coding sequence for a protein that promotes sequence-specific gene transcription, and wherein the coding sequence for the protein that promotes sequence-specific gene transcription is flanked by the inverted repeats but not by the first and the second lox sites. In certain embodiments that may be combined with any of the preceding embodiments, the

protein that promotes sequence-specific gene transcription promotes transcription downstream of a first promoter sequence, wherein the gene of interest is operably linked to the first promoter sequence, and wherein the first promoter sequence is flanked by the first and the second lox sites. In certain embodiments that may be combined with any of the preceding embodiments, the protein that promotes sequence-specific gene transcription is a sequence-specific RNA polymerase. In certain embodiments that may be combined with any of the preceding embodiments, wherein the protein that promotes sequence-specific gene transcription is a T7 RNA polymerase.

[0014] In certain embodiments that may be combined with any of the preceding embodiments, the second plasmid includes the Cre recombinase coding sequence. In certain embodiments that may be combined with any of the preceding embodiments, the donor sequence includes the Cre recombinase coding sequence, and wherein the Cre recombinase coding sequence is flanked by the first and the second lox sites. In certain embodiments that may be combined with any of the preceding embodiments, the Cre recombinase coding sequence is operably linked to a promoter active in the host cell. In certain embodiments that may be combined with any of the preceding embodiments, the promoter is a constitutive promoter. In certain embodiments that may be combined with any of the preceding embodiments, the promoter is a Cas9 promoter. In certain embodiments that may be combined with any of the preceding embodiments, the gene of interest includes a coding sequence of one or more enzymes. In certain embodiments that may be combined with any of the preceding embodiments, the one or more enzymes catalyze one or more steps in synthesis of a polysaccharide, lipopolysaccharide, nonribosomal peptide (NRP), polyketide, siderophore, terpene, lantipeptide, bacteriocin, homoserine lactone, butyrolactone, ectoine, thiopeptide, phenazine, terpenoid, alkaloid, flavonoid, amino acid, biofuel, commodity chemical, vitamin, or fatty acid. In certain embodiments that may be combined with any of the preceding embodiments, the second plasmid includes two or more genes of interest, and wherein the two or more genes of interest are flanked by the first and the second lox sites. In certain embodiments that may be combined with any of the preceding embodiments, the two or more genes of interest are operably linked to the same promoter, the same promoter being flanked by the first and the second lox sites. In certain embodiments that may be combined with any of the preceding embodiments, the two or more genes of interest are operably linked to two or more promoters, each promoter of the two or more promoters being flanked by the first and the second lox sites. In certain embodiments that may be combined with any of the preceding embodiments, the first and

the second lox sites flank a sequence of greater than about 7kb. In certain embodiments that may be combined with any of the preceding embodiments, the first and the second lox sites flank a sequence of less than about 200kb. In certain embodiments that may be combined with any of the preceding embodiments, the vector comprises the polynucleotide sequence of SEQ ID NO:4. In certain embodiments that may be combined with any of the preceding embodiments, the second plasmid is introduced into the host cell by electroporation. In certain embodiments that may be combined with any of the preceding embodiments, the second plasmid is introduced into the bacterial host cell by conjugation with the second bacterial donor cell. In certain embodiments the donor sequence is introduced into the chromosome of the bacterial host cell by electroporation with a plasmid including a transposase coding sequence of the transposase and the donor sequence, wherein upon introduction of the plasmid into the bacterial host cell, the transposase is expressed from the transposase coding sequence, and the donor sequence is integrated into the chromosome of the bacterial host cell between the inverted repeats by the transposase. In certain embodiments that may be combined with any of the preceding embodiments the donor sequence is introduced into the chromosome of the bacterial host cell by conjugation with a bacterial donor cell that includes a plasmid comprising a transposase coding sequence of the transposase and the donor sequence, wherein upon introduction of the plasmid into the bacterial host cell, the transposase is expressed from the transposase coding sequence, and the donor sequence is integrated into the chromosome of the bacterial host cell between the inverted repeats by the transposase. In certain embodiments that may be combined with any of the preceding embodiments the donor sequence includes a Cre recombinase coding sequence, and wherein the Cre recombinase coding sequence is flanked by the first and the second lox sites. In certain embodiments that may be combined with any of the preceding embodiments the donor sequence includes a coding sequence for a protein that promotes sequence-specific gene transcription, and wherein the coding sequence for the protein that promotes sequence-specific gene transcription is flanked by the inverted repeats but not by the first and the second lox sites. In certain embodiments that may be combined with any of the preceding embodiments the protein that promotes sequence-specific gene transcription promotes transcription downstream of a first promoter sequence, wherein the gene of interest is operably linked to the first promoter sequence, and wherein the first promoter sequence is flanked by the first and the second lox sites. In certain embodiments that may be combined with any of the preceding embodiments the protein that promotes sequence-specific gene transcription is a sequence-specific RNA polymerase. In certain embodiments

that may be combined with any of the preceding embodiments the protein that promotes sequence-specific gene transcription is a T7 RNA polymerase. In certain embodiments that may be combined with any of the preceding embodiments the gene of interest and the selectable marker coding sequence are both flanked by a first and a second lox site, wherein the first and the second lox sites are flanked by inverted repeats recognized by a transposase, and wherein the first and the second lox sites are different. In certain embodiments that may be combined with any of the preceding embodiments the gene of interest is integrated into the chromosome of the bacterial host cell by: (a) electroporation with a plasmid including the gene of interest flanked by a first and a second lox site; and (b) recombinase-mediated cassette exchange (RMCE) between the first lox site of the plasmid and a first lox site of a donor sequence integrated into the chromosome of the bacterial host cell, and between the second lox site of the plasmid and a second lox site of the donor sequence, wherein the donor sequence is integrated into the chromosome of the bacterial host cell between the inverted repeats by the transposase, wherein a Cre recombinase is expressed from a coding sequence present on at least one of the plasmid including the gene of interest and the donor sequence. In certain embodiments that may be combined with any of the preceding embodiments the gene of interest is integrated into the chromosome of the bacterial host cell by: (a) conjugation with a bacterial donor cell to introduce into the bacterial host cell a plasmid including the gene of interest flanked by a first and a second lox site; and (b) recombinase-mediated cassette exchange (RMCE) between the first lox site of the plasmid and a first lox site of a donor sequence integrated into the chromosome of the bacterial host cell, and between the second lox site of the plasmid and a second lox site of the donor sequence, wherein the donor sequence is integrated into the chromosome of the bacterial host cell between the inverted repeats by the transposase, wherein a Cre recombinase is expressed from a coding sequence present on at least one of the plasmid comprising the gene of interest and the donor sequence.

[0015] In certain embodiments that may be combined with any of the preceding embodiments, the method includes (d) purifying the phenazine produced by the bacterial host cell from the culture medium. In certain embodiments that may be combined with any of the preceding embodiments, the phenazine is phenazine 1-carboxylic acid, and wherein the phenazine biosynthesis pathway is a phzABCDEFG pathway. In certain embodiments that may be combined with any of the preceding embodiments, the phenazine is phenazine 1,6-dicarboxylic acid, and wherein the phenazine biosynthesis pathway is a phzABGCDEF pathway.

[0016] In certain embodiments that may be combined with any of the preceding embodiments, the method includes purifying the class IIa bacteriocin produced by the bacterial host cell from the culture medium. In certain embodiments that may be combined with any of the preceding embodiments, the class IIa bacteriocin is Sakacin A, and the class IIa bacteriocin biosynthesis pathway is a *sapAKRTE* pathway. In certain embodiments that may be combined with any of the preceding embodiments, the class IIa bacteriocin is Sakacin P, and the class IIa bacteriocin biosynthesis pathway is a *sppKRTE* pathway. In certain embodiments that may be combined with any of the preceding embodiments, the class IIa bacteriocin is Leucocin A, and the class IIa bacteriocin biosynthesis pathway is a *lcaBAECD* pathway. In certain embodiments that may be combined with any of the preceding embodiments, the class IIa bacteriocin is Mesentericin Y105, and the class IIa bacteriocin biosynthesis pathway is a *mesIYCDE* pathway. In certain embodiments that may be combined with any of the preceding embodiments, the class IIa bacteriocin is Pediocin AcH, and the class IIa bacteriocin biosynthesis pathway is a *papABCD* pathway. In certain embodiments that may be combined with any of the preceding embodiments, the class IIa bacteriocin is Divercin V41, and the class IIa bacteriocin biosynthesis pathway is a *divnAT1T2IRK* pathway. In certain embodiments that may be combined with any of the preceding embodiments, the class IIa bacteriocin is Enterocin A, and the class IIa bacteriocin biosynthesis pathway is a *entFAI* pathway. In certain embodiments that may be combined with any of the preceding embodiments, the class IIa bacteriocin is Enterocin P, and the class IIa bacteriocin biosynthesis pathway is a *entP* pathway. In certain embodiments that may be combined with any of the preceding embodiments, the class IIa bacteriocin is Curvacin A, and the class IIa bacteriocin biosynthesis pathway is a *curA* pathway.

[0017] In certain embodiments that may be combined with any of the preceding embodiments, the pathway of interest is an orphan pathway. In certain embodiments that may be combined with any of the preceding embodiments, the gene or pathway of interest is nonribosomal peptide (NRP) or polyketide synthesis.

[0018] In certain embodiments that may be combined with any of the preceding embodiments, the gene or pathway of interest is involved in terpene or terpenoid synthesis. In certain embodiments that may be combined with any of the preceding embodiments, the gene or pathway of interest is involved in vanillin, benzaldehyde (bitter almond, cherry) and 4-(R)-decanolide (fruity±fatty) synthesis. In certain embodiments that may be combined with any of the preceding embodiments, the gene or pathway of interest

is involved in benzaldehyde, butyric acid, 2,3-butanedione, citronellal, (+)-curcumene, γ -decalactone, δ -decalactone, (+)-dehydro-curcumene, (-)-isopulegol, (-)-methol, nor-patchoulanol, (+)-nuciferal, phenolethanol, β -binene, raspberry ketone, thaumatin, monellin, or (+)-turmerone.

[0019] In certain embodiments that may be combined with any of the preceding embodiments, the method includes (d) purifying the vanillin, benzaldehyde (bitter almond, cherry), 4-(R)-decanolide (fruity±fatty), benzaldehyde, butyric acid, 2,3-butanedione, citronellal, (+)-curcumene, γ -decalactone, δ -decalactone, (+)-dehydro-curcumene, (-)-isopulegol, (-)-methol, nor-patchoulanol, (+)-nuciferal, phenolethanol, β -binene, raspberry ketone, thaumatin, monellin, or (+)-turmerone produced by the host cell.

[0020] In some embodiments, the gene or pathway of interest is involved in synthesis of a bacteriocin. In some embodiments the bacteriocin is Leucin A, MesentericinY105, Mundticin, Piscicolin 126, Bavaricin A, Sakacin P, Pediocin PA-1, Bavaricin MN, Divercin V41, Enterocin A, Enterocin P, Carnobacteriocin BM1, Sakacin A, Carnobacterocin B2, Bacteriocin 31, or Acidocin A.

[0021] In certain embodiments that may be combined with any of the preceding embodiments, the method includes (d) purifying the Leucin A, MesentericinY105, Mundticin, Piscicolin 126, Bavaricin A, Sakacin P, Pediocin PA-1, Bavaricin MN, Divercin V41, Enterocin A, Enterocin P, Carnobacteriocin BM1, Sakacin A, Carnobacterocin B2, Bacteriocin 31, or Acidocin A. produced by the host cell.

[0022] In certain embodiments that may be combined with any of the preceding embodiments, the gene or pathway of interest is involved in production of a polysaccharide, siderophore, lantipeptide, homoserine lactone, butyrolactone, ectoine, thiopeptide alkaloids, flavonoid, commodity chemical or a vitamin.

[0023] In certain embodiments that may be combined with any of the preceding embodiments, the method includes (d) purifying the polysaccharide, siderophore, lantipeptide, homoserine lactone, butyrolactone, ectoine, thiopeptide alkaloids, flavonoid, commodity chemical or a vitamin produced by the host cell.

[0024] In certain embodiments that may be combined with any of the preceding embodiments, the gene or pathway of interest is involved in omega-3 or omega-6 fatty acid synthesis. In certain embodiments that may be combined with any of the preceding embodiments, the gene of interest is any of $\Delta 6$ -desaturase (D6D), fatty acid desaturase 2 (FADS2), $\Delta 5$ -desaturase (D5D).

[0025] In certain embodiments that may be combined with any of the preceding embodiments, the method includes (d) purifying the omega-3 or omega-6 fatty acid.

[0026] In some embodiments, at least one of the first and the second plasmid is introduced into the host cell via conjugation. In some embodiments, at least one of the first and the second plasmid is introduced into the host cell via electroporation. In some embodiments, the catalytically dead Cas9 protein/guide RNA complex bind the guide RNA target sequence of the gene of interest and repress expression of the gene of interest. In some embodiments, the catalytically dead Cas9 protein is fused with a transcriptional activator protein, and wherein the catalytically dead Cas9:transcriptional activator fusion protein/guide RNA complex binds the guide RNA target sequence of the gene of interest and promotes expression of the gene of interest. In some embodiments, after introducing the second plasmid into the bacterial host cell, the combined amount of sequence between the first and second *lox* sites and the second and third *lox* sites is up to about 400kb.

[0027] In some embodiments of any of the above embodiments, the kit comprises a third vector comprising (i) one or more restriction or targeted cloning sites suitable for recombining a gene of interest into the second vector; and (ii) a second selectable marker, wherein the second selectable marker and the one or more restriction or targeted cloning sites are flanked by the first and the second *lox* sites. In some embodiments, the second vector is a multiple-copy plasmid, and wherein the third vector is a single-copy plasmid. In some embodiments, the donor sequence further comprises a Cre recombinase coding sequence flanked by the first and the second *lox* sites. In some embodiments, the first and the second *lox* sites are both selected from the group consisting of *loxP*, *lox5171*, *lox2272*, *lox511*, *loxm2*, *loxm3*, *loxm7*, *loxm11*, *lox71*, and *lox66*. In some embodiments, the transposase coding sequence is a coding sequence of a transposase selected from the group consisting of Mariner, Tn1, Tn2, Tn3, Tn4, Tn5, Tn6, Tn7, Tn8, Tn9, Tn10, and Tn917. In some embodiments, the first and the second *lox* sites flank a sequence of greater than about 7kb. In some embodiments, the first and the second *lox* sites flank a sequence of less than about 200kb. In some embodiments, the first vector comprises the polynucleotide sequence of SEQ ID NO:4. In some embodiments, the second vector comprises the polynucleotide sequence of SEQ ID NO:10. In some embodiments, the third vector comprises the polynucleotide sequence of SEQ ID NO:11. In some embodiments, the kit further comprises instructions for using the kit to integrate the gene of interest into a chromosome of a host cell.

[0028] It is to be understood that one, some, or all of the properties of the various embodiments described above and herein may be combined to form other embodiments of the present invention. These and other aspects of the present disclosure will become apparent to one of skill in the art. These and other embodiments of the present disclosure are further described by the detailed description that follows.

BRIEF DESCRIPTION OF THE DRAWINGS

[0029] **FIG. 1** is a map of the pW1 vector. The sequence between the two mariner inverted repeat ends is called the “landing pad.” The landing pad contains the Kanamycin resistance gene flanked by LoxP and Lox5171 sites.

[0030] **FIG. 2** is a map of the pW6 vector. The pW6 vector is comprised of three parts. Part 1 is the pBeloBAC11 backbone, part 2 is the LacI and lac UV5 driven Cre recombinase, and part 3 is the PDC pathway and Apramycin resistance marker between the two lox sites (“PDC + AprR”).

[0031] **FIGS. 3A-3B** show an example of the combined transposition, Cre-Lox strategy. Donor strain, *E. coli* WM3064 pW1, which harbors the pW1 plasmid, is conjugated to a recipient strain, *P. fluorescens* WCS514r, resulting in random integration of the landing pad into the *P. fluorescens* WCS417r chromosome (**FIG. 3A**). The resulting strain is then conjugated to donor strain, *E. coli* WM3064 pW6, which harbors the pW6 plasmid (**FIG. 3B**). After conjugation and recombination by Cre, the PDC and Apramycin genes are integrated into the recipient strain under the control of the T7 RNA polymerase promoter (**FIG. 3B**).

[0032] **FIGS. 4A-4D** show the Phenazine 1,6-dicarboxylic acid (PDC) and phenazine 1-carboxylic (PCA) pathways and chemical products.

[0033] **FIG. 5** is a map of the pW17 vector. The sequence between the two mariner inverted repeat (IR) ends is called the “landing pad.” The landing pad includes LacI-T7 RNA polymerase to enable the T7 driven pathway expression, and also includes LoxP-Km-Cas9Cre-Lox5171 for pathway integration. pW17 is a single copy plasmid.

[0034] **FIG. 6** is a map of the pW20 vector. The pW20 vector is composed of three parts. Part 1 is the pBeloBAC11 backbone, part 2 is the LacI and LacUV5 driven Cre recombinase, and part 3 is the T7 driven PCA and apramycin resistance marker between the two Lox sites (“PCA-AprR”).

[0035] **FIG. 7** is map of the pW21 vector. The pW21 vector is composed of three parts. Part 1 is the pBeloBAC11 backbone, part 2 is the LacI and LacUV5 driven Cre

recombinase, and part 3 is the T7 driven PDC and Apramycin resistance marker between the two Lox sites (“PDC-AprR”).

[0036] FIGS. 8A-8B show an example of the combined transposition, Cre-Lox, and T7 RNA polymerase strategy. Donor strain, *E. coli* WM3064 p17, which harbors the p17 plasmid, is conjugated to a recipient strain, *P. fluorescens* WCS514r or *P. fluorescens* Q8r1, resulting in random integration of the landing pad into the *P. fluorescens* WCS417r or *P. fluorescens* Q8r1 chromosome (**FIG. 8A**). The resulting strain is then conjugated to donor strain, *E. coli* WM3064 pW20 or pW21, which harbors the pW20 or pW21 plasmids (**FIG. 8B**). After conjugation and recombination by Cre, the PDC and Apramycin genes are integrated into the recipient strain where the PDC gene is under the control of the T7 promoter (**FIG. 8B**).

[0037] FIGS. 9A-9E show LCMS chromatograms of *P. fluorescens* with and without the PCA and PDC pathways. New peaks (PCA at 4.4 min and PDC at 3.8 min, as labeled) are observable for the recombinant strains and correspond to standards for PCA and PDC.

[0038] FIG. 10 is a map of the pW34 vector. The pW34 vector is composed of two parts. Part 1 is a backbone carrying OriT, the r6k replication origin, and part 2 is the T7 driven *luxCDABE* pathway and Apramycin resistance marker between the two lox sites. pW34 was generated by cloning the *luxCDABE* pathway into vector pW26 (SEQ ID NO:10).

[0039] FIGS. 11A-11B show an example of the combined transposition, Cre-LoxP, and T7 RNA polymerase strategy. Donor strain, *E. coli* WM3064 p17, which harbors the p17 plasmid, is conjugated to a recipient strain, *P. fluorescens* WCS514r or *P. fluorescens* Q8r1 resulting in random integration of the landing pad into the *P. fluorescens* WCS417r or *P. fluorescens* Q8r1 chromosome (**FIG. 11A**). The resulting strain is then conjugated to donor strain, *E. coli* WM3064 pW34, which harbors the pW34 plasmid. After conjugation and recombination by Cre, the Lux pathway and Apramycin gene are integrated into the recipient strain where the Lux pathway is under the control of the T7 RNA polymerase promoter (**FIG. 11B**).

[0040] FIGS. 12A-12B show the bioluminescence of *P. fluorescence* WCS417r Km-Cre-2lox and *P. fluorescence* WCS417r Apr-Lux (**FIG. 12A**) and *P. fluorescence* Q8r1 Km-Cre-2lox and *P. fluorescence* Q8r1 Apr-lux (**FIG. 12B**) strains with 0, 0.01, 0.1, and 1 mM IPTG.

[0041] FIGS. 13A-13B show an example of the transposition, Cre-LoxP, and T7 RNA polymerase combined strategy. Donor strain, *E. coli* WM3064 p17, which harbors the pW17 plasmid, is conjugated to a recipient strain, resulting in random integration of the

landing pad into the recipient chromosome (**FIG. 13A**). The resulting strain is then conjugated to donor strain, *E. coli* WM3064 pW34, which harbors the pW34 plasmid. After conjugation and recombination by Cre, the Lux pathway and Apramycin gene are integrated into the recipient strain under the control of the T7 RNA polymerase promoter (**FIG. 13B**).

[0042] **FIGS. 14A-14BB** show bioluminescence of 31 strains with the landing pad (control) and with the *luxCDABE* pathway integrated in the chromosome in two potentially different locations. In each figure, the shaded center line shows the average bioluminescence of 4 to 5 colonies with *luxCDABE* under 1 mM IPTG induction (“B”). The outside shaded lines show the average plus and average minus standard deviation under 1 mM IPTG induction, with these entire areas shaded. Green (“G”) and orange (“O”) lines show bioluminescence of strains with the landing pad only and pink lines (“P”) show bioluminescence of the mutant strains with 0 mM IPTG induction. Bioluminescence was measured for *Photorhabdus luminescens* subsp. *Laumondii* TTO1 (**FIG. 14A**), *P. luminescens* subsp. *Luminescens* (**FIG. 14B**), *Photorhabdus temperate* subsp. *khanii* (**FIG. 14C**), *Xenorhabdus doucetia* (**FIG. 14D**) *X. nematophila* (**FIG. 14E**), *X. szentirmaii* (**FIG. 14F**), *Serratia odorifera* (**FIG. 14G**), *Erwinia oleae* (**FIG. 14H**), *E. piriflorinigra* (**FIG. 14I**), *E. pyrifoliae* (**FIG. 14J**), *Yersinia aldovae* (**FIG. 14K**), *Y. bercovieri* (**FIG. 14L**), *Y. mollaretii* (**FIG. 14M**), *Y. ruckeri* (**FIG. 14N**), *Dickeya dadantii* subsp. *Dadantii* (**FIG. 14O**), *D. dadantii* subsp. *Dieffenbachiae* (**FIG. 14P**), *D. solani* (**FIG. 14Q**), *D. zeae* (**FIG. 14R**), *Pectobacterium atrosepticum* (**FIG. 14S**), *P. betavascularum* (**FIG. 14T**), *P. carotovorum* subsp. *carotovorum* (**FIG. 14U**), *P. carotovorum* subsp. *odoriferum* (**FIG. 14V**), *P. wasabiae* (**FIG. 14W**), *Aeromonas encheleia* (**FIG. 14X**), *A. molluscorum* (**FIG. 14Y**), *A. piscicola* (**FIG. 14Z**), *A. salmonicida* subsp. *pectinolytica* (**FIG. 14AA**), *A. salmonicida* subsp. *salmonicida* (**FIG. 14BB**). *A. piscicola* (**FIG. 14Z**) and *A. salmonicida* subsp. *pectinolytica* (**FIG. 14AA**) were induced with 0.1 or 0 mM IPTG rather than 1 or 0 mM.

[0043] **FIG. 15** shows an example of the combined transposition, Cre-LoxP, and T7 RNA polymerase strategy. pW34, is introduced into *E. coli* MG1655 cells by electroporation. After recombination by Cre, the Lux pathway and Apramycin gene are integrated into the recipient strain where the Lux pathway is under the control of the T7 RNA polymerase promoter.

[0044] **FIG. 16** shows bioluminescence of *E. coli* MG1655 Spec-Cre-2lox and *E. coli* MG1655 Apr-lux upon induction with 0, 0.01, 0.1, and 1.0 mM IPTG.

[0045] **FIG. 17** shows an example of the transposition, Cre-LoxP, and T7 RNA polymerase combined strategy. The *E. coli* donor strain is conjugated to a recipient strain, resulting in random integration of the landing pad into the chromosome (1). The resulting strain is then conjugated to an *E. coli* donor strain, which harbors the T7 RNA polymerase promoter. After conjugation and recombination by Cre, the gene pathway of interest is integrated into the recipient strain under control of the T7 RNA polymerase promoter (2).

[0046] **FIGS. 18A-18C** show heat maps of luminescence intensity from engineered gamma proteobacteria strains containing the landing pad with *luxCDABE* integration (**FIG. 18A**) or orphan secondary metabolite T7-PLU3263 pathway integration (**FIG. 18B-18C**) upon induction with 0, 0.01, 0.1, and 1.0 mM IPTG. **FIG. 18B** indicates luminmide A production; **FIG. 18C** indicates luminmide B production. In each figure, black indicates high luminescence intensity and white demonstrates low luminescence intensity.

[0047] **FIGS. 19A-19B** show the MS/MS spectra and structures of luminmide A (**FIG. 19A**) and luminmide B (**FIG. 19B**) (Fu, J., et al., *Full-length RecE enhances linear-linear homologous recombination and facilitates direct cloning for bioprospecting*. Nat Biotechnol, 2012. 30(5): p. 440-6). **FIGS. 19C-19D** show the LC-MS/MS spectra and structures of luminmide A (**FIG. 19C**) and luminmide B (**FIG. 19D**).

[0048] **FIG. 20** shows the ratio of luminmide A (m/z 586.41) to luminmide B (m/z 552.40) production in engineered bacterial strains expressing the orphan secondary metabolite T7-Plu3263 pathway.

[0049] **FIGS. 21A-21B** show the production of a secondary metabolite (m/z 377.30) with a retention time of 3.64 minutes (**FIG. 21A**) and luminescence intensity (**FIG. 21B**) from engineered gamma proteobacteria strains containing the landing pad with orphan secondary metabolite T7-Plu0897-Plu0899 pathway integration upon induction with 0, 0.01, 0.1, and 1.0 mM IPTG. In each figure, black indicates high luminescence intensity and white demonstrates low luminescence intensity. **FIG. 21C** shows the LC-MS/MS spectra and structure of the secondary metabolite.

[0050] **FIG. 22A** shows bioluminescence of an engineered *Rhizobium mongolense* (alpha proteobacteria) strain expressing *luxCDADBE* versus the landing pad alone (control) upon induction with 0 and 1.0 mM IPTG.

[0051] **FIG. 22B** shows bioluminescence of an engineered *Brevundimonas sp. 374* (alpha proteobacteria) strain expressing *luxCDADBE* versus the landing pad alone (control) upon induction with 0 and 1.0 mM IPTG.

[0052] **FIG. 22C** shows bioluminescence of an engineered *Ralstonia* sp.

UNC404CL21Col (beta proteobacteria) strain expressing *luxCDADBE* versus the landing pad alone (control) upon induction with 0 and 1.0 mM IPTG.

[0053] **FIG. 23** shows bioluminescence of an engineered *Arthrobacter* sp. *161MFSha2.1* (actinobacteria) strain expressing *luxCDADBE* versus the landing pad alone (control) upon induction with 0 and 1.0 mM IPTG.

[0054] **FIG. 24** shows an example of the stepwise methodology involving transposition and Cre-LoxP recombination wherein the landing pad is modified to include three loxP sites: (1) the landing pad is inserted to genome, (2) KanR is replaced by dCas9-LacI-Apr or aCas9-LacI-Apr, and (3) Cre is replaced by gRNA-KanR. Subsequently, dCas9 or aCas9 is directed to bind to the LuxA gene and regulate bioluminescence.

[0055] **FIG. 25A-25D** show bioluminescence of *Photorhabdus luminescens* subsp. *laumondii* TTO1 engineered with the three loxP landing pad under 1 mM IPTG induction.

FIGS. 25A & 25C illustrate the sgRNA target sites for dCas9 and aCas9, respectively.

Bioluminescence was measured for strains containing dCas9 integrated into the first loxP site and a set of sgRNA fragments integrated into the second site of the landing pad (**FIG. 25B**). Bioluminescence was measured for engineered strains containing aCas9 integrated into the first loxP site and a set of sgRNA fragments integrated into the second site of the landing pad (**FIG. 25D**).

DETAILED DESCRIPTION

[0056] The present disclosure relates generally to a method for integrating a gene or pathway of interest into a host chromosome comprising integrating a donor sequence comprising inverted repeats flanking two *lox* sites into the chromosome of a host cell, and then introducing a gene or pathway of interest by recombination at the *lox* sites.

[0057] In particular, the present disclosure is based, at least in part, on the demonstration described herein that the present method allows engineering of a wide range of host cells stably, accurately, and efficiently. Specifically, using the Cre recombination pathway to integrate the gene or pathway of interest allows for more efficient recombination of larger pathways compared to homologous recombination, or phage transduction. Moreover, because the first step of the method described herein involves integration of a landing pad comprising two *lox* sites, this method can be used to easily produce a library of engineered host cells by swapping the pathways or genes contained between the Cre sites. Provided herein are studies showing successful integration and expression of pathways in 32 different

strains of bacteria, demonstrating the universality of this approach and improving existing technologies (*see, e.g.*, US PG Pub No. US20120329115).

[0058] Accordingly, certain aspects of the present disclosure relate to a method for integrating a gene of interest into a chromosome of a host cell, the method including providing a bacterial host cell comprising a donor sequence comprising a first selectable marker coding sequence flanked by a first and a second *lox* site, wherein the first and the second *lox* sites are different, and wherein the donor sequence is integrated in a chromosome of the bacterial host cell; providing a plasmid comprising the gene of interest and a second selectable marker coding sequence, wherein the gene of interest and the second selectable marker are both flanked by a first and a second *lox* site, wherein the first and the second *lox* sites are different; and introducing the plasmid into the bacterial host cell, wherein at least one of the plasmid and the donor sequence comprises a Cre recombinase coding sequence, and wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the gene of interest is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the second plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence. Further provided herein is a method for integrating a gene of interest into a chromosome of a host cell, the method including providing a host cell comprising a donor sequence comprising a first selectable marker coding sequence flanked by a first and a second *lox* site, wherein the first and the second *lox* sites are different, and wherein the donor sequence is integrated in a chromosome of the host cell; providing a plasmid comprising the gene of interest and a second selectable marker coding sequence, wherein the gene of interest and the second selectable marker are both flanked by a first and a second *lox* site, wherein the first and the second *lox* sites are different; and introducing the plasmid into the host cell, wherein at least one of the plasmid and the donor sequence comprises a Cre recombinase coding sequence, and wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the gene of interest is integrated into the chromosome of the host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the second plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence, wherein the host cell is a fungal, animal, or plant host cell. Further provided

herein is a method for modulating expression of a gene of interest in a bacterial host cell, the method including: providing a bacterial host cell comprising a donor sequence comprising: (i) a Cre recombinase coding sequence, wherein the Cre recombinase coding sequence is flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; and (ii) a first selectable marker coding sequence flanked by the second *lox* site and a third *lox* site, wherein the third *lox* site is different from the first and second *lox* sites, and wherein the donor sequence is integrated in a chromosome of the bacterial host cell; providing a plasmid comprising a catalytically dead Cas9 protein coding sequence and a second selectable marker coding sequence, wherein the catalytically dead Cas9 protein coding sequence and the second selectable marker are both flanked by the second *lox* site and the third *lox* site; introducing the plasmid into the bacterial host cell, wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the catalytically dead Cas9 protein coding sequence is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the second *lox* site of the plasmid and the second *lox* site of the donor sequence, and between the third *lox* site of the plasmid and the third *lox* site of the donor sequence; providing a second plasmid comprising a guide RNA sequence that targets a guide RNA target sequence of the gene of interest and a third selectable marker coding sequence, wherein the guide RNA sequence and the third selectable marker are both flanked by the first *lox* site and the second *lox* site; and introducing the second plasmid into the bacterial host cell, wherein upon introduction of the second plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the guide RNA sequence is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the second plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence; wherein upon introduction of the second plasmid of the bacterial host cell, the catalytically dead Cas9 protein and guide RNA are expressed, form a complex, and bind the guide RNA target sequence of the gene of interest, thereby modulating expression of the gene of interest. Further provided herein is a method for modulating expression of a gene of interest in a bacterial host cell, the method including: providing a bacterial host cell comprising a donor sequence comprising: (i) a Cre recombinase coding sequence, wherein the Cre recombinase coding sequence is flanked by a first and a second *lox* site, and

wherein the first and the second *lox* sites are different; and(ii) a first selectable marker coding sequence flanked by the second *lox* site and a third *lox* site, wherein the third *lox* site is different from the first and second *lox* sites, and wherein the donor sequence is integrated in a chromosome of the bacterial host cell; providing a first plasmid comprising a catalytically dead Cas9 protein coding sequence, a guide RNA sequence that targets a guide RNA target sequence of the gene of interest, and a second selectable marker coding sequence, wherein the catalytically dead Cas9 protein coding sequence, the guide RNA sequence, and the second selectable marker are flanked by the second *lox* site and the third *lox* site; introducing the first plasmid into the bacterial host cell, wherein upon introduction of the first plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the catalytically dead Cas9 protein coding sequence and guide RNA sequence are integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the second *lox* site of the first plasmid and the second *lox* site of the donor sequence, and between the third *lox* site of the first plasmid and the third *lox* site of the donor sequence; providing a second plasmid comprising the gene of interest and a third selectable marker coding sequence, wherein the gene of interest and the third selectable marker are both flanked by the first *lox* site and the second *lox* site; and introducing the second plasmid into the bacterial host cell, wherein upon introduction of the second plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the gene of interest is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the second plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence; wherein upon introduction of the second plasmid of the bacterial host cell, the catalytically dead Cas9 protein and guide RNA are expressed, form a complex, and bind the guide RNA target sequence of the gene of interest, thereby modulating expression of the gene of interest.

[0059] Accordingly, the present disclosure provides a method for integrating a gene of interest into a chromosome of a host cell, the method including:(a) providing a first plasmid comprising: (i) a transposase coding sequence; and (ii) a donor sequence, wherein the donor sequence is flanked by inverted repeats recognized by the transposase, wherein the donor sequence includes a first selectable marker coding sequence flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; (b) introducing the first

plasmid into the host cell, wherein upon introduction of the first plasmid into the host cell, transposase is expressed from the transposase coding sequence, and the donor sequence is integrated into a chromosome of the host cell between the inverted repeats by the transposase; (c) providing a second plasmid including the gene of interest and a second selectable marker coding sequence, wherein the gene of interest and the second selectable marker are both flanked by a first and a second *lox* site, wherein the first and the second *lox* sites are different; and (d) introducing the second plasmid into the host cell, wherein at least one of the second plasmid and the donor sequence includes a Cre recombinase coding sequence, and wherein upon introduction of the second plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the gene of interest is integrated into the chromosome of the host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the second plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence.

[0060] Further provided herein is a method for integrating a gene of interest into a chromosome of a bacterial host cell, the method including: providing a first bacterial donor cell comprising a first plasmid, the first plasmid comprising: (i) a transposase coding sequence; and (ii) a donor sequence, wherein the donor sequence is flanked by inverted repeats recognized by the transposase, wherein the donor sequence includes a first selectable marker coding sequence flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; (b) introducing the first plasmid into the bacterial host cell by conjugation with the first bacterial donor cell, wherein upon introduction of the first plasmid into the bacterial host cell, transposase is expressed from the transposase coding sequence, and the donor sequence is integrated into the chromosome of the bacterial host cell between the inverted repeats by the transposase; (c) providing a second bacterial donor cell including a second plasmid, the second plasmid comprising the gene of interest and a second selectable marker coding sequence, wherein the gene of interest and the second selectable marker are both flanked by a first and a second *lox* site, wherein the first and the second *lox* sites are different; and (d) introducing the second plasmid into the bacterial host cell, wherein at least one of the second plasmid and the donor sequence comprises a Cre recombinase coding sequence, and wherein upon introduction of the second plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the gene of interest is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette

exchange (RMCE) between the first lox site of the second plasmid and the first lox site of the donor sequence, and between the second lox site of the second plasmid and the second lox site of the donor sequence.

[0061] Also provided herein is a host cell including a chromosomally integrated donor sequence, wherein the donor sequence comprises a selectable marker coding sequence flanked by a first and a second lox site, wherein the donor sequence is flanked in a chromosome of the host cell by inverted repeats recognized by a transposase, and wherein the first and the second lox sites are different. In certain embodiments, the host cell is a bacterial host cell. Also provided herein is a vector including: (a) a transposase coding sequence; and (b) a donor sequence, wherein the donor sequence is flanked by inverted repeats recognized by the transposase, wherein the donor sequence includes a selectable marker coding sequence flanked by a first and a second lox site, and wherein the first and the second lox sites are different. Further provided herein is a method for producing a phenazine, including: (a) providing a bacterial host cell including a chromosomally integrated donor sequence, wherein the donor sequence includes a first selectable marker sequence flanked by a first and a second lox site, wherein the first and the second lox sites are different, and wherein the donor sequence is flanked by inverted repeats recognized by a transposase; (b) introducing a plasmid into the bacterial host cell, the plasmid comprising a phenazine biosynthesis pathway coding sequence and a second selectable marker coding sequence, wherein the phenazine biosynthesis pathway coding sequence and the second selectable marker coding sequence are both flanked by a first and a second lox site, wherein at least one of the chromosomally integrated donor sequence and the plasmid comprises a Cre recombinase coding sequence, and wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the phenazine biosynthesis pathway coding sequence is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first lox site of the plasmid and the first lox site of the donor sequence, and between the second lox site of the plasmid and the second lox site of the donor sequence; and (c) culturing the bacterial host cell comprising the chromosomally integrated phenazine biosynthesis pathway coding sequence in a culture medium under conditions whereby the phenazine biosynthesis pathway coding sequence is expressed in the cell, and whereby the phenazine biosynthesis pathway produces the phenazine. Yet further provided herein is a method for producing a class IIa bacteriocin, including: (a) providing a bacterial host cell including a chromosomally integrated donor

sequence, wherein the donor sequence includes a first selectable marker sequence flanked by a first and a second *lox* site, wherein the first and the second *lox* sites are different, and wherein the donor sequence is flanked by inverted repeats recognized by a transposase; (b) introducing a plasmid into the bacterial host cell, the plasmid including a class IIa bacteriocin biosynthesis pathway coding sequence and a second selectable marker coding sequence, wherein the class IIa bacteriocin biosynthesis pathway coding sequence and the second selectable marker coding sequence are both flanked by a first and a second *lox* site, wherein at least one of the chromosomally integrated donor sequence and the plasmid includes a Cre recombinase coding sequence, and wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the class IIa bacteriocin biosynthesis pathway coding sequence is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the plasmid and the second *lox* site of the donor sequence; and (c) culturing the bacterial host cell including the chromosomally integrated class IIa bacteriocin biosynthesis pathway coding sequence in a culture medium under conditions whereby the class IIa bacteriocin biosynthesis pathway coding sequence is expressed in the cell, and whereby the class IIa bacteriocin biosynthesis pathway produces the class IIa bacteriocin.

I. Methods of Integration and Expression

[0062] Certain aspects of the present disclosure relate to methods of integrating one or more genes or pathways of interest into a chromosome of a host cell. Specifically, the methods described herein comprise introducing into a host cell a plasmid with a donor sequence flanked by inverted repeats, which further flank two *lox* sites, and a transposase coding sequence to randomly introduce the *lox* sites into the chromosome of the host cell to form a landing pad. In the second step, a gene of interest flanked by two *lox* sites is introduced into the host cell so that the gene or pathway of interest integrates into the host chromosome through Cre-*lox* recombination. Various methods known in the art may be used to introduce one or both of the plasmid and the gene of interest into the host cell, depending upon the specific type of host cell (*e.g.*, transfection, electroporation, or transformation for mammalian cells; transformation in yeast, etc.).

[0063] Certain aspects of the present disclosure relate to methods of integrating one or more genes or pathways of interest into a chromosome of a bacterial host cell. Specifically,

the methods described herein comprise introducing into a host cell a plasmid with a donor sequence flanked by inverted repeats, which further flank two *lox* sites, and a transposase coding sequence to randomly introduce the *lox* sites into the chromosome of the host cell to form a landing pad. In the second step, a gene of interest flanked by two *lox* sites is introduced into the host cell so that the gene or pathway of interest integrates into the host chromosome through Cre-*lox* recombination. Various methods known in the art may be used to introduce one or both of the plasmid and the gene of interest into the host cell, including without limitation conjugation, electroporation, and bacterial transformation.

Donor and Host Cells

[0064] In some embodiments, the methods of integration and expression described herein apply to donor and host cells. In some embodiments, the host cell includes unicellular organisms. A host cell may refer to a cell into which genetic material is introduced, *e.g.*, by transposase-mediated integration or recombinase-mediated cassette exchange (RMCE), while a donor cell may refer to a cell that is introducing genetic material into a host cell (*e.g.*, by bacterial conjugation). In some embodiments the unicellular organism can be fungus (*e.g.*, yeast), bacteria, or a unicellular plant (*e.g.*, algae). In other embodiments, the cell may be a cell line or cultured cell derived from an invertebrate or a vertebrate, such as a mammalian cell line.

[0065] In some embodiments, the donor and/or host cells are Alphaproteobacteria, Betaproteobacteria, Gammaproteobacteria, Deltaproteobacteria, Bacteroidetes, Cyanobacteria, Firmicutes, and Actinobacteria cells. In some embodiments, the donor and/or host cells are any of the exemplary organisms listed in Table 1.

Table 1

	Alphaproteobacteria	Caulobacterales
		Kiloniellales
		Kordiimonadales
		Magnetococcales
		Parvularculales
		Pelagibacterales
		Rhizobiales
		Rhodobacterales
		Rhodospirillales
		Rickettsiales
		Sneathiellales

Proteobacteria		Sphingomonadales
	Betaproteobacteria	Burkholderiales
		Ferrovales
		Gallionellales
		Hydrogenophilales
		Methylophilales
		Neisseriales
		Nitrosomonadales
		Rhodocyclales
	Deltaproteobacteria	Bdellovibrionales
		Desulfarculales
		Desulfobacterales
		Desulfovibrionales
		Desulfurellales
		Desulfuromonadales
		Myxococcales
		Syntrophobacterales
	Epsilonproteobacteria	Campylobacterales
		Nautiliales
	Gammaproteobacteria	Acidithiobacillales
		Aeromonadales
		Alteromonadales
		Cardiobacterales
		Chromatiales
		Enterobacterales
		Legionellales
		Lysobacterales
		Methylococcales
		Myoida
		Oceanospirillales
		Orbales
		Pasteurellales
		Pseudomonadales
		Salinisphaerales
		Thiotrichales
		Vibrionales
		Xanthomonadales
	Zetaproteobacteria	Mariprofundales
	Bacilli	Bacillales
		Lactobacillales
	Clostridia	Clostridiales
		Halanaerobiales

Firmicutes		Natranaerobiales
		Thermoanaerobacterales
	Erysipelotrichi	Erysipelotrichales
	Erysipelotrichia	Erysipelotrichales
		Lactobacillales
	Negativicutes	Selenomonadales
Actinobacteria	Acidimicrobiia	Acidimicrobiales
	Actinobacteria	Acidimicrobiales
		Actinomycetales
		Actinopolysporales
		Bifidobacteriales
		Coriobacteriales
		Corynebacteriales
		Frankiales
		Geodermatophilales
		Jiangellales
		Kineosporiales
		Micrococcales
		Micromonosporales
		Nakamurellales
		Nitriliruptorales
		Propionibacteriales
		Pseudonocardiales
		Rubrobacterales
		Solirubrobacterales
		Streptomycetales
		Streptosporangiales
		Thermoleophilales
	Actinobacteria (class)	Actinomycetales
	Coriobacteriia	Coriobacteriales
Bacteroidetes	Bacteroidia	Bacteroidales
	Cytophagia	Cytophagales
		Rhodothermales
	Flavobacteriia	Flavobacteriales
	Sphingobacteriia	Sphingobacteriales
Cyanobacteria	Gloeobacteria	Gloeobacterales
	Melainabacteria	Caenarcaniphilales
		Gastranaerophilales
		Obscuribacterales

[0066] In some embodiments, where the donor and/or host cells are bacteria, the bacteria may be one of the following: *Pseudomonas fluorescens* WCS 417r, *P. fluorescens* Q8r-r, *P. putida*, KT2440, *Photorhabdus luminescens* subsp. laumondii TTO1, *P. luminescens* subsp. Luminescens, *P. temperata* subsp. khanii, *Xenorhabdus doucetiae*, *X. nematophila*, *X. szentirmaii*, *Serratia odorifera*, *Erwinia oleae*, *E. piriflorinigrans*, *E. pyrifoliae*, *Yersinia aldovae*, *Y. bercovieri*, *Y. mollaretii*, *Y. ruckeri*, *Dickeya dadantii* subsp. dadantii, *D. dadantii* subsp. dieffenbachiae, *D. solani*, *D. zaeae*, *Pectobacterium atrosepticum*, *P. betavasculorum*, *P. carotovorum* subsp. carotovorum, *P. carotovorum* subsp. odoriferum, *P. wasabiae*, *Aeromonas encheleia*, *A. molluscorum*, *A. piscicola*, *A. salmonicida* subsp. pectinolytica, and *A. salmonicida* subsp. *salmonicida*. In some embodiments, the donor and/or host cells are Alphaproteobacteria, Betaproteobacteria, Gammaproteobacteria, Deltaproteobacteria, Bacteroidetes, Cyanobacteria, Firmicutes, and Actinobacteria cells (e.g., *Arthrobacter*). In certain embodiments, the Gammaproteobacteria cells are *E. coli*.

[0067] In some embodiments, a donor cell of the present disclosure is a Gammaproteobacteria or Firmicutes cell. In some embodiments, a donor cell of the present disclosure is an *E. coli* cell. Any donor cell suitable for conjugation with a host cell of the present disclosure may be used. For example, *E. coli* cells are known to conjugate with many different types of bacteria (Goessweiner-Mohr, N., et al., *Conjugation in Gram-Positive Bacteria*, Microbiol Spectr, 2014. 2(4); Mazodier, P., R. Petter, and C. Thompson, *Intergeneric Conjugation between Escherichia-Coli and Streptomyces Species*, Journal of Bacteriology, 1989. 171(6): p. 3583-3585). Conjugation assays are known in the art, such as the exemplary assays described herein.

[0068] In some embodiments, the methods of gene and pathway integration described herein apply to host cells such as fungal, plant, or mammalian cells.

[0069] In some embodiments, a host cell of the present disclosure is an invertebrate cell, e.g., an insect cell. In some embodiments, a host cell of the present disclosure is a vertebrate cell. In some embodiments, a host cell of the present disclosure is a fungal or mammalian cell. In some embodiments, the host cell is an Ascomycota, Basidiomycota, Blastocladiomycota, Chytridiomycota, Glomeromycota, Microsporidia, or Neocallimastigomycota cell. In some embodiments, the host cell is a *Saccharomyces* sp., *Saccharomyces cerevisiae*, *Saccharomyces monacensis*, *Saccharomyces bayanus*, *Saccharomyces pastorianus*, *Saccharomyces carlsbergensis*, *Saccharomyces pombe*, *Trichoderma reesei*, *Neurospora crassa*, *Neurospora* sp., *Kluyveromyces* sp., *Kluyveromyces marxianus*, *Kluyveromyces lactis*, *Kluyveromyces fragilis*, *Pichia stipitis*,

Pichia pastoris, *Pichia* sp., *Sporotrichum thermophile*, *Candida shehatae*, *Candida tropicalis*, or *Neurospora crassa* cell. In some embodiments, a host cell of the present disclosure is a mammalian cell line (e.g., Chinese Hamster Ovary cells, HeLa cells, or 293 cells). In some embodiments, a host cell of the present disclosure is a human or rodent cell. In some embodiments, a host cell of the present disclosure is one that is produced using a method described herein.

[0070] Certain aspects of the present disclosure relate to methods for modulating expression of a gene of interest in a bacterial host cell. Any of the host cells described herein may be selected for use by one of skill in the art. The present disclosure provides methods and techniques that allow modified CRISPR/Cas9 systems to be used to repress or activate gene expression in a targeted way. These methods include the utilization of two distinct “landing pad” sites (e.g., a first site flanked by the first and second *lox* sites, and a second site flanked by the second and third *lox* sites), allowing for the integration of more sequence into the bacterial host chromosome.

[0071] It will be appreciated by one of skill in the art that the methods for using this platform to modulate expression of a gene of interest in a bacterial host cell are multi-step processes, and thus the steps can be accomplished in a variety of orders. In some embodiments, the methods include: providing a bacterial host cell comprising a donor sequence comprising: (i) a Cre recombinase coding sequence, wherein the Cre recombinase coding sequence is flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; and (ii) a first selectable marker coding sequence flanked by the second *lox* site and a third *lox* site, wherein the third *lox* site is different from the first and second *lox* sites, and wherein the donor sequence is integrated in a chromosome of the bacterial host cell; providing a plasmid comprising a catalytically dead Cas9 protein coding sequence and a second selectable marker coding sequence, wherein the catalytically dead Cas9 protein coding sequence and the second selectable marker are both flanked by the second *lox* site and the third *lox* site; introducing the plasmid into the bacterial host cell, wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the catalytically dead Cas9 protein coding sequence is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the second *lox* site of the plasmid and the second *lox* site of the donor sequence, and between the third *lox* site of the plasmid and the third *lox* site of the donor sequence; providing a second plasmid comprising a guide RNA sequence that targets a guide RNA target

sequence of the gene of interest and a third selectable marker coding sequence, wherein the guide RNA sequence and the third selectable marker are both flanked by the first *lox* site and the second *lox* site; and introducing the second plasmid into the bacterial host cell, wherein upon introduction of the second plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the guide RNA sequence is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the second plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence; wherein upon introduction of the second plasmid of the bacterial host cell, the catalytically dead Cas9 protein and guide RNA are expressed, form a complex, and bind the guide RNA target sequence of the gene of interest, thereby modulating expression of the gene of interest. In some embodiments, the methods include: providing a bacterial host cell comprising a donor sequence comprising: (i) a Cre recombinase coding sequence, wherein the Cre recombinase coding sequence is flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; and (ii) a first selectable marker coding sequence flanked by the second *lox* site and a third *lox* site, wherein the third *lox* site is different from the first and second *lox* sites, and wherein the donor sequence is integrated in a chromosome of the bacterial host cell; providing a plasmid comprising a guide RNA sequence that targets a guide RNA target sequence of the gene of interest and a second selectable marker coding sequence, wherein the guide RNA sequence and the second selectable marker are both flanked by the first *lox* site and the second *lox* site; and introducing the plasmid into the bacterial host cell, wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the guide RNA sequence is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the second plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence; providing a second plasmid comprising a catalytically dead Cas9 protein coding sequence and a third selectable marker coding sequence, wherein the catalytically dead Cas9 protein coding sequence and the third selectable marker are both flanked by the second *lox* site and the third *lox* site; introducing the second plasmid into the bacterial host cell, wherein upon introduction of the second plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the

catalytically dead Cas9 protein coding sequence is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence, and between the third *lox* site of the second plasmid and the third *lox* site of the donor sequence; wherein upon introduction of the second plasmid of the bacterial host cell, the catalytically dead Cas9 protein and guide RNA are expressed, form a complex, and bind the guide RNA target sequence of the gene of interest, thereby modulating expression of the gene of interest.

[0072] Moreover, if the dCas9 coding sequence and guide RNA are introduced in a single step (*e.g.*, in a single “landing pad” site flanked by a pair of *lox* sites), the other “landing pad” site can be used to integrate a gene or pathway of interest, as described herein. In some embodiments, the methods include: providing a bacterial host cell comprising a donor sequence comprising: (i) a Cre recombinase coding sequence, wherein the Cre recombinase coding sequence is flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; and (ii) a first selectable marker coding sequence flanked by the second *lox* site and a third *lox* site, wherein the third *lox* site is different from the first and second *lox* sites, and wherein the donor sequence is integrated in a chromosome of the bacterial host cell; providing a first plasmid comprising a catalytically dead Cas9 protein coding sequence, a guide RNA sequence that targets a guide RNA target sequence of the gene of interest, and a second selectable marker coding sequence, wherein the catalytically dead Cas9 protein coding sequence, the guide RNA sequence, and the second selectable marker are flanked by the second *lox* site and the third *lox* site; introducing the first plasmid into the bacterial host cell, wherein upon introduction of the first plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the catalytically dead Cas9 protein coding sequence and guide RNA sequence are integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the second *lox* site of the first plasmid and the second *lox* site of the donor sequence, and between the third *lox* site of the first plasmid and the third *lox* site of the donor sequence; providing a second plasmid comprising the gene of interest and a third selectable marker coding sequence, wherein the gene of interest and the third selectable marker are both flanked by the first *lox* site and the second *lox* site; and introducing the second plasmid into the bacterial host cell, wherein upon introduction of the second plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the gene of interest is integrated

into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the second plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence; wherein upon introduction of the second plasmid of the bacterial host cell, the catalytically dead Cas9 protein and guide RNA are expressed, form a complex, and bind the guide RNA target sequence of the gene of interest, thereby modulating expression of the gene of interest.

[0073] In some embodiments, the methods include: providing a bacterial host cell comprising a donor sequence comprising: (i) a Cre recombinase coding sequence, wherein the Cre recombinase coding sequence is flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; and (ii) a first selectable marker coding sequence flanked by the second *lox* site and a third *lox* site, wherein the third *lox* site is different from the first and second *lox* sites, and wherein the donor sequence is integrated in a chromosome of the bacterial host cell; providing a plasmid comprising the gene of interest and a second selectable marker coding sequence, wherein the gene of interest and the second selectable marker are both flanked by the first *lox* site and the second *lox* site; and introducing the plasmid into the bacterial host cell, wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the gene of interest is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the plasmid and the second *lox* site of the donor sequence; providing a second plasmid comprising a catalytically dead Cas9 protein coding sequence, a guide RNA sequence that targets a guide RNA target sequence of the gene of interest, and a third selectable marker coding sequence, wherein the catalytically dead Cas9 protein coding sequence, the guide RNA sequence, and the third selectable marker are flanked by the second *lox* site and the third *lox* site; introducing the second plasmid into the bacterial host cell, wherein upon introduction of the second plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the catalytically dead Cas9 protein coding sequence and guide RNA sequence are integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence, and between the third *lox* site of the second plasmid and the third *lox* site of the donor sequence; wherein upon introduction of the

second plasmid of the bacterial host cell, the catalytically dead Cas9 protein and guide RNA are expressed, form a complex, and bind the guide RNA target sequence of the gene of interest, thereby modulating expression of the gene of interest.

[0074] A variety of methods are contemplated for integrating the donor sequence into the chromosome of the bacterial host cell. In some embodiments, the donor sequence is integrated into the chromosome of the bacterial host cell by: providing a bacterial donor cell comprising a donor plasmid, the donor plasmid comprising: (i) a transposase coding sequence; and (ii) the donor sequence, wherein the donor sequence is flanked by inverted repeats recognized by the transposase; and introducing the donor plasmid into the bacterial host cell by conjugation with the bacterial donor cell, wherein upon introduction of the donor plasmid into the bacterial host cell, transposase is expressed from the transposase coding sequence, and the donor sequence is integrated into the chromosome of the bacterial host cell between the inverted repeats by the transposase. In some embodiments, the donor sequence is integrated into the chromosome of the bacterial host cell by: providing a bacterial donor cell comprising a donor plasmid, the donor plasmid comprising: (i) an integrase coding sequence; and (ii) the donor sequence, wherein the donor sequence contains an attP site; and introducing the donor plasmid into the bacterial host cell by conjugation with the bacterial donor cell, wherein upon introduction of the donor plasmid into the bacterial host cell, integrase is expressed from the integrase coding sequence, and the donor sequence is integrated into the chromosome of the bacterial host cell mediated through the recombination between the attP site and an attB site on the chromosome of the bacterial host cell (for further description of the integrase/attP/attB system, *see, e.g.,* Hong, Y. and Hondalus, M.K. (2008) *FEBS Microbiol. Lett.* 287:63-68). In some embodiments, the donor sequence is integrated into the chromosome of the bacterial host cell by homologous recombination. In some embodiments, the donor sequence is integrated into the chromosome of the bacterial host cell by: providing a donor plasmid, the donor plasmid comprising the donor sequence, wherein the donor sequence is flanked by inverted repeats recognized by a transposase; and introducing the donor plasmid into the bacterial host cell in the presence of the transposase, wherein upon introduction of the donor plasmid into the bacterial host cell, the donor sequence is integrated into the chromosome of the bacterial host cell between the inverted repeats by the transposase (*e.g., in vitro* transposition).

[0075] In some embodiments, at least one of the first and the second plasmid is introduced into the host cell via conjugation. In some embodiments, at least one of the first and the second plasmid is introduced into the host cell via electroporation.

[0076] As known in the art, CRISPR-Cas9 refers to a two component ribonucleoprotein complex with guide RNA and a Cas9 endonuclease. CRISPR refers to the Clustered Regularly Interspaced Short Palindromic Repeats type II system used by bacteria and archaea for adaptive defense. This system enables bacteria and archaea to detect and silence foreign nucleic acids, *e.g.*, from viruses or plasmids, in a sequence-specific manner (Jinek, M., *et al.* (2012) *Science* 337(6096):816-21). In type II systems, guide RNA interacts with Cas9 and directs the nuclease activity of Cas9 to target DNA sequences complementary to those present in the guide RNA. Guide RNA base pairs with complementary sequence in target DNA. Cas9 nuclease activity then generates a double-stranded break in the target DNA.

[0077] In bacteria, Cas9 polypeptides bind to two different guide RNAs acting in concert: a CRISPR RNA (crRNA) and a trans-activating crRNA (tracrRNA). The crRNA and tracrRNA ribonucleotides base pair and form a structure required for the Cas9-mediated cleavage of target DNA. However, it has recently been demonstrated that a single guide RNA (sgRNA) may be engineered to form the crRNA:tracrRNA structure and direct Cas9-mediated cleavage of target DNA (Jinek, M., *et al.* (2012) *Science* 337(6096):816-21). Moreover, since the specificity of Cas9 nuclease activity is determined by the guide RNA, the CRISPR-Cas9 system has been explored as a tool to direct double-stranded DNA breaks in heterologous cells, enabling customizable genome editing (Mali, P., *et al.* (2013) *Science* 339(6121):823-6).

[0078] The CRISPR/Cas9 system has been engineered to promote repression or activation of gene transcription. For example, a CRISPRi system has been developed to repress gene transcription through a catalytically dead Cas9 (dCas9) protein/guide RNA complex (*see* Qi, L.S. *et al.* Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. *Cell*, 2013. **152**: 1173–1183). In some embodiments, a catalytically dead Cas9 (dCas9) protein lacks endonucleolytic activity (*e.g.*, nuclease and/or nickase activities) but retains the ability to bind DNA in a site-specific manner targeted by the complexed guide RNA. In some embodiments, the catalytically dead Cas9 (dCas9) protein comprises mutations corresponding to D10A and H840A of *S. pyogenes* Cas9. Catalytically dead Cas9 proteins have also been used to activate gene expression by introducing a transcriptional activator protein such as the *E. coli* RNA polymerase omega subunit (*see* Bikard, D. *et al.* Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas9 system. *Nucleic Acids Res*, 2013. **41**: 7429–7437). For example, a transcriptional activator protein can be fused to the

N- or C-terminus of a catalytically dead Cas9 protein (thus generating aCas9). One of skill in the art can suitably select a transcriptional activator protein for use in a variety of bacterial host cells.

[0079] In some embodiments, the catalytically dead Cas9 protein/guide RNA complex mediate gene repression, *e.g.*, by binding a guide RNA target sequence of the gene of interest and repressing expression of the gene of interest. In some embodiments, the guide RNA target sequence regulates expression of the gene of interest endogenously, *e.g.*, in the absence of the catalytically dead Cas9 protein/guide RNA complex. In some embodiments, the guide RNA target sequence does not regulate expression of the gene of interest endogenously, but is in sufficient proximity to endogenous regulatory or coding sequences such that binding of the catalytically dead Cas9 protein/guide RNA complex represses gene transcription, *e.g.*, by preventing binding of a transcription factor and/or RNA polymerase.

[0080] In some embodiments, the catalytically dead Cas9 protein is fused with a transcriptional activator protein, and the catalytically dead Cas9:transcriptional activator fusion protein/guide RNA complex binds the guide RNA target sequence of the gene of interest and promotes expression of the gene of interest. In some embodiments, the guide RNA target sequence regulates expression of the gene of interest endogenously, *e.g.*, in the absence of the catalytically dead Cas9 protein/guide RNA complex. In some embodiments, the guide RNA target sequence does not regulate expression of the gene of interest endogenously, but is in sufficient proximity to endogenous regulatory or coding sequences such that binding of the catalytically dead Cas9:transcriptional activator fusion protein/guide RNA complex activates gene transcription, *e.g.*, through the transcriptional activator.

[0081] A variety of *lox* sites are described herein. In some embodiments, the first *lox* site is a *loxP2272* site. In some embodiments, the second *lox* site is a *loxPwt* site. In some embodiments, the third *lox* site is a *loxP5171* site. In some embodiments, the first, second, and third *lox* sites are each different and each selected from *loxP*, *lox5171*, *lox2272*, *lox511*, *lox71*, *lox66*, *M2*, *M3*, *M7*, or *M11*.

[0082] The space between each pair of *lox* sites (*e.g.*, between the first and second *lox* sites, and between the second and third *lox* sites) can be thought of as a “landing pad” for integrating one or more genetic components. In some embodiments, the dCas9 or aCas9 coding sequence is integrated into one landing pad, and the guide RNA is integrated into the other landing pad. In some embodiments, the dCas9 or aCas9 and the guide RNA are integrated into a single landing pad, and a gene or pathway of interest is integrated into the

other landing pad, *e.g.*, as described herein. This system is thought to allow for the integration of large sequences into the host chromosome, *e.g.*, up to about 400kb combined from the use of both landing pad sites.

[0083] A variety of Cas9 proteins are known and can be selected by one of skill in the art. In some embodiments, a Cas9 protein refers to a Cas9 protein derived from *Streptococcus pyogenes*, *e.g.*, a protein having the sequence of the Swiss-Prot accession Q99ZW2. In some embodiments, a Cas9 protein refers to a Cas9 protein derived from *Streptococcus thermophilus*, *e.g.*, a protein having the sequence of the Swiss-Prot accession G3ECR1. In some embodiments, a Cas9 protein refers to a Cas9 protein derived from a bacterial species within the genus *Streptococcus*. In some embodiments, a Cas9 protein refers to a Cas9 protein derived from a bacterial species within the genus *Neisseria* (*e.g.*, GenBank accession number YP_003082577). In some embodiments, a Cas9 protein refers to a Cas9 polypeptide derived from a bacterial species within the genus *Treponema* (*e.g.*, GenBank accession number EMB41078). In some embodiments, a Cas9 protein refers to a protein with Cas9 activity as described above derived from a bacterial or archaeal species. Methods of identifying a Cas9 protein are known in the art. For example, a putative Cas9 protein may be complexed with crRNA and tracrRNA or sgRNA and incubated with DNA bearing a target DNA sequence and a PAM motif, as described in Jinek, M., *et al.* (2012) *Science* 337(6096):816-21.

[0084] In some embodiments, the guide RNA comprises a single guide RNA (sgRNA) that forms a crRNA:tracrRNA structure. In some embodiments, the guide RNA comprises a separate CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA). In some embodiments, the guide target sequence is complementary to the guide RNA target sequence. Any desired target DNA sequence of interest may be targeted by a guide RNA target sequence. Without wishing to be bound to theory, it is thought that the only requirement for a target DNA sequence is the presence of a protospacer-adjacent motif (PAM) adjacent to the sequence complementary to the sgRNA target sequence (Mali, P., *et al.* (2013) *Science* 339(6121):823-6). Different Cas9 complexes are known to have different PAM motifs. For example, Cas9 from *Streptococcus pyogenes* has a GG dinucleotide PAM motif. For further examples, the PAM motif of *N. meningitidis* Cas9 is GATT, the PAM motif of *S. thermophilus* Cas9 is AGAA, and the PAM motif of *T. denticola* Cas9 is AAAAC.

[0085] In some embodiments, the catalytically dead Cas9 protein or catalytically dead Cas9:transcriptional activator fusion protein coding sequence is operably linked to a

promoter. In some embodiments, the promoter is a constitutive promoter. In some embodiments, the promoter is an inducible or repressible promoter (*e.g.*, can be induced or repressed by an external or internal cue, such as a metabolite). This allows control of the Cas9 protein expression. A variety of promoters are known in the art and described herein.

[0086] In some embodiments, the methods described *supra* are used to activate or repress expression of one or more genes of interest, *e.g.*, a single gene, operon, or one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more genes of interest. In some embodiments, the gene(s) of interest encode(s) one or more enzymes. In some embodiments, the one or more enzymes catalyze one or more steps in synthesis of a polysaccharide, lipopolysaccharide, nonribosomal peptide (NRP), polyketide, siderophore, terpene, lantipeptide, bacteriocin, homoserine lactone, butyrolactone, ectoine, thiopeptide, phenazine, terpenoid, alkaloid, flavonoid, amino acid, biofuel, commodity chemical, vitamin, or fatty acid.

Cre-lox Recombination System

[0087] In certain embodiments of the present disclosure related to use of the Cre-lox recombination system. As used herein the expression “lox site” means a nucleotide sequence at which the Cre recombinase can catalyze a site-specific recombination. In some embodiments, the lox site is *loxP*, *lox5171*, *lox2272*, *lox511*, *lox71*, *lox66*, *M2*, *M3*, *M7*, or *M11*. In some embodiments, the *loxP* site has the sequence

ATAACTTCGTATAGCATACATTATACGAAGTTAT (SEQ ID NO.:1) (Langer et al, *Nucleic Acids Research*, 30(14):3067-3077 (2002)). In some embodiments, the *lox5171* site has the sequence ATTACTTCGTATAATGTGTACTATACGAAGTTAT (SEQ ID NO:2) (Parrish et al., *J. Biomed. Biotech.* 2011:924068 (2010)). In some embodiments, various mutated sequences of lox sites can also be used so long as such sequences remain recognizable by the Cre recombinase (Lee & Saito, *Gene*, 216(1):55-65 (1998)). In some embodiments, the lox site comprises *LoxP* mutant 11, 12, 21, 22, 23, 31, 32, 33, 41, 42, 43, 51, 52, 53, 61, 62, 63, 71, 73, 81, 82, 63, 2171, 2271, 2371, 3171, 3271, 4171, 4271, 4371, 5171, 5271, 5371, 2172, 2272, 2372, 3172, 3272, 3372, 4172, 4272, 4372, 5172, 5272, 5372, 2173, 2273, 3373, 4373, or 5373 described in Lee & Saito. In some embodiments, the lox site comprises *LoxP* mutant 39, 33, 9, 28, 14, 29, 592, 64, 37, 25, 4, 10, 412, 7, 512, 17, 6, 21, 3, 23, 42, 20, 57, 56, 55, 38, 8, 53, 49, 51, 41, 47, 6, 30, 48, 59, 24, 19, 492, 206, 270, 271, 268, 267, 207, 269, 265, 202, 203, 208, 266, 204, 201, or 205 described in Sheren et al. (Sheren et al, *NAR*, 35(16):5464-73 (2007)). In some embodiments the lox site

comprises *LoxP* mutant OW71, JT1, JT4, JT5, JT12, JT15, JT21, JT44, JT47, JT510, JT520, JT530, JT540, OW6, JTZ2, JTZ5, JTZ10, or JTZ17 as described in Thompson et al. (Thomson et al., *Genesis*, 36(3):162-7 (2003)). In some embodiments the *lox* site comprises the Lox66, Lox71, loxJTZ1, loxJTZ71, loxKR1, loxKR2, loxKR3, or loxKR4 as described in Araki et al. (Araki et al, *BMC Biotechnology*, 10:29 (2010)).

[0088] As described throughout the present disclosure (see also **FIGS. 3B, 8B, 11B, 13B, and 15**), Cre-*lox* recombination may be used to insert a gene or pathway of interest into a host cell of the present disclosure (*e.g.*, a host cell bearing an integrated landing pad as described herein). In some embodiments, Cre-*lox* recombination refers to recombinase-mediated cassette exchange (RMCE) in which a genetic sequence from a host cell between two flanking *lox* sites is swapped with a genetic sequence from a donor cell or plasmid. Advantageously, this may be used to introduce gene(s) or pathway(s) of interest into a host cell bearing these *lox* sites. In some embodiments, the flanking *lox* sites may be heterospecific (*e.g.*, able to recombine with each other at lesser efficiency than with other *lox* sites of the same type or specificity). This allows for RMCE, rather than deletion of genetic material between the *lox* sites.

[0089] In some embodiments, the first plasmid comprises a donor sequence, wherein the donor sequence comprises a first and second *lox* site, wherein the *lox* sites are different. In some embodiments, the second plasmid comprises a donor sequence, wherein the donor sequence comprises a first and second *lox* site, wherein the *lox* sites are different. In some embodiments, the first *lox* site of the second plasmid and the first *lox* site of the donor sequence are the same *lox* site. In some embodiments, the second *lox* site of the second plasmid and the second *lox* site of the donor sequence are heterospecific to the first *lox* site of the second plasmid and the first *lox* site of the donor sequence, and the second *lox* site of the second plasmid and the second *lox* site of the donor sequence are the same *lox* site. In some embodiments the first *lox* site of the first plasmid and the first *lox* site of the second plasmid are *LoxP*. In some embodiments, the second *lox* site of the first plasmid and the second *lox* site of the second plasmid are *Lox5171*. In some embodiments, the first *lox* site of the first plasmid and the first *lox* site of the second plasmid are *LoxP* and the second *lox* site of the first plasmid and the second *lox* site of the second plasmid are *Lox5171*.

[0090] As described herein, using the Cre recombination pathway to integrate the gene or pathway of interest allows for more efficient recombination of larger pathways, as compared to other methods such as homologous recombination or phage transduction. In some embodiments, the first and the second *lox* sites flank a sequence of greater than about

7kb, greater than about 10kb, greater than about 15kb, greater than about 20kb, greater than about 25kb, greater than about 30kb, greater than about 35kb, greater than about 40kb, greater than about 45kb, greater than about 50kb, greater than about 55kb, greater than about 60kb, greater than about 65kb, greater than about 70kb, greater than about 75kb, greater than about 80kb, greater than about 85kb, greater than about 90kb, greater than about 95kb, greater than about 100kb, greater than about 110kb, greater than about 120kb, greater than about 130kb, greater than about 140kb, or greater than about 150kb. In some embodiments, the first and the second *lox* sites flank a sequence of less than about 200kb, less than about 190kb, less than about 180kb, less than about 170kb, less than about 160kb, less than about 150kb, less than about 140kb, less than about 130kb, less than about 120kb, less than about 110kb, less than about 100kb, less than about 90kb, less than about 80kb, less than about 70kb, or less than about 60kb. In some embodiments, the first and the second *lox* sites flank a sequence greater than about any of the following sizes (in kb): 5, 7, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, or 150. In some embodiments, the first and the second *lox* sites flank a sequence less than about any of the following sizes (in kb): 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 95, 90, 85, 80, 75, 70, 65, 60, 59, 55, 50, 45, 40, 35, 30, 25, or 20. That is, in some embodiments, the first and the second *lox* sites flank a sequence having an upper limit of 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 95, 90, 85, 80, 75, 70, 65, 60, 59, 55, 50, 45, 40, 35, 30, 25, or 20kb and an independently selected lower limit of 5, 7, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, or 150kb, wherein the lower limit is less than the upper limit.

[0091] In some embodiments, the Cre coding sequence has the coding sequence of bacteriophage P1 recombinase or various mutations of this sequence such as described in (*e.g.*, Wierzbicki et al., *J. Mol. Biol.*, 195, 785-794 (1987); Abremski et al., *J. Mol. Biol.*, 202, 59-66 (1988); Abremski et al., *J. Mol. Biol.*, 184, 211-20 (1988); Abremski et al., *Protein Engineering*, 5, 87-91 (1992) Hoess et al., *Proc. Natl. Acad. Sci.*, 84, 6840-6844 (1987); Sternberg et al., *J. Mol. Biol.*, 187, 197-212 (1986)). Further mutations of this Cre coding sequence may be employed so long as variant proteins resulting from such mutations are capable of effecting recombination at *lox* sites.

[0092] In certain embodiments, the gene encoding Cre recombinase is provided on a first plasmid of the present disclosure (*e.g.*, a plasmid bearing a donor sequence flanked by inverted repeats and optionally a transposase coding sequence). In some embodiments, the gene encoding Cre recombinase is provided on a second plasmid of the present disclosure

(*e.g.*, a plasmid bearing a gene of interest). In some embodiments, the gene encoding Cre recombinase is provided on the host chromosome. In some embodiments, the gene encoding Cre recombinase is provided on the host chromosome between flanking *lox* sites. In some embodiments, the gene encoding Cre recombinase is provided under the control of constitutive, inducible, or developmentally-regulated promoters. In some embodiments, the Cre recombinase is under the control of the LacUV5 promoter. In some embodiments, the gene encoding Cre recombinase is under control of the Cas9 promoter. In some embodiments, the gene encoding Cre recombinase is under any promoter that functions in the host cell.

Transposition Systems

[0093] Certain aspects of the present disclosure relate to use of transposition as a means to introduce DNA into a host cell chromosome.

[0094] Transposons or transposable elements typically include a short piece of nucleic acid bounded by repeat sequences. Transposase enzymes facilitate the insertion of the transposon nucleic acid into DNA sequences. Various transposon systems (*e.g.*, inverted repeat sequences and a transposase that acts thereupon) are known in the art and can be used in conjunction with the methods described herein. DNA transposons generally move by a cut-and-paste mechanism in which the transposon is excised from one location and reintegrated elsewhere. Most DNA transposons move through a non-replicative mechanism. DNA transposons consist of a transposase gene that is flanked by two Inverted Repeats (IRs). The transposase recognizes these IRs to perform the excision of the transposon DNA body, which is inserted into a new genomic location. Moreover, DNA transposons are generally not dependent on host factors to mediate their mobility. Thus DNA transposons are particularly useful to introduce DNA sequences across a wide array of host cells. (Lopez and Garcia-Perez, *Curr Genomics*. (2): 115–128 (2010). When used for genome engineering, the transposase gene can be provided in trans, outside of the inverted repeats that flank the transposable element, which prevents the transposon from excising from the host chromosome once it has integrated.

[0095] In some embodiments, the transposase can function across a wide range of host cells. In some embodiments, the transposase is a mariner transposase. The mariner super family of transposases, were originally discovered in *drosophila* but can function across a wide range of host cells, making them suitable for the claimed methods. (Lampe et al., *Genetics* 149:179-187 (1998); Lampe et al., *EMBO J.* 15:5470-5479 (1996)). For example,

mariner transposons have also been found fungi, plants, fish and mammals. Lopez and Garcia-Perez, *Curr Genomics*, (2): 115–128 (2010). The most prominent member of the mariner transposon family is *Sleeping Beauty*, however other members which can be used are *Frog Prince*, (isolated from the Northern Leopard frog) *Minos* (isolated from *Drosophila hydei*), *Himar1* (isolated from *Haematobia irritans*), and *Mboumar-9* (isolated from ant).

[0096] Other exemplary DNA transposases that can be used include the *piggyBac* transposon family, which has been found in plants, fungi, and animals, including humans and hAT, transposons which have been isolated from eukaryotes. In some embodiments, the transposase is Tn1, Tn2, Tn3, Tn4, Tn6, Tn7, Tn8, Tn9, Tn10 or Tn917.

Genetic Markers

[0097] Certain aspects of the present invention related to genetic markers that allow selection of host or donor cells that have a desired DNA segment. In some embodiments, the genetic marker is a positive selection marker that confers a selective advantage to the host organisms. Examples of positive markers are genes that complement a metabolic defect (autotrophic markers) and antibiotic resistance markers.

[0098] In some embodiments, the genetic marker is an antibiotic resistance marker such as Apramycin resistance, Ampicillin resistance, Kanamycin resistance, Spectinomycin resistance, Tetracyclin resistance, Neomycin resistance, Chloramphenicol resistance, Gentamycin resistance, Erythromycin resistance, Carbenicillin resistance, Actinomycin D resistance, Neomycin resistance, Polymyxin resistance, Zeocin resistance and Streptomycin resistance. In some embodiments, the genetic marker includes a coding sequence of an antibiotic resistance protein (*e.g.*, a beta-lactamase for certain Ampicillin resistance markers) and a promoter or enhancer element that drives expression of the coding sequence in a host cell of the present disclosure. In some embodiments, a host cell of the present disclosure is grown under conditions in which an antibiotic resistance marker is expressed and confers resistance to the host cell, thereby selected for the host cell with a successful integration of the marker. Exemplary culture conditions and media are described herein.

[0099] In some embodiments, the genetic marker is an auxotrophic marker, such that marker complements a nutritional mutation in the host cell. In some embodiments, the auxotrophic marker is a gene involved in vitamin, amino acid, fatty acid synthesis, or carbohydrate metabolism; suitable auxotrophic markers for these nutrients are well known in the art. In some embodiments, the auxotrophic marker is a gene for synthesizing an amino acid. In some embodiments, the amino acid is any of the 20 essential amino acids.

In some embodiments, the auxotrophic marker is a gene for synthesizing glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, methionine, asparagine, glutamine, lysine, arginine, histidine, aspartate or glutamate. In some embodiments, the auxotrophic marker is a gene for synthesizing adenosine, biotin, thiamine, leucine, glucose, lactose, or maltose. In some embodiments, a host cell of the present disclosure is grown under conditions in which an auxotrophic resistance marker is expressed in an environment or medium lacking the corresponding nutrient and confers growth to the host cell (lacking an endogenous ability to produce the nutrient), thereby selected for the host cell with a successful integration of the marker. Exemplary culture conditions and media are described herein.

[0100] In some embodiments, the genetic marker is a screenable marker which allows distinction between cells with and without the desired DNA. In some embodiments, the screenable marker is beta galactosidase (lacZ), which results in blue colonies on X-gal plates. In some embodiments, the screenable marker is a fluorescent marker, such as GFP, YFP, or RFP.

[0101] In some embodiments, the selectable marker is the *ura3* gene from yeast which can function as both a positive and negative selectable marker. The *ura3* gene is required for uracil biosynthesis and can complement *ura3* mutants that are auxotrophic for uracil (positive selection). The enzyme *ura3* also converts 5-fluoroorotic acid (5FOA) into the toxic compound 5-fluorouracil, so any cells carrying the *URA3* gene will be killed in the presence of 5FOA (negative selection).

[0102] In some embodiments, the first and second plasmids comprise different selectable markers located between the *lox* sites to enable counter selection. In some embodiments, the first plasmid comprises kanamycin resistance between the *lox* sites and the second plasmid comprises apramycin resistance between the *lox* sites. In some embodiments, the first plasmid comprises apramycin resistance between the *lox* sites and the second plasmid comprises kanamycin resistance between the *lox* sites.

Promoters

[0103] In some embodiments, the gene of interest, transposase, Cre recombinase, T7 RNA polymerase, and antibiotic resistance genes are under control of one or more promoters. “Under the control” refers to a recombinant nucleic acid that is operably linked to a control sequence, enhancer, or promoter. The term “operably linked” as used herein refers to a configuration in which a control sequence, enhancer, or promoter is placed at an appropriate

position relative to the coding sequence of the nucleic acid sequence such that the control sequence, enhancer, or promoter directs the expression of a polypeptide.

[0104] “Promoter” is used herein to refer to any nucleic acid sequence that regulates the initiation of transcription for a particular polypeptide-encoding nucleic acid under its control. A promoter does not typically include nucleic acids that are transcribed, but it rather serves to coordinate the assembly of components that initiate the transcription of other nucleic acid sequences under its control. A promoter may further serve to limit this assembly and subsequent transcription to specific prerequisite conditions. Prerequisite conditions may include expression in response to one or more environmental, temporal, or developmental cues; these cues may be from outside stimuli or internal functions of the cell. Bacterial and fungal cells possess a multitude of proteins that sense external or internal conditions and initiate signaling cascades ending in the binding of proteins to specific promoters and subsequent initiation of transcription of nucleic acid(s) under the control of the promoters. When transcription of a nucleic acid(s) is actively occurring downstream of a promoter, the promoter can be said to “drive” expression of the nucleic acid(s). A promoter minimally includes the genetic elements necessary for the initiation of transcription, and may further include one or more genetic elements that serve to specify the prerequisite conditions for transcriptional initiation. A promoter may be encoded by the endogenous genome of a host cell, or it may be introduced as part of a recombinant, engineered polynucleotide. A promoter sequence may be taken from one host species and used to drive expression of a gene in a host cell of a different species. A promoter sequence may also be artificially designed for a particular mode of expression in a particular species, through random mutation or rational design. In recombinant engineering applications, specific promoters are used to express a recombinant gene under a desired set of physiological or temporal conditions or to modulate the amount of expression of a recombinant nucleic acid. In some embodiments, the promoters described herein are functional in a wide range of host cells.

[0105] In some embodiments, the gene of interest, transposase, Cre recombinase, and/or antibiotic resistance genes are under control of one or more constitutive promoters. In some embodiments, a constitutive promoter is defined herein as a promoter that drives the expression of nucleic acid(s) continuously and without interruption in response to internal or external cues. Constitutive promoters are commonly used in recombinant engineering to ensure continuous expression of desired recombinant nucleic acid(s). Constitutive promoters often result in a robust amount of nucleic acid expression, and, as such, are used in many

recombinant engineering applications to achieve a high level of recombinant protein and enzymatic activity.

[0106] Many constitutive promoters are known and characterized in the art. Exemplary bacterial constitutive promoters include without limitation the *E. coli* promoters P_{spc}, P_{bla}, P_{RNAI}, P_{RNAII}, P₁ and P₂ from *rrnB*, and the lambda phage promoter PL (Liang, S.T. et al. *J Mol. Biol.* 292(1):19-37 (1999)). In some embodiments, the constitutive promoter is functional in a wide range of host cells. In some embodiments, the constitutive promoter is the Cas9 promoter.

[0107] In some embodiments, the gene of interest, transposase, Cre recombinase, and/or antibiotic resistance genes are expressed under the control of an inducible promoter. An inducible promoter is defined herein as a promoter that drives the expression of nucleic acid(s) selectively and reliably in response to a specific stimulus. An ideal inducible promoter will drive no nucleic acid expression in the absence of its specific stimulus but drive robust nucleic acid expression rapidly upon exposure to its specific stimulus. Additionally, some inducible promoters induce a graded level of expression that is tightly correlated with the amount of stimulus received. Stimuli for known inducible promoters include, for example, heat shock, exogenous compounds (*e.g.*, a sugar, metal, drug, or phosphate), salts or osmotic shock, oxygen, and biological stimuli (*e.g.*, a growth factor or pheromone).

[0108] Inducible promoters are often used in recombinant engineering applications to limit the expression of recombinant nucleic acid(s) to desired circumstances. For example, since high levels of recombinant protein expression may sometimes slow the growth of a host cell, the host cell may be grown in the absence of recombinant nucleic acid expression, and then the promoter may be induced when the host cells have reached a desired density. Many inducible promoters are known and characterized in the art. Exemplary bacterial inducible promoters include without limitation the *E. coli* promoters P_{lac}, P_{trp}, P_{tac}, P_{T7}, P_{BAD}, and P_{lacUV5} (Nocadello, S. and Swennen, E.F. *Microb Cell Fact*, 11:3 (2012)). In some preferred embodiments, the inducible promoter is a promoter that functions in a wide range of host cells. Inducible promoters that functional in a wide variety of host bacterial and yeast cells are well known in the art.

[0109] In some embodiments, a genetic element of the present disclosure (*e.g.*, a donor sequence) comprises a coding sequence for a protein that promotes sequence-specific gene transcription. In certain embodiments, as illustrated in **FIG. 8B**, the coding sequence for the protein that promotes sequence-specific gene transcription is flanked by inverted repeats but

lox sites. A protein may promote sequence-specific gene transcription downstream of a promoter of the present disclosure. In some embodiments, the protein is a transcription factor active in a host cell of the present disclosure. In some embodiments, the protein is an RNA polymerase, *e.g.*, a sequence-specific RNA polymerase.

[0110] T7 RNA polymerase is known in the art as an RNA polymerase that catalyzes transcription downstream of a specific DNA sequence, *e.g.*, the T7 RNA polymerase promoter. In some embodiments, an inducible promoter of the present disclosure is the T7 RNA polymerase promoter. In some embodiments, the T7 RNA polymerase promoter is TAATCGACTCACTATG (SEQ ID NO:3). Advantageously, a sequence-specific RNA polymerase allows for sequence-directed transcription in nearly any host cell, since the sequence recognition and transcription machinery are the same modular unit (*e.g.*, T7 RNA polymerase).

[0111] In some embodiments, a Cre recombinase coding sequence of the present disclosure is under control of a promoter that is functional in a wide range of hosts. One of skill in the art will recognize and be able to identify suitable promoters, based upon the desired host, for example by conducting transcriptome analysis of the desired host to identify functional promoters. In some embodiments, the Cre recombinase gene is under control of the Cas9 promoter. In some embodiments, the Cre recombinase gene is under the control of the T7 RNA polymerase promoter.

[0112] In some embodiments, the gene or pathway of interest is under the control of an inducible promoter. In some embodiments the gene or pathway of interest is under the control of universal promoter that functions in a wide range of host cells. In some embodiments, the gene or pathway of interest is under control of a sequence-specific RNA polymerase promoter. In some embodiments, the inducible promoter is controlled by a transcription factor. In some embodiments, the gene or pathway of interest is under the control of the T7 RNA polymerase promoter.

II. Vectors

[0113] Certain aspects of the present disclosure relate to vectors. In some embodiments, a vector of the present disclosure may be used, *inter alia*, to integrate one or more genes or pathways of interest into a chromosome of a host or donor cell. In some embodiments, the vector may be used to integrate one or more genes or pathways of interest into a chromosome of any of the cells described herein.

[0114] As used herein, the term “vector” may refer to a polynucleotide construct designed to introduce and/or express nucleic acids in one or more cell types. In some embodiments, the vector may be a plasmid. Typically plasmids include one or more selectable markers as described herein and an origin of replication. In some embodiments, the origin of replication is the pMB1 origin, the pBR322 origin, the ColE1 origin, the p15A origin, the pSC101 or the R6K origin of replication. In some embodiments, the origin of replication is the R6K origin.

[0115] A vector of the present disclosure may include one or more of the exemplary genetic elements described above. In some embodiments, a vector includes a donor sequence which is a sequence flanked by inverted repeats that can be integrated into a host chromosome. In some embodiments, the inverted repeats are recognized by a transposase. In some embodiments, the inverted repeats are recognized by the mariner transposase. In some embodiments, the donor sequence includes a selectable marker. In some embodiments, the donor sequence includes a first *lox* site and a second *lox* site. In some embodiments the donor sequence includes two different *lox* sites. In some embodiments, the donor sequence includes a selectable marker and a Cre gene. In some embodiments, the donor sequence includes a selectable marker, a Cre gene and a T7 RNA polymerase gene.

[0116] In some embodiments, the vector includes any of the transposase coding sequences described herein. In some embodiments, the transposase coding sequence encodes a mariner transposase. In some embodiments, the vector is a conjugative plasmid. In some embodiments, the vector has an origin of transfer (*oriT*). In some embodiments, the vector comprises one or more genes or pathways of interest as described herein. In some embodiments, the one or more genes or pathways of interest are flanked by two *lox* sites. In some embodiments, the vector comprises one or more genes under the control of a promoter described herein.

[0117] For illustrative purposes, some non-limiting examples of vectors of the present disclosure are provided below. However, it is to be appreciated that any or all of the exemplary features described below may be combined in a vector without departing from the scope of the present disclosure, and additional modifications or features known in the art are possible.

[0118] In some embodiments, the vector includes a transposase gene and a donor DNA sequence flanked by inverted repeats comprising a first and second *lox* site, wherein the first and second *lox* sites are different. In some embodiments the inverted repeats are mariner repeats. In some embodiments, the vector includes a *LoxP* site and a *Lox5171* site. In some embodiments, the vector comprises a donor DNA segment further comprising a selectable

marker located between the two *lox* sites. In some embodiments, the selectable marker is the kanamycin resistance gene. In some embodiments, the vector includes a donor DNA sequence comprising a T7 RNA polymerase gene under control of a promoter that functions in the host cell. In some embodiments, the vector includes a transposase. In some embodiments, the vector includes a transposase located at a position other than in the donor DNA sequence. In some embodiments, the vector is a conjugative vector. In some embodiments, the vector comprises an origin of transfer. In some embodiments, the vector is a medium copy plasmid. In some embodiments, the vector comprises the R6K origin. An exemplary vector with these features is illustrated in **FIG. 3A**.

[0119] In some embodiments, the vector includes a donor sequence flanked by inverted repeats comprising a T7 RNA polymerase gene, a *LacI* gene, an antibiotic resistance gene, a *Cre* gene, and first and second *lox* sites. In some embodiments, the vector includes a *LoxP* site and a *Lox5171* site. In some embodiments, the antibiotic resistance gene and *Cre* gene are located between the two *lox* sites. In some embodiments, the antibiotic resistance gene is kanamycin resistance. In some embodiments, the *Cre* gene is under control of a promoter that functions in the host cell. In some embodiments, the *Cre* gene is under control of the *Cas9* promoter. In some embodiments, the vector includes T7 RNA polymerase under control of the *LacUV5* promoter. In some embodiments, the vector includes an origin of transfer and a transposase gene. In some embodiments, the transposase gene is located in the vector other than in the donor DNA sequence. In some embodiments, the vector is a single copy plasmid. An exemplary vector with these features is illustrated in **FIG. 8A**.

[0120] In some embodiments, the vector comprises one or more genes or pathways of interest. In some embodiments, the vector comprises one or more genes or pathways of interest located between a first and second *lox* site. In some embodiments, the vector comprises a *LoxP* site and a *Lox5171* site. In some embodiments, the vector comprises a selectable marker and one or more genes or pathways of interest located between a first and second *lox* site. In some embodiments, the selectable marker is apramycin. In some embodiments, the vector comprises one or more genes or pathways of interest under the control of an inducible promoter. In some embodiments the vector comprises the one or more genes or pathways of interest under the control of the T7 promoter. In some embodiments the genes or pathways of interest include the bacterial luciferase operon *luxCDABE*. In some embodiments the gene or pathway of interest is a phenazine pathway. In some embodiments the gene or pathway of interest is the phenazine 1-carboxylic acid (PCA) pathway. In some embodiments, the pathway of interest is the phenazine 1,6-

dicarboxylic acid (PDC) pathway. In some embodiments, the vector includes a LacI gene and a Cre gene. In some embodiments, the LacI and Cre genes are under control of the LacUV5 promoter. Exemplary vectors with these features are illustrated in **FIGS. 3B** and **8B**. In some embodiments, the vector includes one or more genes or pathways of interest and a selectable marker located between a first and second *lox* site and does not comprise LacI or Cre genes. In some embodiments, the vector is a medium copy plasmid. In some embodiments, the vector includes the R6K replication origin. Exemplary vectors with these features are illustrated in **FIG. 11B**.

[0121] In some embodiments, the vector includes a transposase coding sequence and a donor sequence, wherein the donor sequence is flanked by inverted repeats recognized by the transposase, wherein the donor sequence includes a selectable marker coding sequence flanked by a first and a second *lox* site, and wherein the first and second *lox* sites are different.

[0122] Further provided herein are kits comprising the vectors of the present disclosure. In some embodiments, the vectors are supplied in lyophilized format in a container. In some embodiments, the vectors are supplied as purified vectors in a suitable buffer such as TE. In some embodiments, the vectors are supplied as bacterial or yeast stocks. In some embodiments, the kits include a first vector comprising: (i) a transposase coding sequence; and (ii) a donor sequence, wherein the donor sequence is flanked by inverted repeats recognized by the transposase, wherein the donor sequence comprises a first selectable marker coding sequence flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; and a second vector comprising: (i) one or more restriction or targeted cloning sites suitable for recombining a gene of interest into the second vector; and (ii) a second selectable marker, wherein the second selectable marker and the one or more restriction or targeted cloning sites are flanked by the first and the second *lox* sites. In some embodiments, the kits further include a third vector comprising (i) one or more restriction or targeted cloning sites suitable for recombining a gene of interest into the second vector; and (ii) a second selectable marker, wherein the second selectable marker and the one or more restriction or targeted cloning sites are flanked by the first and the second *lox* sites. In some embodiments, the second vector is a multiple-copy plasmid, and wherein the third vector is a single-copy plasmid. For example, the second vector (*e.g.*, pW26) can be used for cloning relatively smaller sequences of interest (*e.g.*, shorter genes or pathways), whereas the third vector (*e.g.* pW5Y) can be used to accommodate relatively longer sequences of interest (*e.g.*, larger genes or pathways).

[0123] A variety of restriction or targeted cloning sites are known in the art and can be selected by one of skill in the art. For example, multiple cloning sites (MCSs) have been used to insert sequences of interest into a vector using restriction digest and ligation. More recently, targeted cloning sites have come into use, such as site-specific recombination using phage/bacterial attP and attB sites mediated by phage integrase. For further description of suitable cloning sites and methods, *see, e.g.*, www.addgene.org/plasmid-reference/cloning-choice/.

[0124] In some embodiments, the first vector comprises the polynucleotide sequence of SEQ ID NO:4. In some embodiments, the second vector comprises the polynucleotide sequence of SEQ ID NO:10. In some embodiments, the third vector comprises the polynucleotide sequence of SEQ ID NO:11. In some embodiments, the kits further include instructions for using the kit to integrate the gene of interest into a chromosome of a host cell (*e.g.*, a bacterial host cell).

[0125] Any of the *lox* sites, selectable markers, origins of replication, transposase coding sequences, and so forth described herein may be selected for use in a kit of the present disclosure by one of skill in the art.

III. Methods of Pathway Engineering

[0126] Certain aspects of the present disclosure relate to methods of producing a product, *e.g.*, using the methods, vectors, and cells described herein. For example, any of the methods of integrating one or more genes or pathways of interest into a chromosome of a bacterial host cell described herein may find use, *inter alia*, in generating a bacterial host cell that produces a product. As described herein, a potential application of the methods of integration and expression of the present disclosure is in the generation of host cells that produce a product of interest, *e.g.*, using one or more of the integrated genes or pathways of interest. In some embodiments, one or more of the integrated genes or pathways of interest may produce a product of interest, or an intermediate in the synthesis thereof.

[0127] In some embodiments, methods of integration and expression described herein relate to generation of host cells comprising a phenazine pathway. In some embodiments, the phenazine pathway is introduced into a host cell to produce phenazine 1-carboxylic acid (PCA). In some embodiments the PCA phenazine core pathway is introduced into a host cell to produce PCA. In some embodiments, the PCA phenazine core pathway comprises *phz*ABCDEFGF. In some embodiments, the phenazine pathway is introduced into a host cell to produce phenazine 1,6-dicarboxylic acid (PDC). In some embodiments, the PDC

phenazine core pathway is introduced into a host cell to produce PDC. In some embodiments, the PDC core pathway comprises *phz*ABGCDEF.

[0128] In some embodiments, the methods described herein comprise generation of host cells comprising a gene or pathway of interest, wherein the gene or pathway of interest comprises a gene encoding a metabolic enzyme. In some embodiments, the metabolic enzyme comprises an enzyme involved in amino acid metabolism, biofuel production, commodity chemical production, vitamin metabolism, or fatty acid production. In some embodiments, the gene of or pathway of interest produces one or more secondary metabolites. Various secondary metabolites known in the art include without limitation lipopolysaccharides, polysaccharides, non-ribosomal peptide (NRP), polyketide, siderophore, terpene, lantipeptide, bacteriocin, homoserine lactone, butyrolactone, ectoine, thiopeptide, phenazine, terpinoids, alkanoids, and flavonoids.

[0129] Since various genes and pathways sufficient for the production of these secondary metabolites are known, it will be appreciated that the exemplary methods described *supra* with respect to production of phenazines could readily be adapted to produce these secondary metabolites based on the methods and techniques described herein. For example, gene clusters sufficient to produce various biofuels (Wargacki, A.J. *et al.* (2012) *Science* 335:308-13; Enquist-Newman, M. *et al.* (2014) *Nature* 505:239-43), antibiotics (Wohlleben, W. *et al.* (2012) *FEBS Letters* 586:2171-6), secondary metabolites (Omura, S. *et al.* (2001) *Proc. Natl. Acad. Sci.* 98:12215-20; Chaudhary, A.K. *et al.* (2013) *Biomed Res. Int.* 968518), alkaloids (Sato, F. *et al.* (2013) *Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.* 89:165-82), and small molecule therapeutics (Arsenault, P.R. *et al.* (2008) *Curr. Med. Chem.* 15:2886-96) are known in the art. In some embodiments, the gene(s) and/or pathway(s) of interest may be engineered to produce non-natural products (see, *e.g.*, Dietrich, J.A. *et al.* (2009) *ACS Chem. Biol.* 4:261-7).

[0130] In some embodiments, the gene or pathway of interest is an orphan pathway. In some embodiments, the gene or pathway of interest is any of those described in Fu, J., *et al.*, at *Nat. Biotechnol.*, 2012. 30(5):440-6 (2012). In some embodiments, the gene or pathway of interest is a pathway involved in terpene or terpenoid synthesis. In some embodiments the gene or pathway of interest includes a gene or pathway involved in vanillin, benzaldehyde (bitter almond, cherry) and 4-(R)-decanolide (fruity±fatty) synthesis. In certain embodiments that may be combined with any of the preceding embodiments, the method comprises expressing a gene or pathway involved in benzaldehyde, butyric acid, 2,3-butanedione, citronellal, (+)-curcumene, γ -decalactone, δ -decalactone, (+)-dehydro-

curcumene, (-)-isopulegol, (-)-methol, nor-patchoulenol, (+)-nuciferal, phenolethanol, β -binene, raspberry ketone, thaumatin, monellin, or (+)-turmerone as described in Gupta *et al.*, *Biotechnological Approach to Microbial Based Perfumes and Flavours. Journal of Microbiology & Experimentation*, 2015 or Krigs et al., *Applied Microbio. and Biotech.*, 49(1):1-8 (1998).

[0131] In some embodiments, the gene or pathway of interest is involved in bacteriocin synthesis. In some embodiments, the bacteriocin is a class IIa bacteriocin. In some embodiments the bacteriocin is Leucin A, Mesentericin Y105, Mundtacin, Piscicolin 126, Bavaricin A, Sakacin P, Pediocin PA-1, Bavaricin MN, Divercin V41, Enterocin A, Enterocin P, Carnobacteriocin BM1, Sakacin A, Carnobacteriocin B2, Bacteriocin 31, or Acidocin A, as described in Ennahar, S., et al., *FEMS Microbiol Rev*, **24**(1):85-106 (2000). Non-limiting examples of bacteriocins, and their corresponding biosynthesis pathways, include Sakacin A and *sapAKRTE*; Sakacin P and *sppKRTE*; Leucocin A and *IcaBAECD*; Mesentericin Y105 and *mesIYCDE*; Pediocin AcH and *papABCD*; Divercin V41 and *dvnAT1T2IRK*; Enterocin A and *entFAI*; Enterocin P and *entP*; and Curvacin A and *curA* (see, *e.g.*, Ennahar, S., et al., *FEMS Microbiol Rev*, **24**(1):85-106 (2000) for additional descriptions and references describing these pathways and products). In some embodiments, the bacteriocin may be purified, *e.g.*, from the host cell and/or culture medium. Efficient protocols for purification of these peptides are standard in the art (see, *e.g.*, Ennahar, S., et al., *FEMS Microbiol Rev*, **24**(1):85-106 (2000)).

[0132] In some embodiments, the gene or pathway of interest is involved in production of a polysaccharide, siderophore, lantipeptide, homoserine lactone, butyrolactone, ectoine, thiopeptide alkaloids, flavonoid, commodity chemical or a vitamin.

[0133] In some embodiments, the gene or pathway of interest is involved in omega-3 or omega-6 fatty acid synthesis. In certain embodiments that may be combined with any of the preceding embodiments, the gene of interest is any of $\Delta 6$ -desaturase (D6D), fatty acid desaturase 2 (FADS2), $\Delta 5$ -desaturase (D5D).

[0134] In some embodiments, the gene or pathway of interest is involved in lipopolysaccharide synthesis. A non-limiting list of genes and pathways involved in lipopolysaccharide synthesis may be found, *e.g.*, at www.genome.jp/kegg-bin/show_pathway?map00540.

[0135] In some embodiments, the methods of the present disclosure include culturing a host cell of the present disclosure comprising a gene or pathway coding sequence (*e.g.*, chromosomally integrated using any of the methods described herein) in a culture medium

under conditions whereby the gene or pathway coding sequence is expressed in the cell, and whereby the gene or pathway produces a product, such as the exemplary secondary metabolites described above. Exemplary culture media and conditions are described herein.

[0136] In some embodiments, the gene or pathway of interest is an orphan pathway, which is integrated into a host cell to determine its function *in vivo*. For example, a gene or pathway may be integrated into a host cell of the present disclosure (*e.g.*, using the methods described herein), cultured, and one or more products of the gene or pathway may be detected and/or identified as a product of the cell, *e.g.*, using standard methods known in the art including without limitation mass spectrometry or liquid/gas chromatography.

Cell Culture Media and Methods

[0137] Certain aspects of the present disclosure relate to methods of culturing a cell. As used herein, “culturing” a cell refers to introducing an appropriate culture medium, under appropriate conditions, to promote the growth of a cell. Methods of culturing various types of cells are known in the art. Culturing may be performed using a liquid or solid growth medium. Culturing may be performed under aerobic or anaerobic conditions where aerobic, anoxic, or anaerobic conditions are preferred based on the requirements of the microorganism and desired metabolic state of the microorganism. In addition to oxygen levels, other important conditions may include, without limitation, temperature, pressure, light, pH, and cell density.

[0138] In some embodiments, a culture medium is provided. A “culture medium” or “growth medium” as used herein refers to a mixture of components that supports the growth of cells. In some embodiments, the culture medium may exist in a liquid or solid phase. A culture medium of the present disclosure can contain any nutrients required for growth of microorganisms. In certain embodiments, the culture medium may further include any compound used to reduce the growth rate of, kill, or otherwise inhibit additional contaminating microorganisms, preferably without limiting the growth of a host cell of the present disclosure (*e.g.*, an antibiotic, in the case of a host cell bearing an antibiotic resistance marker of the present disclosure). The growth medium may also contain any compound used to modulate the expression of a nucleic acid, such as one operably linked to an inducible promoter (for example, when using a yeast cell, galactose may be added into the growth medium to activate expression of a recombinant nucleic acid operably linked to a *GAL1* or *GAL10* promoter). In further embodiments, the culture medium may lack specific nutrients or components to limit the growth of contaminants, select for microorganisms with a

particular auxotrophic marker, or induce or repress expression of a nucleic acid responsive to levels of a particular component.

[0139] In some embodiments, the methods of the present disclosure may include culturing a host cell under conditions sufficient for the production of a product, such as one or more of the secondary metabolites or other products described herein. In certain embodiments, culturing a host cell under conditions sufficient for the production of a product entails culturing the cells in a suitable culture medium. Suitable culture media may differ among different microorganisms depending upon the biology of each microorganism. Selection of a culture medium, as well as selection of other parameters required for growth (*e.g.*, temperature, oxygen levels, pressure, etc.), suitable for a given microorganism based on the biology of the microorganism are well known in the art. Examples of suitable culture media may include, without limitation, common commercially prepared media, such as Luria Bertani (LB) broth, Sabouraud Dextrose (SD) broth, or Yeast medium (YM) broth. In other embodiments, alternative defined or synthetic culture media may also be used.

Purification of Products from Host Cells

[0140] In some aspects, the methods described herein can be used to engineer cells to express one or more genes or pathways of interest to produce a chemical or biological product, such as a chemical, small molecule, protein, peptide, nucleic acid, fuel, perfume, or secondary metabolite, for example. In some embodiments, the methods described herein involve introducing a gene or pathway of interest into a host cell and culturing the host cell under conditions where the gene or pathway of interest is expressed to produce a desired product. In some embodiments, the method comprises purifying the product produced by the host cell.

[0141] A variety of methods known in the art may be used to purify a product from a host cell or host cell culture. In some embodiments, one or more products may be purified continuously, *e.g.*, from a continuous culture. In other embodiments, one or more products may be purified separately from fermentation, *e.g.*, from a batch or fed-batch culture. One of skill in the art will appreciate that the specific purification method(s) used may depend upon, *inter alia*, the host cell, culture conditions, and/or particular product(s).

EXAMPLES

[0142] The present disclosure will be more fully understood by reference to the following examples. They should not, however, be construed as limiting the scope of the present

disclosure. It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.

Example 1: Chromosomal Integration of a 7.0 kb Pathway

[0143] This study shows the integration of pathways to bacterial chromosome using a combined transposition and Cre-Lox P strategy (**FIGS. 3A, 3B**). In this study, a 7.0-kb PDC pathway was integrated into the strain *P. fluorescens* WCS417r.

[0144] Phenazines are nitrogen containing heterocyclic secondary metabolites of bacterial origin. Almost all phenazines exhibit broad antibacterial and antifungal bioactivity due to their redox activity. Phenazine biosynthesis proceeds via a core pathway (*phz*ABCDEFGF) that is found in all phenazine-producing bacteria and is responsible for producing the phenazine tricycle nucleus (**FIGS. 4A-4D**). Phenazine 1,6-dicarboxylic acid (PDC) is a core phenazine structure from which many phenazine derivatives may be formed. The 7kbPDC core pathway (**FIG. 4A**) is used in this study to test for integration.

Materials and Methods

Strains

[0145] Strains used in this study are listed in Table 2. Plasmids pW1 and pW6 were constructed in this study. Vector maps are shown in **FIG. 1** and **FIG. 2**.

Table 2: Strains and Plasmids Used in Example 1

Names	Features
Strains	
<i>E. coli</i> WM3064	Conjugation donor, derived from <i>E. coli</i> B2155, auxotrophic to 2,3-Diaminopropionic Acid (DAP)
<i>P. fluorescens</i> WCS417r	Wild type, root colonizer of <i>Arabidopsis</i>
<i>P. fluorescens</i> WCS417r Km-2lox	A wild type strain with landing pad insertion, Kanamycin resistant
<i>P. fluorescens</i> WCS417r Apr-PDC	PDC integrated to the chromosome, Apramycin resistant
Plasmids	
pKMW2	r6k replication origin, carrying OriT for conjugation, Kanamycin resistant, contain marine transposon
pW1	pKMW2 with loxP and lox5171 within the transposon sequence
pW6	Single copy plasmid, constructed based on pBeloBAC-11, carrying LacI driven Cre recombinase, carrying T7-PDC between loxP and lox5171 sites.

Conjugation

[0146] Conjugation was conducted as follows. Donor *E. coli* bacterial strain, WM3064 is derived from B2155 and is auxotrophic for Diaminopimelic acid (DAP). DAP is an amino acid, representing an epsilon-carboxy derivative of lysine. This strain can be used for conjugation experiments (by mobilizing plasmids with RP4) and for the replication of plasmids with the R6K origin of replication (WM3064 has the *pir* gene). WM3064 was developed by William Metcalf at UIUC. Strain APA752 contains the plasmid pKMW5 in WM3064. pKMW5 is a mariner class transposon vector that confers resistance to kanamycin and is DNA barcoded with a 20mer. Strain APA766 contains the plasmid pKMW7 in WM3064. pKMW7 is a Tn5 class transposon vector that confers resistance to kanamycin and is DNA barcoded with a 20mer.

[0147] Different ratios of acceptor to donor (WM3064 with transposon vector) were tested to determine the optimal ratio for maximizing the number of mutants.

[0148] On day 1, 10 mL of media was inoculated with the acceptor or recipient strain and the cells were grown to late log phase. 10 mL of LB/Kan/DAP was inoculated with donor strain and grown at 37°C with shaking until late log phase.

[0149] On day 2, the donor cells were pelleted by spinning at 4,000 rpm for 5 minutes. The pellet was washed twice by resuspending in 10 mL of LB and spinning at 4,000 rpm for 5 minutes. The pellet was then resuspended in 10 mL LB. The OD of the washed donor and recipient cultures was determined.

[0150] Conjugation was performed with different ratios of donor to recipient cells, for example 4:1, 1:1, and 1:4 (donor: recipient). After the cultures were mixed together, the cells were centrifuged and the supernatant was removed. The cells were then resuspended in 100 μ L of the media required for the recipient supplemented with DAP. Three Millipore filters were placed on recipient media with DAP. 40 μ L of cell suspension was added to each filter. The conjugation was incubated for 6 to 8 hours at a temperature appropriate for both the donor and recipient.

[0151] Filters were placed in 15 mL falcon tube with 2mL donor media and vortexed to resuspend the cells. 10^{-1} , 10^{-2} and 10^{-3} dilutions were plated on recipient media plus kanamycin to select mutants.

Results

[0152] *E. coli* WM3064pW1 was conjugated to *P. fluorescence* WCS417r (**FIG. 3A**). After conjugation, thousands of colonies were obtained on LB Kanamycin (150 μ g/ml) plate, and

only one colony (*P. fluorescens* 417r Km-2lox 2.2.2) was selected for subsequent pathway integration. The selected *P. fluorescens* 417r Km-2lox grew well on M9 minimum medium, and the landing pad (sequence between two IRs) was detected in it by colony PCR. Since the r6k replication origin is not functional in *P. fluorescens*, the plasmid was not able to replicate in the *P. fluorescens* strain. Therefore, the colony PCR results show the landing pad was successfully inserted into the chromosome of *P. fluorescens* WCS417r (**FIG. 3A**, right).

[0153] *E. coli* WM3064pW6 was conjugated to *P. fluorescens* WCS417r Km-2lox, and colonies were selected by LB Apramycin (50ug/ml) (**FIG. 3B**). In this conjugation, IPTG was added to the mixture of donor and recipient cells on the membrane filter during conjugation to induce the expression of Cre recombinase. After conjugation, thousands of colonies were obtained on LB Apramycin (50ug/ml) plate. 16 colonies were separately streaked on LB Apramycin (50ug/ml) and LB Kanamycin (150ug/ml) plates. This counter selection showed that 100% of the colonies grew on LB Apramycin (50ug/ml), and none of them grew on LB Kanamycin (150ug/ml). In addition, the PDC pathway between the two lox sites was detected by colony PCR and colony PCR also confirmed the PDC integration occurred at the loxP and lox5171 sites (**FIG. 3B**, right).

[0154] The pW6 backbone outside the loxP and lox5171 region was not detected by colony PCR, indicating that the pW6 was not able to replicate in *P. fluorescens* WCS 417r. This study demonstrates successful integration of the 7.0kb PDC pathway in the *P. fluorescens* 417r chromosome.

Example 2: Chromosomal Integration of the PCA and PDC Pathways

[0155] This study shows the integration and expression of pathways to bacterial chromosomes using the combined transposition, Cre-Lox P, and T7 RNA polymerase strategy. Specifically, in this study, integration and expression of the PCA and the PDC pathways in the chromosome of both *P. fluorescens* WCS417r and *P. fluorescens* Q8r1 was demonstrated.

Table 3: Strains and Plasmids used in Example 2

Names	Features
Strains	
<i>E. coli</i> WM3064	Conjugation donor, derived from <i>E. coli</i> B2155, auxotrophic to 2,3-Diaminopropionic Acid (DAP)
<i>P. fluorescens</i> WCS417r	Wild type, root colonizer of <i>Arabidopsis</i>

<i>P. fluorescens</i> Q8r1	Wild type, root colonizer of wheat and corn
<i>P. fluorescens</i> WCS417r Km-Cre-2lox_C	Mixture of colonies obtained after pW17 conjugated to <i>P. fluorescens</i> WCS417r, Kanamycin resistant
<i>P. fluorescens</i> Q8r1 Km-Cre-2lox_C	Mixture of colonies obtained after pW17 conjugated to <i>P. fluorescens</i> Q8r1, Kanamycin resistant
<i>P. fluorescens</i> 417r Apr-PCA	<i>P. fluorescens</i> 417r with PCA pathway integrated to the chromosome
<i>P. fluorescens</i> Q8r1 Apr-PCA	<i>P. fluorescens</i> Q8r1 with PCA pathway integrated to the chromosome
<i>P. fluorescens</i> Q8r1 Apr-PDC	<i>P. fluorescens</i> 417r with PDC2 pathway integrated to the chromosome
<i>P. fluorescens</i> 417r Apr-PDC	<i>P. fluorescens</i> Q8r1 with PDC2 pathway integrated to the chromosome
Plasmids	
pW17	Plasmid carrying transposable landing pad, landing pad contains lacI-T7RP, LoxP, Lxo5171 Cas9-driven Cre and Kanamycin resistance
pW20	Single copy plasmid, constructed based on pBeloBAC-11, carrying LacI driven Cre recombinase, carrying T7-PCA between loxP and lox5171 sites.
pW21	Single copy plasmid, constructed based on pBeloBAC-11, carrying LacI driven Cre recombinase, carrying T7-PDC2 between loxP and lox5171 sites.

[0156] *E. coli* WM3064pW17 was conjugated to *P. fluorescence* WCS417r and *P. fluorescens* Q8r1 (**FIG. 8A**). After conjugation, thousands of colonies were obtained on LB Kanamycin (150ug/ml) plate, and all colonies on the plates were pooled to make a *P. fluorescens* 417r Km-Cre-2lox consortia and *P. fluorescens* Q8r1 Km-Cre-2lox consortia. The landing pad randomly integrated into the genomes of these two strains, and the presence of the landing pad was detected by colony PCR using each consortium as the template. These two consortia were used for the following experiments.

[0157] *E. coli* WM3064pW20 and *E. coli* WM3064pW21 was conjugated to *P. fluorescens* 417r Km-Cre-2lox consortia and *P. fluorescens* Q8r1 Km-Cre-2lox consortia (**FIG. 8B**). Colonies were selected by LB Apramycin (50ug/ml). After conjugation, thousands of colonies were obtained on LB Apramycin (50ug/ml) plate. Four colonies of each combination were picked out and sub-cultured. The rest of the colonies in this conjugation were pulled together and sub-cultured (marked as consortia). The sub-cultured consortia and single colonies were fermented separately downstream for PCA or PDC production detection.

[0158] In this conjugation, IPTG was not added to the mixture of donor and recipient cells on the membrane filter during conjugation. However, the Cre-lox recombination efficiency was very high. This could be because of the leaky expression of Cre in the pW20 or pW21 plasmids or due to the Cas9 promoter driven Cre expression in the landing pad.

[0159] Engineered strains were cultivated in Luria-Bertani (LB) broth at 28°C for 72 hrs. Antibiotic supplements were used at the following concentrations: ampicillin: 50 µg/ml, kanamycin 100 µg/ml, rifampicin 50 µg/ml. Cultures were induced for expression with 0.1 mM Isopropyl-β-D-thiogalactopyranoside (IPTG) when they reached of 0.6 OD 600. Cultures were centrifuged and 1.5 ml of supernatant was used for extraction. Supernatants

were extracted with 0.5 ml 1.25% TFA and 1.5 ml of ethyl acetate. The ethyl acetate was removed and dried via speed vacuum. Extracts were suspended in acetonitrile and filtered using 0.2 μ m PTFE filters. Filtered extracts were analyzed via LCMS using an Agilent HPLC and Thermo Q Exactive detector. Separation via HPLC was completed using a C-18 reverse phase column with a 2 μ l injection volume. Phenazines were detected and confirmed using comparisons of exact mass, ms/ms fragmentation, and retention time to authentic standards.

[0160] The production of PCA or PDC from the consortia or from single colonies was detected qualitatively by LCMS analysis (**FIGS. 9A-9E** and Table 3). Since PCA is the precursor of PDC, to detect PDC production, both PCA and PDC should be present (**FIGS. 9A-9D**). The expression of phenazine pathways in the consortia and in the single colonies was successfully detected. All strains exhibited PCA production, indicating that both core phenazine pathways are functional in the recombinant strains and the T7 promoter is functionally driving expression of the pathway. Representative LCMS data were shown in **FIGS. 9A-9E** only for *P. fluorescens* Q8R1.

Table 4: Conjugation Scheme and Compound Production

Donor	Recipient	Obtained Strain	Production	
			PCA	PDC
<i>E. coli</i> WM3064pW20	<i>P. fluorescens</i> 417r Km-Cre-2lox_C	<i>P. fluorescens</i> 417r Apr-PCA consortia	Yes	No
		<i>P. fluorescens</i> 417r Apr-PCA	Yes	No
<i>E. coli</i> WM3064pW20	<i>P. fluorescens</i> Q8r1 Km-Cre-2lox_C	<i>P. fluorescens</i> Q8r1 Apr-PCA consortia	Yes	No
		<i>P. fluorescens</i> Q8r1 Apr-PCA	Yes	No
<i>E. coli</i> WM3064pW21	<i>P. fluorescens</i> 417r Km-Cre-2lox_C	<i>P. fluorescens</i> 417r Apr-PDC2 consortia	Yes	Yes
		<i>P. fluorescens</i> 417r Apr-PDC2	Yes	Yes
<i>E. coli</i> WM3064pW21	<i>P. fluorescens</i> Q8r1 Km-Cre-2lox_C	<i>P. fluorescens</i> Q8r1 Apr-PDC2 consortia	Yes	Yes
		<i>P. fluorescens</i> Q8r1 Apr-PDC2 #1	Yes	Yes

[0161] This study showed successful integration and expression of the PCA and PDC pathways in the *P. fluorescens* 417r and *P. fluorescens* Q8r1 chromosomes.

Example 3: Chromosomal Integration and Expression of Bacterial Luciferase Pathways in Two *Pseudomonas fluorescens* Strains

[0162] This study shows the chromosomal integration and expression of pathways using the transposition, Cre-Lox P, and T7 RNA polymerase combined strategy. Specifically, this study demonstrates integration and expression bacterial luciferase *luxCDABE* pathway in the chromosome of both *P. fluorescens* WCS417r and *P. fluorescens* Q8r1.

Table 5: Strains and Plasmids Used in Example 3

Names	Features
Strains	
<i>E. coli</i> WM3064	Conjugation donor, derived from <i>E. coli</i> B2155, auxotrophic to 2,3-Diaminopropionic Acid (DAP)
<i>P. fluorescens</i> WCS417r	Wild type, root colonizer of <i>Arabidopsis</i>
<i>P. fluorescens</i> Q8r1	Wild type, root colonizer of wheat and corn
<i>P. fluorescens</i> WCS417r Km-Cre-2lox	Obtained after pW17 conjugated to <i>P. fluorescens</i> WCS417r, Kanamycin resistant
<i>P. fluorescens</i> Q8r1 Km-Cre-2lox	Obtained after pW17 conjugated to <i>P. fluorescens</i> Q8r1, Kanamycin resistant
<i>P. fluorescens</i> 417r Apr-lux	<i>P. fluorescens</i> 417r with <i>luxCDABE</i> pathway integrated to the chromosome
<i>P. fluorescens</i> Q8r1 Apr-lux	<i>P. fluorescens</i> Q8r1 with <i>luxCDABE</i> pathway integrated to the chromosome
Plasmids	
pW17	Plasmid carrying transposable landing pad, landing pad contains <i>lacI</i> -T7RP, <i>LoxP</i> , <i>Lxo5171</i> Cas9-driven Cre and Kanamycin resistance
pW34	Medium copy plasmid, carrying T7- <i>luxCDABE</i> between <i>loxP</i> and <i>lox5171</i> sites.

[0163] *E. coli* WM3064pW17 was conjugated to *P. fluorescens* WCS417r and *P. fluorescens* Q8r1 (**FIG. 11A**). After conjugation, thousands of colonies were obtained on LB Kanamycin (150ug/ml) plate. One single colony from each group was selected and it was confirmed that the landing pad has inserted to these two colonies by colony PCR. These two strains *P. fluorescens* 417r Km-Cre-2lox and *P. fluorescens* Q8r1 Km-Cre-2lox were used for following study.

[0164] *E. coli* WM3064pW34 (SEQ ID NO:5) was conjugated to *P. fluorescens* 417r Km-Cre-2lox and *P. fluorescens* Q8r1 Km-Cre-2lox (**FIG. 11B**). Colonies were selected by LB Apramycin (50ug/ml). After conjugation, thousands of colonies were obtained on LB Apramycin (50ug/ml) plate. Three colonies of each combination were picked out and sub-cultured for bioluminescence assay.

[0165] *P. fluorescens* strains with the landing pad or with *luxCDABE* were inoculated to 1 mL of LB Kanamycin (150ug/ml) or LB Apramycin (50ug/ml). After overnight growth at 28°C overnight with shaking at 220rpm, each culture was diluted to OD600 of 0.1. IPTG was added to each well at a final concentration of 0mM, 0.01mM, 0.1mM, and 1.0mM. Luminescence and OD600 was read at 0, 0.17, 1, 2, 3, 5, and 10 hours using a Synergy H1 Micro-plate reader.

[0166] Three independent colonies of *P. fluorescens* WCS417r lux and *P. fluorescens* Q8r1 lux were tested for Bioluminescence. *P. fluorescens* WCS417r Km-Cre-2lox and *P. fluorescens* Q8r1 Km-Cre-2lox were used as control. The results in **FIGS. 12A-12B** show

that the within 5 hours after IPTG induction, the intensity of bioluminescence increased with time. High IPTG induction caused faster increase of the bioluminescence signals.

[0167] This study showed the successfully integration and expression of the bacterial luciferase luxCDABE pathway into the *P. fluorescens* 417r and *P. fluorescens* Q8r1 chromosomes. The Cre in the landing pad expressed by the Cas promoter, thus enabling the recombination.

[0168] The Cas9 promoter that drives Cre expression in the landing pad is known in the art as a broad host promoter. Therefore, this landing pad could be used in many other strains. Moreover, the pW34 donor vector is constructed from a medium copy vector of about 2 kb, which is easy to construct and can be used to engineer other pathways.

Example 4: Chromosomal Integration and Expression in 32 Strains of Proteobacteria

[0169] This study was conducted to show that the combined transposition, Cre-LoxP, and T7 RNA polymerase strategy is effective across a wide range of bacterial species.

Materials and Methods

[0170] Bacterial strains used in this study are listed in Table 5. *E. coli* TOP10 was used to construct pBeloBAC11 based plasmid pW17. *E. coli* EC100D pir+ was used to construct pW34 with r6k replication of origin. 32 strains of γ -proteobacteria to be engineered were purchased from DSMZ (Germany), ATCC, or a gift from David Weller (USDA-ARS) and Jeff Dangl (UNC, Chapel Hill).

Table 6: Strains Used in Example 4

Strain name	Features
<i>E. coli</i> TOP10	Cloning host for construction pW17
<i>E. coli</i> EC100D pir+	Constitutively express the π protein (the <i>pir</i> gene product) for replication of plasmids containing the R6K γ origin of replication; cloning host for constructing pW34
<i>E. coli</i> WM3064	Conjugation donor, derived from <i>E. coli</i> B2155, auxotrophic to 2,3-diaminopropionic acid (DAP)
<i>Pseudomonas fluorescens</i> WCS 417r	
<i>P. fluorescens</i> Q8r-r1	
<i>P. putida</i> KT2440 ATCC_47054	
<i>Photobacterium luminescens</i> subsp. <i>laumondii</i> TTO1 DSM_15139	
<i>P. luminescens</i> subsp. <i>Luminescens</i> DSM_3368	

<i>P. temperata</i> subsp. <i>khanii</i> DSM_3369	γ -proteobacteria to be engineered in this study; conjugation recipients
<i>Xenorhabdus doucetiae</i> DSM_17909	
<i>X. nematophila</i> DSM_3370	
<i>X. szentirmaii</i> DSM_16338	
<i>Serratia odorifera</i> DSM_4582	
<i>Erwinia oleae</i> DSM_23398	
<i>E. piriflorinigra</i> DSM_26166	
<i>E. pyrifoliae</i> DSM_12163	
<i>Yersinia aldovae</i> DSM_18303	
<i>Y. bercovieri</i> DSM_18528	
<i>Y. mollaretii</i> DSM_18520	
<i>Y. ruckeri</i> DSM_18270	
<i>Y. ruckeri</i> DSM_18506	
<i>Dickeya dadantii</i> subsp. <i>dadantii</i> DSM_18020	
<i>D. dadantii</i> subsp. <i>dieffenbachiae</i> DSM_18013	
<i>D. solani</i> DSM_28711	
<i>D. zeae</i> DSM_18068	
<i>Pectobacterium atrosepticum</i> DSM_18077	
<i>P. betavascularum</i> DSM_18076	
<i>P. carotovorum</i> subsp. <i>carotovorum</i> DSM_30168	
<i>P. carotovorum</i> subsp. <i>odoriferum</i> DSM_22556	
<i>P. wasabiae</i> DSM_18074	
<i>Aeromonas encheleia</i> DSM_11577	
<i>A. molluscorum</i> DSM_17090	
<i>A. piscicola</i> DSM_23451	
<i>A. salmonicida</i> subsp. <i>pectinolytica</i> DSM_12609	
<i>A. salmonicida</i> subsp. <i>salmonicida</i> DSM_19634	

[0171] Conjugation was conducted as described above. Colony PCR was performed using KAPA HiFi PCR kits (KAPA Biosystems, MA) according to standard protocol.

[0172] pW17 was transformed to *E. coli* WM3064 by electroporation. Conjugation was established between the donor strain *E. coli* WM3064pW17 and each of the 32 γ -proteobacteria recipients. After pW17 was conjugated to the recipients, the landing pad (sequence between two IRs in pW17) was expected to transpose randomly into the recipient chromosome (**FIG. 13A**). As a result, lawn of colonies were obtained on LB Kanamycin (50 ~ 200 ug/ml) plate for 20 strains, hundreds of colonies appeared for 7 strains and less than 100 colonies were obtained for 5 strains. Among them, only 8 and 9 colonies were obtained for *Photobacterium luminescens* subsp. *laumondii* TTO1 and *P. luminescens* subsp. *luminescens*, suggesting low but detectable conjugation efficiency for those two strains.

[0173] After conjugation, 4 to 40 single colonies on the LB Km plates for each of the 32 proteobacteria were randomly selected and screened by colony PCR to detect the landing pad existence. 2 to 24 colonies of each strain carried the landing pad (number varies for each strain). 2 to 10 colonies for each strain with landing pad were inoculated to M9 medium with appropriate kanamycin concentration and their growth were compared with the wild type in M9 medium. At least 2 colonies with landing pad insertion in 28 strains of the 32 strains grew

as well as the wild type. Neither wild type nor landing pad insertion colonies of *Photorhabdus temperata subsp. khanii*, *Xenorhabdus doucetiae*, *X. nematophila* and *Aeromonas salmonicida subsp. salmonicida* grew in M9 medium. As an alternative, 5 to 7 landing pad insertion colonies of those four strains in LB with antibiotics were compared with their wild type in LB medium. All 4 of them grew similarly to wild type.

[0174] Finally, two colonies (recipient iLP_1 and recipient iLP_2) of each strain with positive testing results were subcultured for subsequent *luxCDABE* pathway integration experiment (**FIG. 13B**). These two colonies were thought to most probably contain landing pad insertions into different locations of the bacterial chromosome, and the insertion of landing pad did not affect normal growth of the bacteria. In addition, two lines of each strain were sent to MiSeq sequencing to identify the landing pad insertion locations.

Results

[0175] pW34 was transformed to *E. coli* WM3064 by electroporation. *E. coli* WM3064pW34 was conjugated to each of the two variants of each recipient carrying the landing pad. *LuxCDABE* was expected to be integrated into the landing pad at the *loxP* and *lox5171* sites (**FIG. 13B**). After conjugation, a spot of mixed cultures on the filter was taken with a sterile inoculation loop and streaked on LB apramycin plates (50 or 100ug/ml) or the mixture were totally plated out on LB apramycin plates (50 or 100ug/ml). Many colonies were obtained for 30 of the 32 strains. Only a few colonies were obtained for *P. luminescens subsp. laumondii TTO1* and *P. luminescens subsp. luminescens*. The second conjugation efficiencies for *P. temperata subsp. khanii*, *X. doucetiae*, *X. nematophila*, *X. szentirmaii*, *Erwinia oleae*, *P. carotovorum subsp. carotovorum*, *P. carotovorum subsp. odoriferum*, *P. wasabiae*, *A. molluscorum* and *A. piscicola* were higher than the first conjugation efficiencies. Ten single colonies were randomly picked and streaked on LB Apr and LB Km plates for counter selection. If the Apr-*luxCDABE* was successfully integrated to the chromosome under Cre-*lox* recombination, the resulted colonies were expected to grow and exhibit luminescence LB Apr plates, but show no growth or luminescence on LB Km plates.

[0176] The counter selection results showed that among all the 32 strains tested, 22, 4, 1, 1, and 3 of the strains showed 100%, 95%, 90.0%, 80.0%, and 50%, respectively, of the expected antibiotic resistance and luminescence patterns (Table 6). No colony of *Yersinia rohdei* showed the expected pattern. This indicated that 96.9% of the selected strains were able to be engineered, at a very high success rate (87.5% of them have a > 80% success rate).

[0177] In this plate luminescence assay, no IPTG was added. The leaky expression of T7 RNA polymerase drove the expression of the weak expression of *luxCDABE*, and therefore images were taken after 20 min of exposure to ensure strong signal. Leaky expression of *luxCDABE* significantly shortened the screening time and increased the efficiency.

[0178] Five colonies of each recipient with *luxCDABE* integrated into the landing pads in both insertion locations were selected for further luminescent assays in LB under the induction of IPTG. Two sets of 5 colonies were tested for each strain, except *Y. ruckeri* and *Erwinia oleae* which only have one set. The recipient strains with landing pads were used as controls. Single colonies were inoculated to 1ml LB with appropriate antibiotics and incubated at 28°C overnight with shaking. Cultures were diluted to OD600 of 0.1-0.2 and added to 96 well black plates with clear bottoms. IPTG was added to the cultures at a final concentration of 0mM or 1mM.

[0179] Without adding IPTG in the solid media, plates with (or without obvious) bacterial cultures were placed in the Gel Documentation System (BioRad, CA) to collect bioluminescent signals. Images were taken after 20 min of exposure.

[0180] Bioluminescence of the culture was measured using a Synergy H1 Micro-plate reader at intervals of 12 min for up to 10 hours. All of the 1 mM IPTG induced recipients with *luxCDABE* showed significant higher luminescence than uninduced cells and the controls (except *Dickeya dadantii* subsp. *dadantii* and *Serratia odorifera*) (FIGS. 14A-14BB).

Table 7: Bioluminescent Plate Bioassay and Counter Selection Results

Bacterial strain	iLP_1-lux				iLP_2-lux			
	Apr		Kan		Apr		Kan	
	Gro ww+ *	Lum+ *	Grow +	Lum +	Grow +	Lum +	Grow +	Lum+
<i>Photorhabdus luminescens</i> subsp. <i>laumondii</i> T101	10	10	1	0	10	10	0	0
<i>P. luminescens</i> subsp. <i>Luminescens</i>	10	10	0	0	10	10	0	0
<i>P. temperata</i> subsp. <i>Khanii</i>	10	10	0	0	10	10	0	0
<i>Xenorhabdus doucetiae</i>	10	9	4	0	10	10	0	0
<i>X. nematophila</i>	10	10	0	0	10	10	0	0
<i>X. szentirmaii</i>	10	10	0	0	10	10	1	1
<i>Serratia odorifera</i>	10	10	0	0	10	10	0	0
<i>Erwinia oleae</i>	10	10	10	10	10	10	0	0
<i>E. piriflorinigrans</i>	10	10	0	0	10	10	0	0
<i>E. pyrifoliae</i>	10	10	0	0	10	10	0	0
<i>Yersinia aldovae</i>	10	10	0	0	10	0	0	0

<i>Y. bercovieri</i>	10	10	0	0	10	10	0	0
<i>Y. mollaretii</i>	10	10	0	0	10	10	0	0
<i>Y. rohdei</i>	10	0	10	0	10	0	10	0
<i>Y. ruckeri</i>	10	10	10	10	10	10	0	0
<i>Dickeya dadantii</i> subsp. <i>Dadantii</i>	10	10	0	0	10	10	0	0
<i>D. dadantii</i> subsp. <i>Dieffenbachiae</i>	10	10	0	0	10	10	0	0
<i>D. solani</i>	10	10	0	0	10	10	0	0
<i>D. zeae</i>	10	10	0	0	10	10	0	0
<i>Pectobacterium atrosepticum</i>	10	10	0	0	10	10	0	0
<i>P. betavascularum</i>	10	10	0	0	10	10	0	0
<i>P. carotovorum</i> subsp. <i>carotovorum</i>	10	10	0	0	10	10	0	0
<i>P. carotovorum</i> subsp. <i>odoriferum</i>	10	10	0	0	10	10	0	0
<i>P. wasabiae</i>	10	10	0	0	10	10	0	0
<i>Aeromonas encheleia</i>	10	10	0	0	10	10	1	1
<i>A. molluscorum</i>	10	10	1	0	10	10	0	0
<i>A. piscicola</i>	10	10	2	2	10	10	0	0
<i>A. salmonicida</i> subsp. <i>pectinolytica</i>	10	10	0	0	10	10	0	0
<i>A. salmonicida</i> subsp. <i>salmonicida</i>	10	10	0	0	10	10	0	0
<i>P. fluorescence</i> WCS 417r	10	10	0	0	10	10	0	0
<i>P. putida</i> KT2440	10	10	0	0	10	10	0	0
<i>P. fluorescence</i> Q8-R1	10	10	0	0	10	10	0	0

*“grow+” indicates the streaked culture from single colonies grow well on LB plates with corresponding antibiotics.

*“lum+” indicates the streaked culture from single colonies exhibited luminescence on LB plates with corresponding antibiotics.

Discussion

[0181] These results demonstrate that a ~7 kb bacterial luciferase gene cluster *luxCDABE* was successfully integrated into the genome of 31 gamma-proteobacteria, and the gene cluster was successfully expressed under IPTG induction. Interestingly, the conjugation efficiency for pathway integration was generally higher than in the first conjugation for landing pad transposition. Without being bound by theory, it is possible that the Cre-lox recombination is more efficient than the landing pad insertion after the plasmid was conjugated into the recipient cells. In this study, we selected two variants that contain the landing pad after the first conjugation for following pathway integration. Since those two variants grew as robustly as the wild type in M9 minimum medium, without being bound by theory, we hypothesize that the insertions of the landing pads are likely in non-essential regions in the genome that do not cause detrimental effects on the host.

[0182] This strategy can provide a universal means to engineer bacteria across all phyla, since it does not depend on traditional plasmid expression systems or homologous

recombination. This strategy uses conjugation to transfer DNA from *E. coli* to different bacteria, which has been previously demonstrated between *E. coli* to many bacteria (Goessweiner-Mohr, N., et al., *Conjugation in Gram-Positive Bacteria*, Microbiol Spectr, 2014. 2(4); Mazodier, P., R. Petter, and C. Thompson, *Intergeneric Conjugation between Escherichia-Coli and Streptomyces Species*, Journal of Bacteriology, 1989. 171(6): p. 3583-3585), or even yeast (Hayman, G.T. and P.L. Bolen, *Movement of Shuttle Plasmids from Escherichia coli into Yeasts Other Than Saccharomyces cerevisiae Using Trans-kingdom Conjugation*. *Plasmid*, 1993. 30(3): p. 251-257). Mariner transposon (Himar1) also has a broad distribution, and its horizontal transfer does not require species-specific host factors, because it binds to the inverted terminal repeat sequences of its cognate transposon and mediates 5' and 3' cleavage of the element termini (Lampe, D.J., M.E.A. Churchill, and H.M. Robertson, *Purified mariner transposase is sufficient to mediate transposition in vitro*, Embo Journal, 1996. 15(19): p. 5470-5479). It has been reported to transpose into a very broad host range that includes various species of Proteobacteria, Bacteroidetes, Firmicutes, Actinobacteria and Spirochaetes (Ongley, S.E., et al., *Recent advances in the heterologous expression of microbial natural product biosynthetic pathways*, Natural Product Reports, 2013. 30(8): p. 1121-1138), even *in vitro* (Pelicic, V., et al., *Mutagenesis of Neisseria meningitidis by in vitro transposition of Himar1 mariner*, Journal of Bacteriology, 2000. 182(19): p. 5391-5398. and mammalian cells Zhang, L.N., et al., *The Himar1 mariner transposase cloned in a recombinant adenovirus vector is functional in mammalian cells*. Nucleic Acids Research, 1998. 26(16): p. 3687-3693).

[0183] Meanwhile, the Cre-lox recombination strategy has already allowed implementation of large pathways comprising at least ~59 kb in some species of γ -proteobacteria with high efficiency, accuracy, and precision (Santos, C.N., D.D. Regitsky, and Y. Yoshikuni, *Implementation of stable and complex biological systems through recombinase-assisted genome engineering*, Nat Commun, 2013. 4: p. 2503). In addition, both the Cre-lox recombination and T7 drive gene or pathways expression have been demonstrated to function *in vitro* (Qin, M.M., et al., *Site-Specific Cleavage of Chromosomes in-Vitro through Cre-Lox Recombination*, Nucleic Acids Research, 1995. 23(11): p. 1923-1927; Kohrer, C., et al., *Use of T7 RNA polymerase in an optimized Escherichia coli coupled in vitro transcription-translation system - Application in regulatory studies and expression of long transcription units*, European Journal of Biochemistry, 1996. 236(1): p. 234-239.), and in various bacteria (Marx, C.J. and M.E. Lidstrom, *Broad-host-range cre-lox system for antibiotic marker recycling in Gram-negative bacteria*, Biotechniques, 2002. 33(5): p. 1062-1067; Lussier,

F.X., F. Denis, and F. Shareck, *Adaptation of the highly productive T7 expression system to Streptomyces lividans*, Appl Environ Microbiol, 2010. 76(3): p. 967-70; Conrad, B., et al., *A T7 promoter-specific, inducible protein expression system for Bacillus subtilis*, Mol Gen Genet, 1996. 250(2): p. 230-6), or even yeast (Ribeiro, O., et al., *Application of the Cre-loxP system for multiple gene disruption in the yeast Kluyveromyces marxianus*, J Biotechnol, 2007. 131(1): p. 20-6; Pinkham, J.L., A.M. Dudley, and T.L. Mason, *T7 RNA polymerase-dependent expression of COXII in yeast mitochondria*, Mol Cell Biol, 1994. 14(7): p. 4643-52) and mammalian cells (Yu, Y. and A. Bradley, *Engineering chromosomal rearrangements in mice*, Nat Rev Genet, 2001. 2(10): p. 780-90; Lieber, A., U. Kiessling, and M. Strauss, *High level gene expression in mammalian cells by a nuclear T7-phase RNA polymerase*, Nucleic Acids Res, 1989. 17(21): p. 8485-93). Since each of the steps functions in a broad range of hosts, the technology describe herein could represent a universal strategy. Besides the γ -proteobacteria, this technology can be applied, for example, to α -proteobacteria, β -proteobacteria, Bacteroidetes, Firmicutes, and Actinobacteria.

[0184] Successful engineering of broad hosts of bacteria would allow generation of a host library, which would be a powerful tool in pharmaceutical and chemical industries. The diverse collection of bacteria provides diverse metabolic environments (for example, transcription, translation, post-translational modification, tolerance to products and availability of substrates and co-factors, etc.), which can improve the likelihood of expression of orphan pathways. For example, these results demonstrated that expressing the same pathway in different hosts under same IPTG induction resulted in dramatic different production levels (**FIGS. 14A-14BB**). This strategy may also lead to breakthroughs in engineering plant root microbiome and human gut microbiome, providing means to agricultural and health (including pharmaceutical) industries to enhance sustainable crop production for food, chemicals and energy and health.

[0185] This study demonstrated successful integration and expression of bacterial luciferase *luxCDABE* in 31 strains of gamma-proteobacteria, but can be expanded to a broader range of bacterial hosts, thereby providing a common toolbox for microbe and microbiome engineering in the field of synthetic biology.

Example 5: Chromosomal Integration and Expression of Bacterial Luciferase Pathways in *E. coli*

[0186] This study shows the integration and expression of pathways to bacterial chromosome using the transposition, Cre-Lox, and T7 RNA polymerase combined strategy

(**FIG. 15**). Specifically, in this study, integration and expression bacterial luciferase *luxCDABE* pathway in the chromosome of *E.coli* str. K-12 substr. MG1655 (DE3) is shown.

[0187] *E. coli* MG1655 Spec-Cre-2lox was previously constructed by Jan-Fang Chen. pW34 was transformed into *E. coli* MG1655 Spec-Cre-2lox. 3 transformants on the LB Apramycin (50ug/ml) plate were observed.

[0188] To test for integration and expression of the *lux* pathway, *E. coli* MG1655 with the landing pad or with *luxCDABE* were inoculated to 1ml of LB Spectinomycin (50ug/ml) or LB Apramycin (50ug/ml). After overnight growth at 28°C overnight with shaking at 220rpm, each culture were diluted to OD600 of 0.1. IPTG was added to each well at a final concentration of 0mM, 0.01mM, 0.1mM, and 1.0mM. Luminescence and OD600 were read at 0, 0.17, 1, 2, 3, 5, 10 hours using Synergy H1 Micro-plate reader. The cells transformed with pW34 showed bioluminescence when induced with IPTG (**FIG. 16**).

Table 8: Strains and Plasmids Used in Example 5

Names	Features
Strains	
<i>E. coli</i> str. K-12 substr. MG1655 (DE3)	Genotype is F- ilvG- rfb-50 rph-1 (λ DE3)
<i>E. coli</i> MG1655 Spec-Cre-2lox	Landing pad containing Cre and <i>speR</i> were introduced into the genome near the <i>atpI</i> gene using the Cas9-CRISPR editing method.
<i>E. coli</i> MG1655 Apr-lux	<i>LuxCDABE</i> and Apr resistance gene integrated to <i>E. coli</i> MG1655 genome
Plasmids	
pW34	Medium copy plasmid, carrying T7- <i>luxCDABE</i> between loxP and lox5171 sites.

[0189] This study demonstrates successful integration and expression of bacterial luciferase *luxCDABE* in the *E. coli* MG1655 chromosome.

Example 6: Pathway Integration and Expression in 23 Gamma Proteobacteria Strains

[0190] This study shows the chromosomal integration and expression of pathways using the transposition, Cre-Lox P, and T7 RNA polymerase combined strategy. Specifically, this study demonstrates integration and expression of the bacterial luciferase operon *luxCDABE* and orphan secondary metabolite biosynthetic pathways Plu3263 and Plu0897-Plu0899 in 23 gamma proteobacteria strains.

Materials and Methods

[0191] Bacterial strains used in this study are listed in Table 9. *E. coli* WM3064 was the conjugation donor developed by William Metcalf (UIUC). *E. coli* WM3064 was derived from *E. coli* B2155 and was auxotrophic to 2,3-diaminopropionic acid (DAP). *E. coli* BL21 sfp + was used as a control strain.

Table 9: Strains Used in Example 6.

Bacterial Strain	Landing pad insertion location**	Counter Selection***
<i>Pseudomonas fluorescens</i> Q8r1	2945409	10 /10
<i>Pseudomonas simiae</i> WCS417	5480832	10 /10
<i>Photorhabdus luminescens</i> subsp. <i>laumondii</i> TTO1	1716132	10 /10
<i>Photorhabdus luminescens</i> subsp. <i>luminescens</i>	1739259	10 /10
<i>Photorhabdus temperata</i> subsp. <i>khanii</i>	3819789	10 /10
<i>Xenorhabdus doucetiae</i>	559513	8/8
<i>Serratia odorifera</i>	4691627	10 /10
<i>Erwinia oleae</i>	1475937	10 /10
<i>Erwinia pyrifoliae</i>	2063242	10 /10
<i>Yersinia bercovieri</i>	1776696	10 /10
<i>Yersinia mollaretii</i>	479824	10 /10
<i>Dickeya dadantii</i> subsp. <i>dadantii</i>	3060401	10 /10
<i>Dickeya dadantii</i> subsp. <i>dieffenbachiae</i>	2594266	10 /10
<i>Dickeya solani</i>	1635144	10 /10
<i>Dickeya zeae</i>	3297764	10 /10
<i>Aeromonas encheleia</i>	3673285	10 /10
<i>Aeromonas piscicola</i>	3518388	10 /10
<i>Aeromonas salmonicida</i> subsp. <i>pectinolytica</i>	489248	10 /10
<i>Aeromonas salmonicida</i> subsp. <i>salmonicida</i>	2218778	10 /10
<i>Pantoea agglomerans</i>	5029470	10 /10
<i>Pseudomonas putida</i> KT2440	5256355	10 /10
<i>Pectobacterium carotovorum</i> subsp. <i>odoriferum</i>	Not Determined	10/10
<i>Aeromonas molluscorum</i>	3673285	10/10
<i>E.coli</i> BL21 sfp+*	Not applicable	Not Applicable

* *E.coli* BL21 sfp+ is a control strain. ** Indicates the location of insertion in each strain's genome. *** Indicates the luminescent, Apr resistant, Kan sensitive colonies over the totally colonies assayed.

[0192] The plasmid pW17 (SEQ ID NO:4) contained a landing pad. The plasmid pW34 contained *LuxCDABE* and the plasmid pT7_Plu3263 contained a 15.651kb orphan secondary metabolite pathway (Plu3263) from *Photorhabdus luminescens* TTO1. This pathway started from position 3880777 and ended in position 3865127 in the genome (Fu, J., et al., *Full-length RecE enhances linear-linear homologous recombination and facilitates direct cloning for bioprospecting*. Nat Biotechnol, 2012. 30(5): p. 440-6). Plu3263 was previously reported to produce secondary metabolites luminmide A and luminmide B with the m/z [M+H]⁺ of 586.3963 and 552.4117 (Fu, J., et al., *Full-length RecE enhances linear-linear homologous recombination and facilitates direct cloning for bioprospecting*. Nat Biotechnol, 2012. 30(5): p. 440-6); (Bian, X.Y., et al., *Rational and efficient site-directed mutagenesis of adenylation domain alters relative yields of luminmide derivatives in vivo*. Biotechnology and Bioengineering, 2015. 112(7): p. 1343-1353). This plasmid was assembled using a yeast TAR cloning method. pW5Y (SEQ ID NO:11) was also constructed using a pBeloBAC11 backbone as a single copy plasmid useful for accomodating larger sequences of interest (e.g., pathways). pW5Y can be PCR cloned in 3 pieces, the sequence of interest can also be cloned via PCR, and all 4 PCR fragments can be put into yeast and assembled into pW5Y bearing the sequence of interest between two *lox* sites.

[0193] pT7_Plu0897-Plu0899 contained a 14.262kb orphan secondary metabolite pathway (Plu0897-Plu0899) from *Photorhabdus luminescens* TTO1. This pathway started from position 1021625 and ended in position 1035887 in the genome (Fu, J., et al., *Full-length RecE enhances linear-linear homologous recombination and facilitates direct cloning for bioprospecting*. Nat Biotechnol, 2012. 30(5): p. 440-6). This plasmid was assembled using the yeast TAR cloning method.

[0194] The method was demonstrated in **FIG. 17** wherein: (1) an engineered mariner transposon carrying an inducible T7 RNA polymerase, a Cre recombinase and two mutually exclusive *lox* sites was transposed to the desired bacterial chromosome and (2) a pathway under the control of the T7 promoter flanked by two mutually exclusive *lox* sites was integrated to the bacterial genome mediated by the Cre-*lox* recombination, leading to Lac inducible expression of the pathway in the chromosome.

[0195] Conjugation was conducted as described in Example 1. In each conjugation reaction, some variations were made regarding to the amount of donor and/or recipient cultures, incubation temperature, and/or incubation time to optimize the reaction conditions and/or to increase transformation efficiency.

[0196] For counter selection, the same single colony was streaked on a LB plate with Kanamycin and on a LB plate with Apramycin; slightly above the minimal inhibitory concentration of 100% was used for each strain. These plates were incubated at 28°C for two days to check growth.

[0197] Whole genome sequencing analysis was performed using an Illumina MiSeq sequencing system. Reads were mapped to the landing pad sequence using Geneious software. The flanking sequences were mapped to the genome sequence of each corresponding host to identify the insertion location of the landing pad.

[0198] For bioluminescence assays, single colonies were inoculated to 1 ml of LB with appropriate antibiotics and incubated at 28°C overnight with shaking. Cultures were diluted to OD₆₀₀ 0.1-0.2 and were added to a 96 well black plate with clear bottom. IPTG was added to the cultures at final concentrations of 0, 0.01, 0.1 and 1.0 mM, respectively. Bioluminescence of the culture was measured using Synergy H1 Micro-plate reader (Biotek) at an interval of 12 minutes.

[0199] Fermentation and Extraction techniques were performed as follows. On day 1, all strains were streaked onto an LB Apr50 plate and incubated at 28°C for 2 days. On day 2, glycerol stock or colonies were seeded on plates to 3mL LB Apr10 at 28°C in 15mL tubes and incubated at 28°C for 2 days at 200rpm. On day 3, cultures were diluted 20X, OD was measured on a 96-well plate, and the amount of culture needed for seeding 25mL medium was calculated. This amount of bacteria was centrifuged at 3000g for 5 minutes, supernatant discarded, and pellets were resuspended in 25 ml special M9 medium to the final OD 600nm of 0.1. Special M9 medium with Apr10 was made as shown in Table 10.

Table 10. Recipe for special M9 medium with Apr10

	Chemicals	Volume (ml)
1	5* M9	200 ml
2	1M MgSO ₄	2.0 ml
3	20% glucose	20 ml
4	1M CaCl ₂	0.1 ml
5	25g/L Yeast Extract	200 ml
6	Vitamin Solution	2.5 ml
7	Trace Metal Solution	2.5 ml
8	0.1M Citric Acid solution	100 ml
9	50mg/ml Apr	0.2 ml
	Fill water to 1L	
	Filter Sterilize	

[0200] Cultures were incubated at 28°C at 200rpm for 5-6 hours. 5mL culture from each strain was distributed into each of 4 tubes. 100µL of 0, 0.5, 5, or 50mM IPTG was added into each tube. Cultures were incubated at 28°C at 200rpm for 3 days. On day 6, 2.10 mL of each culture was transferred into 2ml tubes, and another 2.10 ml was transferred to 48 well plate as backup. 100µl was taken from each tube and diluted 10 times, OD was measured using 96 well plate. Cultures were centrifuged at 3300*g for 10 min at room temperature, then supernatant was discarded. On day 7, for acetone extraction, pellets were vibrated to loosen, and 1.0mL acetone was added to each tube. Tubes were placed in an ultrasonic bath for 15 minutes, then rotated for 2 hours at room temperature. For ethyl acetate extraction, tubes were centrifuged at 5000*g (4°C) for 15 min. Supernatants were transferred into new tubes, then extracts were dried by speed-vac (~40-60 mins). Dried solids were resuspended with 1.0mL ethyl acetate and pipetted up and down to homogenize. Tubes were rotated overnight for extraction. On day 8, for filtration, tubes were centrifuged at 16000g 4 °C for 15 min. Supernatants were transferred into new tubes, then extracts were dried by speed-vac (~40-60 mins). 0.1mL internal standard ABMBA(200 fold) was mixed with 19.9mL methanol. Dried solids were resuspended in 100µL methanol with internal standard ABMBA. This was transferred to a 96-well filter with a 96-well plate (solvent resistant) downside. The plate was centrifuged at 2500 rpm at 15°C for 3 minutes to collect filtrate, then plate was sealed and stored at -20°C for LCMS analysis.

[0201] HPLC-MS/MS analyses were performed for each sample, and the data were analyzed using a Maven software package.

Results

[0202] pW17 was conjugally transformed into 23 gamma proteobacteria strains from the donor *E. coli* strain WM3064. The landing pad within a Mariner transposon was randomly integrated into the chromosome of each strain. After the conjugation, colonies for each strain were obtained from the LB agar plate with appropriate kanamycin concentration. Colony PCR was used to identify the colonies for each strain containing the landing pad. Preliminary assessment suggested that pW17 is sometimes maintained in the transformants. Therefore, colony PCR was used to screen transformants with the chromosomally integrated landing pad (positive to the landing pad and negative to the pW17 plasmid backbone). For those transformants for which the correct colony PCR patterns could not be determined initially, serial culture and screening was performed until a transformant demonstrating the correct colony PCR patterns was identified. To identify the genomic location where the landing pad

was inserted, low coverage (10-100) whole-genome sequencing was carried out for these transformants. The insertion location in the genome of each strain is listed on Table 9.

[0203] *luxCDABE* integration was performed by conjugation. Specifically, donor strain *E. coli* WM3064 pW34 was conjugated to the 23 strains containing landing pad. After conjugation, colonies were obtained on LB agar plate with the appropriate Apramycin concentration. About 10 colonies were spotted both on LB agar Kanamycin and LB agar Apramycin for counter section. Most colonies grew only on LB agar Apramycin, which indicated that the pathway successfully replaced the landing pad within the genome, and the pW34 backbone is cured from the transformants. The bioluminescence was measured in triplicate for all strains containing the landing pad with *luxCDABE* (without the Lux operon as a control) at 8 hours after induction with various concentrations of IPTG (**FIG. 18A**). These engineered strains produced significantly higher bioluminescence compared to the control strains. In general, the bioluminescence production was induced by the addition of IPTG.

[0204] Integration of pathways T7-Plu3263 and T7-Plu0897-Plu0899 was performed by conjugation. The donor strains, *E. coli* WM3064 harboring pT7_Pl3263 or T7-Plu0897-Plu0899, were conjugated to the 23 strains with landing pads. After the conjugation, colonies were obtained from a LB agar plate with appropriate Apramycin concentration. Subsequent counter-selection with Km and Apr identified successful transformants of this pathway. *E. coli* BL21 sfp + pT7_Pl3263 or T7-Plu0897-Plu0899 were included as controls. For each strain, the engineered variant containing only the landing pad (control) and the landing pad replaced with the pathways, T7-Plu3263 and T7-Plu0897-Plu0899, were fermented for 3 days. During the fermentation, these cultures were induced by 0, 0.01, 0.1, and 1.0 mM of IPTG at 5 hours after inoculation respectively. Secondary metabolites were extracted and analyzed by HPLC-MS/MS.

[0205] In addition to the native producers, *Photorhabdus* and *Xenorhabdus* species, luminmide A (m/z 586.40) and luminmide B (m/z 552.41) at the retention times of 6.42 min and 6.35 min, respectively, were only produced by strains expressing Plu3263 (**FIGS. 18B-18C**). The MS/MS and structure of luminmide A (**FIG. 19A & FIG. 19C**) and B (**FIG. 19B & FIG. 19D**) are indicated. While *P. agglomerans* and *Y. mollaharetti* showed the highest level of luminmide A production, *X. doucetiae* and *A. piscicola* showed the highest level of luminmide B production, suggesting that this approach could provide a rapid means to identify more suitable strains for production of secondary metabolites than traditional model hosts such as *E. coli*. Also, the ratio of luminmide A to B production varies ~10-fold from *X.*

doucetiae to *P. simiae* WCS417 (**FIG. 20**), suggesting that this approach may provide a means to activate hidden functions of pathways.

[0206] Several strains expressing Plu0897-Plu0899 showed the production of a secondary metabolite with m/z 377.30 at the retention time 3.64 min (**FIG. 21A**). This secondary metabolite was most highly produced by *Yersinia mollaretii* among the panel of strains examined (**FIG. 21B**) and further analyzed by LC-MS/MS (**FIG. 21C**). Interestingly, this secondary metabolite was not produced by *P. luminescens* sp. *Luminescens TTO1* (both a wild type strain with the landing pad and the strain expressing Plu0897-Plu0899), suggesting that this approach provides a means to activate the function of orphan secondary metabolite biosynthetic pathways.

Discussion

[0207] This study showed successful integration and expression of bacterial luciferase *luxCDABE*, and orphan secondary metabolite biosynthetic pathways Plu3263 and Plu0897-Plu0899 in 23 gamma proteobacteria strains. Because one or more strains produced secondary metabolites which are not found in the respective native strain, this approach may prove to be an effective strategy to activate and characterize the function of orphan biosynthetic pathways and to identify novel bioactive secondary metabolites. Additionally, since the abundance and ratio of secondary metabolite production (e.g., luminide A and B) varied significantly among the examined strains, this approach may offer an effective strategy to identify more commercially suitable production host strains compared to traditional model strains.

Example 7: Pathway Integration and Expression in Two Alpha Proteobacteria Strains and One Beta Proteobacteria Strain

[0208] This study was conducted to show integration and expression of pathways to bacterial chromosomes using the combined transposition, Cre-Lox P, and T7 RNA polymerase strategy. Specifically, integration and expression of the *luxCDABE* pathway in the chromosome of two representative alpha proteobacteria and one representative beta proteobacteria was demonstrated.

Materials and Methods

[0209] *E. coli* WM3064 was the conjugation donor. *Rhizobium mongolense* and *Brevundimonas* sp. 374 were the alpha proteobacteria recipients. *Ralstonia* sp.

UNC404CL21Col was the beta proteobacteria recipient. For culture medium, R2A was used for *Rhizobium mongolense* and LB was used for all other strains. The plasmids pW17 and pW34 were used to engineer the bacterial chromosomes. The integration and expression methodology, including conjugation, counter selection, MiSeq analysis and bioluminescence assays, is described in Example 6.

Results

[0210] Landing pad transposition was achieved by conjugation. Specifically, donor strain *E. coli* WM3064pW17 was conjugated to the alpha proteobacteria or beta proteobacteria strains. The landing pad insertion to the chromosomes was confirmed via colony PCR and MiSeq analysis.

[0211] For *luxCDABE* integration, the donor strain *E. coli* WM3064pW34 was conjugated to the alpha proteobacteria or beta proteobacteria strains containing the landing pads. After conjugation, colonies were obtained on selection plate with appropriate Apramycin concentrations. Integration of the Lux operon was confirmed through antibiotic counter selection (resistant to Apramycin; sensitive to Kanamycin).

[0212] Bioluminescence assays demonstrated that alpha proteobacteria *Rhizobium mongolense* containing *luxCDABE* (10 replicates) showed higher bioluminescence than its landing pad counterpart (1 replicate) as shown in **FIG. 22A**. Alpha proteobacteria *Brevundimonas sp. 374* containing *luxCDABE* (3 replicates) showed higher bioluminescence than its landing pad counterpart (1 replicate) as shown in **FIG. 22B**. Beta Proteobacteria *Ralstonia sp. UNC404CL21Col* containing *luxCDABE* (3 replicates) showed higher bioluminescence than its landing pad counterpart (1 replicate) as shown in **FIG. 22C**. Actinobacteria *Arthrobacter sp. 161MFSha2.1* containing *luxCDABE* (3 replicates) showed higher bioluminescence than its landing pad counterpart (1 replicate) as shown in **FIG. 23**. These results indicated that under IPTG induction, engineered strains produced significantly higher bioluminescent signals than strains only containing landing pad in all three strains.

[0213] This study showed that the combined transposition, Cre-LoxP, and T7 RNA polymerase strategy is effective in engineering a broad range of gram negative bacteria, particularly in the phylum of proteobacteria.

Example 8: Pathway Integration and Expression in One *Actinobacteria* Strain

[0214] This study was conducted to show that the combined transposition, Cre-LoxP, and T7 RNA polymerase strategy is effective for chromosomal integration and expression of pathways in one strain of *Actinobacteria*.

Materials and Methods

[0215] *E. coli* WM3064 was the conjugation donor. *Arthrobacter sp. 161MFSha2.1* was the recipient. The plasmids pW17 and pW34 were used to engineer the actinobacterium. The integration and expression methodology, including conjugation and bioluminescence assays, is described in Example 6.

Results

[0216] Transposition of the landing pad was achieved by conjugation. Specifically, donor strain *E. coli* WM3064pW17 was conjugated to the *Arthrobacter sp. 161MFSha2.1* strain. PCR confirmed the landing pad insertion.

[0217] For *luxCDABE* integration, donor strain *E. coli* WM3064 pW34 was conjugated to the actinobacterium containing the landing pad. After conjugation, colonies were obtained on a selection plate with appropriate Apramycin concentration, suggesting that Apr^R-Lux operon is successfully integrated into the landing pad. One colony was picked as it demonstrated acquired Apramycin resistance (Figure not shown here). Colonies containing *luxCDABE* showed higher bioluminescence than colonies containing only landing pad as shown in **FIG. 23**.

[0218] This study indicated that combined transposition, Cre-LoxP, and T7 RNA polymerase strategy is effective in engineering a broad range of bacteria including both gram-positive bacteria, particularly in the phylum of actinobacteria.

Example 9: Three LoxP Landing Pad and Applications in *Phototrhhabdus luminescens*

[0219] This study was conducted to show that the combined transposition and Cre-LoxP strategy is effective for pathway integration and expression in proteobacteria. In particular, *Phototrhhabdus luminescens* subsp. *laumondii* TTO1 was engineered with a landing pad containing three lox sites, and the landing pad was replaced with dCas9 or aCas9 to modulate gene expression in a targeted manner.

[0220] The additional loxP site created the ability to insert a second piece of DNA fragment into the host genome adjacent to the first inserted fragment. Using this modified landing pad in combination with the CRISPR-Cas9 technology, the operon responsible for generating bioluminescence in *Photorhabdus luminescens* subsp. *laumondii* TTO1 was repressed or activated through insertion of a set of sgRNA fragments into the second site on the landing pad. The Cas9 proteins used in this example were the catalytically defective Cas9 (dCas9) and the activating Cas9 (aCas9), which is a fusion protein containing the catalytically defective Cas9 fused with the omega subunit of RNA polymerase. These Cas9 variants were shown to repress or activate gene expression in prokaryotes and eukaryotes (aCas9: Bikard, D. *et al.* Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas9 system. *Nucleic Acids Res*, 2013. **41**: 7429–7437); (dCas9: Qi, L.S. *et al.* Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. *Cell*, 2013. **152**: 1173–1183).

Materials and Methods

[0221] *E. coli* WM3064 was the conjugation donor developed by William Metcalf (UIUC). *E. coli* WM3064 was derived from *E. coli* B2155 and was auxotrophic to 2,3-diaminopropionic acid (DAP). The plasmids used in the study were pCC1-KMW2-SpCre-3L (SEQ ID NO:6), pR6K-2L-dCas9 (SEQ ID NO:7), pR6K-2L-aCas9 (SEQ ID NO:8), and pR6K-Km-loxWT2272-gRNA (SEQ ID NO:9). As shown in **FIG. 24**, the landing pad contained three lox sites: loxPwt, loxP5171, and loxP2272. The integration and expression methodology, including conjugation, counter selection, and bioluminescence assays, is described in Example 6.

Results

[0222] The landing pad transposition was achieved by conjugation (**FIG. 24**, step 1). Specifically, the donor strain was *E. coli* WM3064 pCC1-KMW2-SpCre-3L and recipient was *Photorhabdus luminescens* subsp. *laumondii* TTO1. PCR analysis was used to confirm that the landing pad was inserted into the *P. luminescens* chromosome

[0223] For dCas9 or aCas9 integration, the donor strain *E. coli* WM3064 containing the pR6K-2L-dCas9 or the pR6K-2L-aCas9 plasmid was conjugated with the recipient containing the three loxP landing pad (**FIG. 24**, step 2). After conjugation, colonies were obtained on selection plate with appropriate Apramycin. Counter selection confirmed that

those colonies lost Kanamycin resistance, which indicated the kanamycin resistant marker has been replaced.

[0224] For sgRNA integration, the donor strain *E. coli* WM3064 containing the sgRNA plasmid, pR6K-Km-loxWT2272-gRNA, was conjugated with the recipient containing dCas9 (FIG. 24, step 3). After conjugation, colonies were obtained on a selection plate with an appropriate Kanamycin concentration. The sgRNAs were designed such that dCas9+sgRNA was directed to bind to the promoter and RBS region of the *luxCDABE* operon in the recipient genome, thereby repressing the production of bioluminescence (FIG. 25A). In contrast, the aCas9+sgRNA was directed to bind to the promoter region of the *luxCDABE* operon, thereby activating the production of bioluminescence (FIG. 25C).

[0225] The engineered strains were inoculated for bioluminescent assays in liquid as described in Example 6. The results showed that the engineered strains containing the dCas9 integrated into the first landing pad location and the sgRNA in the second location produced significantly lower bioluminescent signals than the wild type strain (FIG. 25B). In contrast, the strains containing the aCas9+sgRNA produced significantly higher bioluminescence than controls lacking the sgRNA (FIG. 25D).

[0226] This study showed that the combined transposition, Cre-LoxP, and T7 RNA polymerase strategy with the three loxP landing pad worked well in *Photorhabdus luminescens* subsp. *laumondii* TTO1.

Example 10: Pathway Integration and Expression in *Delta Proteobacteria*

[0227] This study is conducted to show that the combined transposition and Cre-LoxP strategy is effective for pathway integration and expression in the delta proteobacteria strain *Myxococcus xanthus* TM-12. In particular, using the same methodology as described in Example 9, the delta proteobacterium is engineered with a landing pad containing three loxP sites and the landing pad is replaced with dCas9 or aCas9.

Materials and Methods

[0228] *E. coli* WM3064 is selected as the conjugation donor, which was developed by William Metcalf (UIUC). *E. coli* WM3064 was derived from *E. coli* B2155 and was auxotrophic to 2,3-diaminopropionic acid (DAP). The delta proteobacteria *Myxococcus xanthus* TM-12 is selected as the recipient. The plasmid pCC1-KMW2-SpCre-3L is used to

engineer the delta proteobacterium. The integration and expression methodology, including conjugation, counter selection, and MiSeq analysis, is described in Example 6.

Results

[0229] The landing pad transposition is achieved by conjugation. Specifically, the donor strain is *E. coli* WM3064 pCC1-KMW2-SpCre-3L and the recipient is the delta proteobacteria strain *Myxococcus xanthus* TM-12. Additionally, the landing pad is replaced with dCas9 and aCas9 to provide greater versatility.

CLAIMS

What is claimed is:

1. A method for integrating a gene of interest into a chromosome of a bacterial host cell, the method comprising:

- (a) providing a bacterial host cell comprising a donor sequence comprising a first selectable marker coding sequence flanked by a first and a second *lox* site, wherein the first and the second *lox* sites are different, and wherein the donor sequence is integrated in a chromosome of the bacterial host cell;
- (b) providing a plasmid comprising the gene of interest and a second selectable marker coding sequence, wherein the gene of interest and the second selectable marker are both flanked by a first and a second *lox* site, wherein the first and the second *lox* sites are different; and
- (c) introducing the plasmid into the bacterial host cell, wherein at least one of the plasmid and the donor sequence comprises a Cre recombinase coding sequence, and wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the gene of interest is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the second plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence.

2. The method of claim 1, wherein, prior to step (a), the donor sequence is integrated into the chromosome of the bacterial host cell by:

providing a bacterial donor cell comprising a donor plasmid, the donor plasmid comprising:

- (i) a transposase coding sequence; and
- (ii) the donor sequence, wherein the donor sequence is flanked by inverted repeats recognized by the transposase; and

introducing the donor plasmid into the bacterial host cell by conjugation with the bacterial donor cell, wherein upon introduction of the donor plasmid into the bacterial host cell, transposase is expressed from the transposase coding sequence, and the donor sequence is integrated into the chromosome of the bacterial host cell between the inverted repeats by the transposase.

3. The method of claim 1, wherein, prior to step (a), the donor sequence is integrated into the chromosome of the bacterial host cell by:

providing a bacterial donor cell comprising a donor plasmid, the donor plasmid comprising:

(i) an integrase coding sequence; and

(ii) the donor sequence, wherein the donor sequence contains an attP site; and

introducing the donor plasmid into the bacterial host cell by conjugation with the bacterial donor cell, wherein upon introduction of the donor plasmid into the bacterial host cell, integrase is expressed from the integrase coding sequence, and the donor sequence is integrated into the chromosome of the bacterial host cell mediated through the recombination between the attP site and an attB site on the chromosome of the bacterial host cell.

4. The method of claim 1, wherein, prior to step (a), the donor sequence is integrated into the chromosome of the bacterial host cell by homologous recombination.

5. The method of claim 1, wherein, prior to step (a), the donor sequence is integrated into the chromosome of the bacterial host cell by:

providing the donor sequence, wherein the donor sequence is flanked by inverted repeats recognized by a transposase; and

introducing the donor sequence into the bacterial host cell in the presence of the transposase, wherein upon introduction of the donor sequence into the bacterial host cell, the donor sequence is integrated into the chromosome of the bacterial host cell between the inverted repeats by the transposase.

6. A method for integrating a gene of interest into a chromosome of a bacterial host cell, the method comprising:

- (a) providing a bacterial donor cell comprising a donor plasmid, the donor plasmid comprising:
- (i) a transposase coding sequence; and
 - (ii) a landing pad, wherein the landing pad is flanked by a first and a second *lox* site, wherein the first and the second *lox* sites are different, and wherein the first and second *lox* sites are flanked by a pair of inverted repeats recognized by the transposase; and
- (b) introducing the donor plasmid into the bacterial host cell by conjugation with the bacterial donor cell, wherein upon introduction of the donor plasmid into the bacterial host cell, transposase is expressed from the transposase coding sequence, and the landing pad is integrated into the chromosome of the bacterial host cell between the inverted repeats by the transposase;
- (c) providing a plasmid comprising the gene of interest, wherein the gene of interest is flanked by a first and a second *lox* site, wherein the first and the second *lox* sites are different; and
- (d) introducing the plasmid into the bacterial host cell, wherein at least one of the plasmid and the landing pad comprises a Cre recombinase coding sequence, and wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the gene of interest is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the plasmid and the first *lox* site of the landing pad, and between the second *lox* site of the plasmid and the second *lox* site of the landing pad.
7. The method of any one of claims 1-6, wherein the bacterial host cell is not an *E. coli* cell.
8. The method of any one of claims 1-6, wherein the bacterial host cell is a Proteobacteria cell.
9. The method of claim 8, wherein the bacterial host cell is a cell selected from the group consisting of Alphaproteotacteria, Betaproteotacteria, Gammaproteobacteria, Deltaproteotacteria, Epsilonproteotacteria, and Zetaproteotacteria.

10. The method of claim 9, wherein the bacterial host cell is a cell of a genus selected from the group consisting of *Pseudomonas*, *Photorhabdus*, *Xenorhabdus*, *Serratia*, *Erwinia*, *Yersinia*, *Dickeya*, *Pectobacterium*, *Rhizobium*, *Brevundimonas*, *Ralstonia*, and *Aeromonas*.
11. The method of any one of claims 1-6, wherein the bacterial host cell is a cell selected from the group consisting of Bacteroidetes, Cyanobacteria, Firmicutes, and Actinobacteria.
12. The method of claim 11, wherein the bacterial host cell is a cell of the genus *Arthrobacter*.
13. The method of claim 2, wherein the bacterial host cell and the bacterial donor cell are both Gammaproteobacteria or Firmicutes cells.
14. The method of claim 13, wherein the bacterial host cell and the bacterial donor cell are both *E. coli* cells.
15. The method of claim 2, wherein the bacterial donor cell is an *E. coli* cell, and wherein the bacterial host cell is not an *E. coli* cell.
16. A method for integrating a gene of interest into a chromosome of a host cell, the method comprising:
 - (a) providing a host cell comprising a donor sequence comprising a first selectable marker coding sequence flanked by a first and a second *lox* site, wherein the first and the second *lox* sites are different, and wherein the donor sequence is integrated in a chromosome of the host cell;
 - (b) providing a plasmid comprising the gene of interest and a second selectable marker coding sequence, wherein the gene of interest and the second selectable marker are both flanked by a first and a second *lox* site, wherein the first and the second *lox* sites are different; and
 - (c) introducing the plasmid into the host cell, wherein at least one of the plasmid and the donor sequence comprises a Cre recombinase coding sequence, and wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the gene of interest is integrated into the chromosome of the host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the second plasmid and the first *lox* site of the donor

sequence, and between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence, wherein the host cell is a fungal, animal, or plant host cell.

17. The method of claim 16, wherein the host cell is a mammalian host cell.

18. The method of any one of claims 1-17, wherein the first *lox* site of the plasmid and the first *lox* site of the donor sequence are the same *lox* site selected from the group consisting of *loxP*, *lox5171*, *lox2272*, *lox511*, *loxm2*, *loxm3*, *loxm7*, *loxm11*, *lox71*, and *lox66*.

19. The method of claim 18, wherein the second *lox* site of the plasmid and the second *lox* site of the donor sequence are heterospecific to the first *lox* site of the plasmid and the first *lox* site of the donor sequence, and wherein the second *lox* site of the plasmid and the second *lox* site of the donor sequence are the same *lox* site selected from the group consisting of *loxP*, *lox5171*, *lox2272*, *lox511*, *loxm2*, *loxm3*, *loxm7*, *loxm11*, *lox71*, and *lox66*.

20. The method of claim 2 or claim 5, wherein the transposase is a transposase selected from the group consisting of Mariner, Tn1, Tn2, Tn3, Tn4, Tn5, Tn6, Tn7, Tn8, Tn9, Tn10, and Tn917.

21. The method of any one of claims 1-20, wherein the first selectable marker coding sequence encodes a first antibiotic resistance marker.

22. The method of claim 21, further comprising:

after step (b), growing the host cell under conditions in which the first antibiotic resistance marker is expressed, wherein the host cell is grown in the presence of a first antibiotic to which the first antibiotic resistance marker confers resistance, such that the host cell comprising the donor sequence is selected.

23. The method of any one of claims 1-20, wherein the first selectable marker coding sequence encodes a first auxotrophic marker, and wherein the host cell lacks an endogenous ability to produce a compound generated by the first auxotrophic marker.

24. The method of claim 23, further comprising:

after step (b), growing the host cell under conditions in which the first auxotrophic marker is expressed, wherein the host cell is grown in the absence of the compound generated

by the first auxotrophic marker, such that the host cell comprising the donor sequence is selected.

25. The method of any one of claims 1-24, wherein the second selectable marker is different from the first selectable marker.

26. The method of claim 25, wherein the second selectable marker coding sequence encodes a second antibiotic resistance marker.

27. The method of claim 26, further comprising:

after step (d), growing the host cell under conditions in which the second antibiotic resistance marker is expressed, wherein the host cell is grown in the presence of a second antibiotic to which the second antibiotic resistance marker confers resistance, such that the host cell comprising the gene of interest and the second selectable marker coding sequence is selected.

28. The method of claim 25, wherein the second selectable marker coding sequence encodes a second auxotrophic marker, and wherein the host cell lacks an endogenous ability to produce a second compound generated by the second auxotrophic marker.

29. The method of claim 28, further comprising:

after step (d), growing the host cell under conditions in which the second auxotrophic marker is expressed, wherein the host cell is grown in the absence of the second compound generated by the second auxotrophic marker, such that the host cell comprising the gene of interest and the second selectable marker coding sequence is selected.

30. The method of any one of claims 1-29, wherein the donor sequence further comprises a coding sequence for a protein that promotes sequence-specific gene transcription, and wherein the coding sequence for the protein that promotes sequence-specific gene transcription is not flanked by the first and the second *lox* sites.

31. The method of claim 30, wherein the protein that promotes sequence-specific gene transcription promotes transcription downstream of a first promoter sequence, wherein the gene of interest is operably linked to the first promoter sequence, and wherein the first promoter sequence is flanked by the first and the second *lox* sites.

32. The method of claim 30 or claim 31, wherein the protein that promotes sequence-specific gene transcription is a sequence-specific RNA polymerase.
33. The method of claim 32, wherein the protein that promotes sequence-specific gene transcription is a T7 RNA polymerase.
34. The method of any one of claims 1-33, wherein the plasmid comprises the Cre recombinase coding sequence.
35. The method of any one of claims 1-34, wherein the donor sequence comprises the Cre recombinase coding sequence, and wherein the Cre recombinase coding sequence is flanked by the first and the second *lox* sites.
36. The method of claim 34 or claim 35, wherein the Cre recombinase coding sequence is operably linked to a promoter active in the host cell.
37. The method of claim 36, wherein the promoter is a constitutive promoter.
38. The method of claim 36, wherein the promoter is a Cas9 promoter.
39. The method of any one of claims 1-38, wherein the gene of interest comprises a coding sequence of one or more enzymes.
40. The method of claim 39, wherein the one or more enzymes catalyze one or more steps in synthesis of a polysaccharide, lipopolysaccharide, nonribosomal peptide (NRP), polyketide, siderophore, terpene, lantipeptide, bacteriocin, homoserine lactone, butyrolactone, ectoine, thiopeptide, phenazine, terpenoid, alkaloid, flavonoid, amino acid, biofuel, commodity chemical, vitamin, or fatty acid.
41. The method of any one of claims 1-40, wherein the plasmid comprises two or more genes of interest, and wherein the two or more genes of interest are flanked by the first and the second *lox* sites.
42. The method of claim 41, wherein the two or more genes of interest are operably linked to the same promoter, the same promoter being flanked by the first and the second *lox* sites.

43. The method of claim 41, wherein the two or more genes of interest are operably linked to two or more promoters, each promoter of the two or more promoters being flanked by the first and the second *lox* sites.
44. The method of any one of claims 1-43, wherein the first and the second *lox* sites flank a sequence of greater than about 7kb.
45. The method of any one of claims 1-44, wherein the first and the second *lox* sites flank a sequence of less than about 200kb.
46. A bacterial host cell comprising a chromosomally integrated donor sequence, wherein the donor sequence comprises a selectable marker coding sequence flanked by a first and a second *lox* site, wherein the donor sequence is flanked in the chromosome of the bacterial host cell by inverted repeats recognized by a transposase, and wherein the first and the second *lox* sites are different.
47. The bacterial host cell of claim 46, wherein the donor sequence is introduced into the chromosome of the bacterial host cell by electroporation with a plasmid comprising a transposase coding sequence of the transposase and the donor sequence, wherein upon introduction of the plasmid into the bacterial host cell, the transposase is expressed from the transposase coding sequence, and the donor sequence is integrated into the chromosome of the bacterial host cell between the inverted repeats by the transposase
48. The bacterial host cell of claim 46, wherein the donor sequence is introduced into the chromosome of the bacterial host cell by conjugation with a bacterial donor cell comprising a plasmid comprising a transposase coding sequence of the transposase and the donor sequence, wherein upon introduction of the plasmid into the bacterial host cell, the transposase is expressed from the transposase coding sequence, and the donor sequence is integrated into the chromosome of the bacterial host cell between the inverted repeats by the transposase.
49. The bacterial host cell of any one of claims 46-48, wherein the donor sequence further comprises a Cre recombinase coding sequence, and wherein the Cre recombinase coding sequence is flanked by the first and the second *lox* sites.
50. The bacterial host cell of any one of claims 46-49, wherein the donor sequence further comprises a coding sequence for a protein that promotes sequence-specific gene transcription,

and wherein the coding sequence for the protein that promotes sequence-specific gene transcription is flanked by the inverted repeats but not by the first and the second *lox* sites.

51. The bacterial host of claim 50, wherein the protein that promotes sequence-specific gene transcription promotes transcription downstream of a first promoter sequence, wherein the gene of interest is operably linked to the first promoter sequence, and wherein the first promoter sequence is flanked by the first and the second *lox* sites.

52. The bacterial host of claim 50 or claim 51, wherein the protein that promotes sequence-specific gene transcription is a sequence-specific RNA polymerase.

53. The bacterial host of claim 52, wherein the protein that promotes sequence-specific gene transcription is a T7 RNA polymerase.

54. A bacterial host cell comprising a chromosomally integrated gene of interest and a selectable marker coding sequence, wherein the gene of interest and the selectable marker coding sequence are both flanked by a first and a second *lox* site, wherein the first and the second *lox* sites are flanked by inverted repeats recognized by a transposase, and wherein the first and the second *lox* sites are different.

55. The bacterial host cell of claim 54, wherein the gene of interest is integrated into the chromosome of the bacterial host cell by:

(a) electroporation with a plasmid comprising the gene of interest flanked by a first and a second *lox* site; and

(b) recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the plasmid and a first *lox* site of a donor sequence integrated into the chromosome of the bacterial host cell, and between the second *lox* site of the plasmid and a second *lox* site of the donor sequence, wherein the donor sequence is integrated into the chromosome of the bacterial host cell between the inverted repeats by the transposase, wherein a Cre recombinase is expressed from a coding sequence present on at least one of the plasmid comprising the gene of interest and the donor sequence.

56. The bacterial host cell of claim 54, wherein the gene of interest is integrated into the chromosome of the bacterial host cell by:

- (a) conjugation with a bacterial donor cell to introduce into the bacterial host cell a plasmid comprising the gene of interest flanked by a first and a second *lox* site; and
 - (b) recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the plasmid and a first *lox* site of a donor sequence integrated into the chromosome of the bacterial host cell, and between the second *lox* site of the plasmid and a second *lox* site of the donor sequence, wherein the donor sequence is integrated into the chromosome of the bacterial host cell between the inverted repeats by the transposase, wherein a Cre recombinase is expressed from a coding sequence present on at least one of the plasmid comprising the gene of interest and the donor sequence.
57. The bacterial host cell of any one of claims 49-53, 55, and 56, wherein the Cre recombinase coding sequence is operably linked to a promoter active in the host cell.
58. The bacterial host cell of claim 57, wherein the promoter is a constitutive promoter.
59. The bacterial host cell of claim 57, wherein the promoter is a Cas9 promoter.
60. The bacterial host cell of any one of claims 46-59, wherein the bacterial host cell is a Proteobacteria cell.
61. The bacterial host cell of claim 59, wherein the bacterial host cell is a cell selected from the group consisting of Alphaproteotacteria, Betaproteotacteria, Gammaproteobacteria, Deltaproteotacteria, Epsilonproteotacteria, and Zetaproteotacteria.
62. The bacterial host cell of claim 61, wherein the bacterial host cell is a cell of a genus selected from the group consisting of *Pseudomonas*, *Photorhabdus*, *Xenorhabdus*, *Serratia*, *Erwinia*, *Yersinia*, *Dickeya*, *Pectobacterium*, *Rhizobium*, *Brevundimonas*, *Ralstonia*, and *Aeromonas*.
63. The bacterial host cell of any one of claims 46-59, wherein the bacterial host cell is a cell selected from the group consisting of Bacteroidetes, Cyanobacteria, Firmicutes, and Actinobacteria.
64. The bacterial host cell of claim 63, wherein the bacterial host cell is a cell of the genus *Arthrobacter*.

65. The bacterial host cell of any one of claims 46-59, wherein the bacterial host cell is not an *E. coli* cell.
66. The bacterial host cell of any one of claims 48-53 and 56-63, wherein the bacterial donor cell is a Gammaproteobacteria or Firmicutes cell.
67. The bacterial host cell of claim 66, wherein the bacterial donor cell is an *E. coli* cell.
68. The bacterial host cell of any one of claims 46-67, wherein the first *lox* site of the plasmid and the first *lox* site of the donor sequence are the same *lox* site selected from the group consisting of *loxP*, *lox5171*, *lox2272*, *lox511*, *loxm2*, *loxm3*, *loxm7*, *loxm11*, *lox71*, and *lox66*.
69. The bacterial host cell of claim 68, wherein the second *lox* site of the plasmid and the second *lox* site of the donor sequence are heterospecific to the first *lox* site of the plasmid and the first *lox* site of the donor sequence, and wherein the second *lox* site of the plasmid and the second *lox* site of the donor sequence are the same *lox* site selected from the group consisting of *loxP*, *lox5171*, *lox2272*, *lox511*, *loxm2*, *loxm3*, *loxm7*, *loxm11*, *lox71*, and *lox66*.
70. The bacterial host cell of any one of claims 46-69, wherein the selectable marker coding sequence encodes a first antibiotic resistance marker.
71. The bacterial host cell of any one of claims 46-69, wherein the selectable marker coding sequence encodes an auxotrophic marker, and wherein the bacterial host cell lacks an endogenous ability to produce a compound generated by the auxotrophic marker.
72. The bacterial host cell of any one of claims 55-71, wherein the donor sequence further comprises a coding sequence for a protein that promotes sequence-specific gene transcription, and wherein the coding sequence for the protein that promotes sequence-specific gene transcription is flanked by the inverted repeats but not by the first and the second *lox* sites.
73. The bacterial host cell of claim 72, wherein the protein that promotes sequence-specific gene transcription promotes transcription downstream of a first promoter sequence, wherein the gene of interest is operably linked to the first promoter sequence, and wherein the first promoter sequence is flanked by the first and the second *lox* sites.
74. The bacterial host cell of claim 72 or claim 73, wherein the protein that promotes sequence-specific gene transcription is a sequence-specific RNA polymerase.

75. The bacterial host cell of claim 74, wherein the protein that promotes sequence-specific gene transcription is a T7 RNA polymerase.
76. The bacterial host cell of any one of claims 54-75, wherein the gene of interest comprises a coding sequence of one or more enzymes.
77. The bacterial host cell of claim 76, wherein the one or more enzymes catalyze one or more steps in synthesis of a polysaccharide, lipopolysaccharide, nonribosomal peptide (NRP), polyketide, siderophore, terpene, lantipeptide, bacteriocin, homoserine lactone, butyrolactone, ectoine, thiopeptide, phenazine, terpenoid, alkaloid, flavonoid, amino acid, biofuel, commodity chemical, vitamin, or fatty acid.
78. The bacterial host cell of any one of claims 54-75, comprising two or more chromosomally integrated genes of interest flanked by the first and the second *lox* sites.
79. The bacterial host cell of claim 78, wherein the two or more genes of interest are operably linked to the same promoter, the same promoter being flanked by the first and the second *lox* sites.
80. The bacterial host cell of claim 78, wherein the two or more genes of interest are operably linked to two or more promoters, each promoter of the two or more promoters being flanked by the first and the second *lox* sites.
81. The bacterial host cell of any one of claims 46-80, wherein the first and the second *lox* sites flank a sequence of greater than about 7kb.
82. The bacterial host cell of any one of claims 46-81, wherein the first and the second *lox* sites flank a sequence of less than about 200kb.
83. A host cell produced by the method of any one of claims 1-45.
84. A vector comprising:
- (a) a transposase coding sequence; and
 - (b) a donor sequence, wherein the donor sequence is flanked by inverted repeats recognized by the transposase, wherein the donor sequence comprises a selectable marker

coding sequence flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different.

85. The vector of claim 84, wherein the donor sequence further comprises a Cre recombinase coding sequence flanked by the first and the second *lox* sites.

86. The vector of claim 84 or claim 85, wherein the first and the second *lox* sites are both selected from the group consisting of *loxP*, *lox5171*, *lox2272*, *lox511*, *loxm2*, *loxm3*, *loxm7*, *loxm11*, *lox71*, and *lox66*.

87. The vector of any one of claims 84-86, wherein the transposase coding sequence is a coding sequence of a transposase selected from the group consisting of Mariner, Tn1, Tn2, Tn3, Tn4, Tn5, Tn6, Tn7, Tn8, Tn9, Tn10, and Tn917.

88. The vector of any one of claims 84-87, wherein the selectable marker coding sequence encodes an antibiotic resistance marker.

89. The vector of any one of claims 84-87, wherein the selectable marker coding sequence encodes an auxotrophic marker.

90. The vector of any one of claims 84-89, wherein the donor sequence further comprises a coding sequence for a protein that promotes sequence-specific gene transcription, and wherein the coding sequence for the protein that promotes sequence-specific gene transcription is flanked by the inverted repeats but not by the first and the second *lox* sites.

91. The vector of claim 90, wherein the protein that promotes sequence-specific gene transcription promotes transcription downstream of a first promoter sequence, wherein the gene of interest is operably linked to the first promoter sequence, and wherein the first promoter sequence is flanked by the first and the second *lox* sites.

92. The vector of claim 90 or claim 91, wherein the protein that promotes sequence-specific gene transcription is a sequence-specific RNA polymerase.

93. The vector of claim 92, wherein the protein that promotes sequence-specific gene transcription is a T7 RNA polymerase.

94. The vector of any one of claims 85-93, wherein the Cre recombinase coding sequence is operably linked to a promoter.

95. The vector of claim 94, wherein the promoter is a constitutive promoter.
96. The vector of claim 94, wherein the promoter is a Cas9 promoter.
97. The vector of any one of claims 84-96, wherein the first and the second *lox* sites flank a sequence of greater than about 7kb.
98. The vector of any one of claims 84-97, wherein the first and the second *lox* sites flank a sequence of less than about 200kb.
99. The vector of claim 84, wherein the vector comprises the polynucleotide sequence of SEQ ID NO:4.
100. A method for producing a phenazine, comprising:
- (a) providing a bacterial host cell comprising a chromosomally integrated donor sequence, wherein the donor sequence comprises a first selectable marker sequence flanked by a first and a second *lox* site, wherein the first and the second *lox* sites are different;
 - (b) introducing a plasmid into the bacterial host cell, the plasmid comprising a phenazine biosynthesis pathway coding sequence and a second selectable marker coding sequence, wherein the phenazine biosynthesis pathway coding sequence and the second selectable marker coding sequence are both flanked by a first and a second *lox* site, wherein at least one of the chromosomally integrated donor sequence and the plasmid comprises a Cre recombinase coding sequence, and wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the phenazine biosynthesis pathway coding sequence is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the plasmid and the second *lox* site of the donor sequence; and
 - (c) culturing the bacterial host cell comprising the chromosomally integrated phenazine biosynthesis pathway coding sequence in a culture medium under conditions whereby the phenazine biosynthesis pathway coding sequence is expressed in the cell, and whereby the phenazine biosynthesis pathway produces the phenazine.
101. The method of claim 100, further comprising:

(d) purifying the phenazine produced by the bacterial host cell from the culture medium.

102. The method of claim 100 or claim 101, wherein the phenazine is phenazine 1-carboxylic acid, and wherein the phenazine biosynthesis pathway is a *phz*ABCDEFG pathway.

103. The method of claim 100 or claim 101, wherein the phenazine is phenazine 1,6-dicarboxylic acid, and wherein the phenazine biosynthesis pathway is a *phz*ABGCDEF pathway.

104. A method for producing a class IIa bacteriocin, comprising:

- (a) providing a bacterial host cell comprising a chromosomally integrated donor sequence, wherein the donor sequence comprises a first selectable marker sequence flanked by a first and a second *lox* site, wherein the first and the second *lox* sites are different;
- (b) introducing a plasmid into the bacterial host cell, the plasmid comprising a class IIa bacteriocin biosynthesis pathway coding sequence and a second selectable marker coding sequence, wherein the class IIa bacteriocin biosynthesis pathway coding sequence and the second selectable marker coding sequence are both flanked by a first and a second *lox* site, wherein at least one of the chromosomally integrated donor sequence and the plasmid comprises a Cre recombinase coding sequence, and wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the class IIa bacteriocin biosynthesis pathway coding sequence is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the plasmid and the second *lox* site of the donor sequence; and
- (c) culturing the bacterial host cell comprising the chromosomally integrated class IIa bacteriocin biosynthesis pathway coding sequence in a culture medium under conditions whereby the class IIa bacteriocin biosynthesis pathway coding sequence is expressed in the cell, and whereby the class IIa bacteriocin biosynthesis pathway produces the class IIa bacteriocin.

105. The method of claim 104, further comprising:

(d) purifying the class IIa bacteriocin produced by the bacterial host cell from the culture medium.

106. The method of claim 104 or claim 105, wherein the class IIa bacteriocin is Sakacin A, and wherein the class IIa bacteriocin biosynthesis pathway is a *sap*AKRTE pathway.

107. The method of claim 104 or claim 105, wherein the class IIa bacteriocin is Sakacin P, and wherein the class IIa bacteriocin biosynthesis pathway is a *spp*KRTE pathway.

108. The method of claim 104 or claim 105, wherein the class IIa bacteriocin is Leucocin A, and wherein the class IIa bacteriocin biosynthesis pathway is a *lca*BAECD pathway.

109. The method of claim 104 or claim 105, wherein the class IIa bacteriocin is Mesentericin Y105, and wherein the class IIa bacteriocin biosynthesis pathway is a *mes*IYCDE pathway.

110. The method of claim 104 or claim 105, wherein the class IIa bacteriocin is Pediocin AcH, and wherein the class IIa bacteriocin biosynthesis pathway is a *pap*ABCD pathway.

111. The method of claim 104 or claim 105, wherein the class IIa bacteriocin is Divercin V41, and wherein the class IIa bacteriocin biosynthesis pathway is a *dvn*AT1T2IRK pathway.

112. The method of claim 104 or claim 105, wherein the class IIa bacteriocin is Enterocin A, and wherein the class IIa bacteriocin biosynthesis pathway is a *ent*FAI pathway.

113. The method of claim 104 or claim 105, wherein the class IIa bacteriocin is Enterocin P, and wherein the class IIa bacteriocin biosynthesis pathway is a *ent*P pathway.

114. The method of claim 104 or claim 105, wherein the class IIa bacteriocin is Curvacin A, and wherein the class IIa bacteriocin biosynthesis pathway is a *cur*A pathway.

115. The method of any one of claims 100-114, wherein the plasmid is introduced into the bacterial host cell by electroporation.

116. The method of any one of claims 100-114, wherein the plasmid is introduced into the bacterial host cell by conjugation with a bacterial donor cell.

117. The method of any one of claims 100-116, wherein the bacterial host cell is not an *E. coli* cell.

118. The method of any one of claims 100-116, wherein the bacterial host cell is a Proteobacteria cell.
119. The method of claim 118, wherein the bacterial host cell is a cell selected from the group consisting of Alphaproteotacteria, Betaproteotacteria, Gammaproteobacteria, Deltaproteotacteria, Epsilonproteotacteria, and Zetaproteotacteria.
120. The method of claim 119, wherein the bacterial host cell is a cell of a genus selected from the group consisting of *Pseudomonas*, *Photorhabdus*, *Xenorhabdus*, *Serratia*, *Erwinia*, *Yersinia*, *Dickeya*, *Pectobacterium*, *Rhizobium*, *Brevundimonas*, *Ralstonia*, and *Aeromonas*.
121. The method of any one of claims 99-116, wherein the bacterial host cell is a cell selected from the group consisting of Bacteroidetes, Cyanobacteria, Firmicutes, and Actinobacteria.
122. The method of claim 121, wherein the bacterial host cell is a cell of the genus *Arthrobacter*.
123. The method of any one of claims 116-122, wherein the bacterial donor cell is a Gammaproteobacteria or Firmicutes cell.
124. The method of claim 123, wherein the bacterial donor cell is an *E. coli* cell.
125. The method of any one of claims 99-124, wherein the first and the second *lox* sites of the donor sequence are both selected from the group consisting of *loxP*, *lox5171*, *lox2272*, *lox511*, *loxm2*, *loxm3*, *loxm7*, *loxm11*, *lox71*, and *lox66*.
126. The method of claim 125, wherein the second *lox* site of the plasmid and the second *lox* site of the donor sequence are heterospecific to the first *lox* site of the plasmid and the first *lox* site of the donor sequence, and wherein the second *lox* site of the plasmid and the second *lox* site of the donor sequence are the same *lox* site selected from the group consisting of *loxP*, *lox5171*, *lox2272*, *lox511*, *loxm2*, *loxm3*, *loxm7*, *loxm11*, *lox71*, and *lox66*.
127. The method of any one of claims 99-126, wherein the chromosomally integrated donor sequence is integrated into the chromosome of the bacterial host cell by electroporation with a plasmid comprising a transposase coding sequence of the transposase and the donor sequence, wherein upon introduction of the plasmid into the bacterial host cell, the transposase is expressed from the transposase coding sequence, and the donor sequence is

integrated into the chromosome of the bacterial host cell between the inverted repeats by the transposase.

128. The method of any one of claims 99-126, wherein the chromosomally integrated donor sequence is integrated into the chromosome of the bacterial host cell by conjugation with a bacterial donor cell comprising a plasmid comprising a transposase coding sequence of the transposase and the donor sequence, wherein upon introduction of the plasmid into the bacterial host cell, the transposase is expressed from the transposase coding sequence, and the donor sequence is integrated into the chromosome of the bacterial host cell between the inverted repeats by the transposase.

129. The method of any one of claims 99-128, wherein the transposase is a transposase selected from the group consisting of Mariner, Tn1, Tn2, Tn3, Tn4, Tn5, Tn6, Tn7, Tn8, Tn9, Tn10, and Tn917.

130. The method of any one of claims 99-129, wherein the first selectable marker coding sequence encodes a first antibiotic resistance marker.

131. The method of claim 130, further comprising:

prior to step (b), growing the bacterial host cell under conditions in which the first antibiotic resistance marker is expressed, wherein the bacterial host cell is grown in the presence of a first antibiotic to which the first antibiotic resistance marker confers resistance, such that the bacterial host cell comprising the donor sequence is selected.

132. The method of any one of claims 99-129, wherein the first selectable marker coding sequence encodes a first auxotrophic marker, and wherein the bacterial host cell lacks an endogenous ability to produce a compound generated by the first auxotrophic marker.

133. The method of claim 132, further comprising:

prior to step (b), growing the bacterial host cell under conditions in which the first auxotrophic marker is expressed, wherein the bacterial host cell is grown in the absence of the compound generated by the first auxotrophic marker, such that the bacterial host cell comprising the donor sequence is selected.

134. The method of any one of claims 99-133, wherein the second selectable marker is different from the first selectable marker.

135. The method of claim 134, wherein the second selectable marker coding sequence encodes a second antibiotic resistance marker.

136. The method of claim 135, further comprising:

after step (b), growing the bacterial host cell under conditions in which the second antibiotic resistance marker is expressed, wherein the bacterial host cell is grown in the presence of a second antibiotic to which the second antibiotic resistance marker confers resistance, such that the bacterial host cell comprising the phenazine or class IIa bacteriocin biosynthesis pathway coding sequence and the second selectable marker coding sequence is selected.

137. The method of claim 134, wherein the second selectable marker coding sequence encodes a second auxotrophic marker, and wherein the bacterial host cell lacks an endogenous ability to produce a second compound generated by the second auxotrophic marker.

138. The method of claim 137, further comprising:

after step (b), growing the bacterial host cell under conditions in which the second auxotrophic marker is expressed, wherein the bacterial host cell is grown in the absence of the second compound generated by the second auxotrophic marker, such that the bacterial host cell comprising the gene of interest and the second selectable marker is selected

139. The method of any one of claims 99-138, wherein the donor sequence further comprises a coding sequence for a protein that promotes sequence-specific gene transcription, and wherein the coding sequence for the protein that promotes sequence-specific gene transcription is flanked by the inverted repeats but not by the first and the second *lox* sites.

140. The method of claim 139, wherein the protein that promotes sequence-specific gene transcription promotes transcription downstream of a first promoter sequence, wherein the gene of interest is operably linked to the first promoter sequence, and wherein the first promoter sequence is flanked by the first and the second *lox* sites.

141. The method of claim 139 or claim 140, wherein the protein that promotes sequence-specific gene transcription is a sequence-specific RNA polymerase.

142. The method of claim 141, wherein the protein that promotes sequence-specific gene transcription is a T7 RNA polymerase.

143. The method of any one of claims 99-142, wherein the plasmid comprises the Cre recombinase coding sequence.

144. The method of any one of claims 99-142, wherein the donor sequence comprises the Cre recombinase coding sequence, and wherein the Cre recombinase coding sequence is flanked by the first and the second *lox* sites.

145. The method of claim 143 or claim 144, wherein the Cre recombinase coding sequence is operably linked to a promoter active in the bacterial host cell.

146. The method of claim 145, wherein the promoter is a constitutive promoter.

147. The method of claim 145, wherein the promoter is a Cas9 promoter.

148. A method for modulating expression of a gene of interest in a bacterial host cell, the method comprising:

(a) providing a bacterial host cell comprising a donor sequence comprising:

(i) a Cre recombinase coding sequence, wherein the Cre recombinase coding sequence is flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; and

(ii) a first selectable marker coding sequence flanked by the second *lox* site and a third *lox* site, wherein the third *lox* site is different from the first and second *lox* sites, and wherein the donor sequence is integrated in a chromosome of the bacterial host cell;

(b) providing a plasmid comprising a catalytically dead Cas9 protein coding sequence and a second selectable marker coding sequence, wherein the catalytically dead Cas9 protein coding sequence and the second selectable marker are both flanked by the second *lox* site and the third *lox* site;

(c) introducing the plasmid into the bacterial host cell, wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the catalytically dead Cas9 protein coding sequence is integrated into

the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the second *lox* site of the plasmid and the second *lox* site of the donor sequence, and between the third *lox* site of the plasmid and the third *lox* site of the donor sequence;

(d) providing a second plasmid comprising a guide RNA sequence that targets a guide RNA target sequence of the gene of interest and a third selectable marker coding sequence, wherein the guide RNA sequence and the third selectable marker are both flanked by the first *lox* site and the second *lox* site; and

(e) introducing the second plasmid into the bacterial host cell, wherein upon introduction of the second plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the guide RNA sequence is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the second plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence;

wherein upon introduction of the second plasmid of the bacterial host cell, the catalytically dead Cas9 protein and guide RNA are expressed, form a complex, and bind the guide RNA target sequence of the gene of interest, thereby modulating expression of the gene of interest.

149. A method for modulating expression of a gene of interest in a bacterial host cell, the method comprising:

(a) providing a bacterial host cell comprising a donor sequence comprising:

(i) a Cre recombinase coding sequence, wherein the Cre recombinase coding sequence is flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; and

(ii) a first selectable marker coding sequence flanked by the second *lox* site and a third *lox* site, wherein the third *lox* site is different from the first and second *lox* sites, and wherein the donor sequence is integrated in a chromosome of the bacterial host cell;

(b) providing a first plasmid comprising a catalytically dead Cas9 protein coding sequence, a guide RNA sequence that targets a guide RNA target sequence of the gene of

interest, and a second selectable marker coding sequence, wherein the catalytically dead Cas9 protein coding sequence, the guide RNA sequence, and the second selectable marker are flanked by the second *lox* site and the third *lox* site;

(c) introducing the first plasmid into the bacterial host cell, wherein upon introduction of the first plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the catalytically dead Cas9 protein coding sequence and guide RNA sequence are integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the second *lox* site of the first plasmid and the second *lox* site of the donor sequence, and between the third *lox* site of the first plasmid and the third *lox* site of the donor sequence;

(d) providing a second plasmid comprising the gene of interest and a third selectable marker coding sequence, wherein the gene of interest and the third selectable marker are both flanked by the first *lox* site and the second *lox* site; and

(e) introducing the second plasmid into the bacterial host cell, wherein upon introduction of the second plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the gene of interest is integrated into the chromosome of the bacterial host cell by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the second plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence;

wherein upon introduction of the second plasmid of the bacterial host cell, the catalytically dead Cas9 protein and guide RNA are expressed, form a complex, and bind the guide RNA target sequence of the gene of interest, thereby modulating expression of the gene of interest.

150. The method of claim 148 or claim 149, wherein, prior to step (a), the donor sequence is integrated into the chromosome of the bacterial host cell by:

providing a bacterial donor cell comprising a donor plasmid, the donor plasmid comprising:

(i) a transposase coding sequence; and

(ii) the donor sequence, wherein the donor sequence is flanked by inverted repeats recognized by the transposase; and

introducing the donor plasmid into the bacterial host cell by conjugation with the bacterial donor cell, wherein upon introduction of the donor plasmid into the bacterial host cell, transposase is expressed from the transposase coding sequence, and the donor sequence is integrated into the chromosome of the bacterial host cell between the inverted repeats by the transposase.

151. The method of claim 148 or claim 149, wherein, prior to step (a), the donor sequence is integrated into the chromosome of the bacterial host cell by:

providing a bacterial donor cell comprising a donor plasmid, the donor plasmid comprising:

(i) an integrase coding sequence; and

(ii) the donor sequence, wherein the donor sequence contains an attP site; and

introducing the donor plasmid into the bacterial host cell by conjugation with the bacterial donor cell, wherein upon introduction of the donor plasmid into the bacterial host cell, integrase is expressed from the integrase coding sequence, and the donor sequence is integrated into the chromosome of the bacterial host cell mediated through the recombination between the attP site and an attB site on the chromosome of the bacterial host cell.

152. The method of claim 148 or claim 149, wherein, prior to step (a), the donor sequence is integrated into the chromosome of the bacterial host cell by homologous recombination.

153. The method of claim 148 or claim 149, wherein, prior to step (a), the donor sequence is integrated into the chromosome of the bacterial host cell by:

providing a donor plasmid, the donor plasmid comprising the donor sequence, wherein the donor sequence is flanked by inverted repeats recognized by a transposase; and

introducing the donor plasmid into the bacterial host cell in the presence of the transposase, wherein upon introduction of the donor plasmid into the bacterial host cell, the donor sequence is integrated into the chromosome of the bacterial host cell between the inverted repeats by the transposase.

154. The method of any one of claims 148-153, wherein at least one of the first and the second plasmid is introduced into the host cell via conjugation.

155. The method of any one of claims 148-153, wherein at least one of the first and the second plasmid is introduced into the host cell via electroporation.

156. A method for modulating expression of a gene of interest in a bacterial host cell, the method comprising:

(a) providing a bacterial host cell comprising a donor sequence comprising:

(i) a first landing pad comprising a Cre recombinase coding sequence, wherein the landing pad is flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; and

(ii) a second landing pad, wherein the second landing pad comprises a first selectable marker coding sequence and is flanked by the second *lox* site and a third *lox* site, wherein the third *lox* site is different from the first and second *lox* sites, and wherein the donor sequence is integrated in a chromosome of the bacterial host cell;

(b) providing a plasmid comprising a catalytically dead Cas9 protein coding sequence and a second selectable marker coding sequence, wherein the catalytically dead Cas9 protein coding sequence and the second selectable marker are both flanked by the second *lox* site and the third *lox* site;

(c) introducing the plasmid into the bacterial host cell, wherein upon introduction of the plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the catalytically dead Cas9 protein coding sequence is integrated into the second landing pad by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the second *lox* site of the plasmid and the second *lox* site of the donor sequence, and between the third *lox* site of the plasmid and the third *lox* site of the donor sequence;

(d) providing a second plasmid comprising a guide RNA sequence that targets a guide RNA target sequence of the gene of interest and a third selectable marker coding sequence, wherein the guide RNA sequence and the third selectable marker are both flanked by the first *lox* site and the second *lox* site; and

(e) introducing the second plasmid into the bacterial host cell, wherein upon introduction of the second plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the guide RNA sequence is integrated into the first landing pad by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the second plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence;

wherein upon introduction of the second plasmid of the bacterial host cell, the catalytically dead Cas9 protein and guide RNA are expressed, form a complex, and bind the guide RNA target sequence of the gene of interest, thereby modulating expression of the gene of interest.

157. A method for modulating expression of a gene of interest in a bacterial host cell, the method comprising:

(a) providing a bacterial host cell comprising a donor sequence comprising:

(i) a first landing pad comprising a Cre recombinase coding sequence, wherein the landing pad is flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; and

(ii) a second landing pad, wherein the second landing pad comprises a first selectable marker coding sequence and is flanked by the second *lox* site and a third *lox* site, wherein the third *lox* site is different from the first and second *lox* sites, and wherein the donor sequence is integrated in a chromosome of the bacterial host cell;

(b) providing a first plasmid comprising a catalytically dead Cas9 protein coding sequence, a guide RNA sequence that targets a guide RNA target sequence of the gene of interest, and a second selectable marker coding sequence, wherein the catalytically dead Cas9 protein coding sequence, the guide RNA sequence, and the second selectable marker are flanked by the second *lox* site and the third *lox* site;

(c) introducing the first plasmid into the bacterial host cell, wherein upon introduction of the first plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the catalytically dead Cas9 protein coding sequence and guide RNA sequence are integrated into the second landing pad by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the second *lox* site of the

first plasmid and the second *lox* site of the donor sequence, and between the third *lox* site of the first plasmid and the third *lox* site of the donor sequence;

(d) providing a second plasmid comprising the gene of interest and a third selectable marker coding sequence, wherein the gene of interest and the third selectable marker are both flanked by the first *lox* site and the second *lox* site; and

(e) introducing the second plasmid into the bacterial host cell, wherein upon introduction of the second plasmid into the bacterial host cell, Cre recombinase is expressed from the Cre recombinase coding sequence, and the gene of interest is integrated into the first landing pad by the Cre recombinase through recombinase-mediated cassette exchange (RMCE) between the first *lox* site of the second plasmid and the first *lox* site of the donor sequence, and between the second *lox* site of the second plasmid and the second *lox* site of the donor sequence;

wherein upon introduction of the second plasmid of the bacterial host cell, the catalytically dead Cas9 protein and guide RNA are expressed, form a complex, and bind the guide RNA target sequence of the gene of interest, thereby modulating expression of the gene of interest.

158. The method of any one of claims 148-157, wherein the catalytically dead Cas9 protein/guide RNA complex bind the guide RNA target sequence of the gene of interest and repress expression of the gene of interest.

159. The method of any one of claims 148-157, wherein the catalytically dead Cas9 protein is fused with a transcriptional activator protein, and wherein the catalytically dead Cas9:transcriptional activator fusion protein/guide RNA complex binds the guide RNA target sequence of the gene of interest and promotes expression of the gene of interest.

160. The method of any one of claims 148-159, wherein the bacterial host cell is a *Proteobacteria* cell.

161. The method of claim 160, wherein the bacterial host cell is a cell selected from the group consisting of *Alphaproteotacteria*, *Betaproteotacteria*, *Gammaproteobacteria*, *Deltaproteotacteria*, *Epsilonproteotacteria*, and *Zetaproteotacteria*.

162. The method of claim 161, wherein the bacterial host cell is a cell of a genus selected from the group consisting of *Escherichia*, *Pseudomonas*, *Photorhabdus*, *Xenorhabdus*,

Serratia, *Erwinia*, *Yersinia*, *Dickeya*, *Pectobacterium*, *Rhizobium*, *Brevundimonas*, *Ralstonia*, and *Aeromonas*.

163. The method of any one of claims 148-159, wherein the bacterial host cell is a cell selected from the group consisting of Bacteroidetes, Cyanobacteria, Firmicutes, and Actinobacteria.

164. The method of claim 163, wherein the bacterial host cell is a cell of the genus *Arthrobacter*.

165. The method of any one of claims 148-164, wherein the first *lox* site is selected from the group consisting of *loxP*, *lox2272*, *lox511*, *lox5171*, *lox2272*, *loxM2*, *loxM3*, *loxM7*, *loxM11*, *lox71*, and *lox66*.

166. The method of any one of claims 148-165, wherein the second *lox* site is selected from the group consisting of *loxP*, *lox2272*, *lox511*, *lox5171*, *lox2272*, *loxM2*, *loxM3*, *loxM7*, *loxM11*, *lox71*, and *lox66*.

167. The method of any one of claims 148-166, wherein the third *lox* site is selected from the group consisting of *loxP*, *lox2272*, *lox511*, *lox5171*, *lox2272*, *loxM2*, *loxM3*, *loxM7*, *loxM11*, *lox71*, and *lox66*.

168. The method of any one of claims 148-167, wherein the first selectable marker coding sequence encodes a first antibiotic resistance marker.

169. The method of claim 168, further comprising:

after step (b), growing the host cell under conditions in which the first antibiotic resistance marker is expressed, wherein the host cell is grown in the presence of a first antibiotic to which the first antibiotic resistance marker confers resistance, such that the host cell comprising the donor sequence is selected.

170. The method of any one of claims 148-167, wherein the first selectable marker coding sequence encodes a first auxotrophic marker, and wherein the host cell lacks an endogenous ability to produce a compound generated by the first auxotrophic marker.

171. The method of claim 170, further comprising:

after step (b), growing the host cell under conditions in which the first auxotrophic marker is expressed, wherein the host cell is grown in the absence of the compound generated by the first auxotrophic marker, such that the host cell comprising the donor sequence is selected.

172. The method of any one of claims 148-171, wherein the second selectable marker is different from the first selectable marker.

173. The method of claim 172, wherein the second selectable marker coding sequence encodes a second antibiotic resistance marker.

174. The method of claim 173, further comprising:

after step (d), growing the host cell under conditions in which the second antibiotic resistance marker is expressed, wherein the host cell is grown in the presence of a second antibiotic to which the second antibiotic resistance marker confers resistance, such that the host cell comprising the catalytically dead Cas9 protein coding sequence and the second selectable marker coding sequence is selected.

175. The method of claim 172, wherein the second selectable marker coding sequence encodes a second auxotrophic marker, and wherein the host cell lacks an endogenous ability to produce a second compound generated by the second auxotrophic marker.

176. The method of claim 175, further comprising:

after step (d), growing the host cell under conditions in which the second auxotrophic marker is expressed, wherein the host cell is grown in the absence of the second compound generated by the second auxotrophic marker, such that the host cell comprising the gene of interest and the second selectable marker coding sequence is selected.

177. The method of any one of claims 148-176, wherein the third selectable marker is different from the first and the second selectable markers.

178. The method of claim 177, wherein the third selectable marker coding sequence encodes a third antibiotic resistance marker.

179. The method of claim 178, further comprising:

after step (f), growing the host cell under conditions in which the third antibiotic resistance marker is expressed, wherein the host cell is grown in the presence of a third antibiotic to which the third antibiotic resistance marker confers resistance, such that the host cell comprising the guide RNA sequence and the third selectable marker coding sequence is selected.

180. The method of claim 177, wherein the third selectable marker coding sequence encodes a third auxotrophic marker, and wherein the host cell lacks an endogenous ability to produce a third compound generated by the third auxotrophic marker.

181. The method of claim 180, further comprising:

after step (f), growing the host cell under conditions in which the third auxotrophic marker is expressed, wherein the host cell is grown in the absence of the third compound generated by the third auxotrophic marker, such that the host cell comprising the guide RNA sequence and the third selectable marker coding sequence is selected.

182. The method of any one of claims 148-181, wherein the second plasmid further comprises a coding sequence for a protein that promotes sequence-specific gene transcription, and wherein the coding sequence for the protein that promotes sequence-specific gene transcription is flanked by the second and the third *lox* sites.

183. The method of claim 182, wherein the protein that promotes sequence-specific gene transcription promotes transcription downstream of a first promoter sequence, wherein the catalytically dead Cas9 protein coding sequence is operably linked to the first promoter sequence, and wherein the first promoter sequence is flanked by the second and the third *lox* sites.

184. The method of claim 182 or claim 183, wherein first promoter sequence is an inducible or repressible promoter sequence.

185. The method of any one of claims 148-184, wherein the gene of interest comprises a coding sequence of one or more enzymes.

186. The method of claim 185, wherein the one or more enzymes catalyze one or more steps in synthesis of a polysaccharide, lipopolysaccharide, nonribosomal peptide (NRP), polyketide, siderophore, terpene, lantipeptide, bacteriocin, homoserine lactone, butyrolactone,

ectoine, thiopeptide, phenazine, terpenoid, alkaloid, flavonoid, amino acid, biofuel, commodity chemical, vitamin, or fatty acid.

187. A bacterial host cell produced by the method of any one of claims 148-186.

188. A kit, comprising:

(a) a first vector comprising:

(i) a transposase coding sequence; and

(ii) a donor sequence, wherein the donor sequence is flanked by inverted repeats recognized by the transposase, wherein the donor sequence comprises a first selectable marker coding sequence flanked by a first and a second *lox* site, and wherein the first and the second *lox* sites are different; and

(b) a second vector comprising:

(i) one or more restriction or targeted cloning sites suitable for recombining a gene of interest into the second vector; and

(ii) a second selectable marker, wherein the second selectable marker and the one or more restriction or targeted cloning sites are flanked by the first and the second *lox* sites.

189. The kit of claim 188, further comprising a third vector comprising (i) one or more restriction or targeted cloning sites suitable for recombining a gene of interest into the second vector; and (ii) a second selectable marker, wherein the second selectable marker and the one or more restriction or targeted cloning sites are flanked by the first and the second *lox* sites.

190. The kit of claim 189, wherein the second vector is a multiple-copy plasmid, and wherein the third vector is a single-copy plasmid.

191. The kit of any one of claims 188-190, wherein the donor sequence further comprises a Cre recombinase coding sequence flanked by the first and the second *lox* sites.

192. The kit of any one of claims 188-191, wherein the first and the second *lox* sites are both selected from the group consisting of *loxP*, *lox5171*, *lox2272*, *lox511*, *loxm2*, *loxm3*, *loxm7*, *loxm11*, *lox71*, and *lox66*.

193. The kit of any one of claims 188-192, wherein the transposase coding sequence is a coding sequence of a transposase selected from the group consisting of Mariner, Tn1, Tn2, Tn3, Tn4, Tn5, Tn6, Tn7, Tn8, Tn9, Tn10, and Tn917.

194. The kit of claim 188, wherein the first vector comprises the polynucleotide sequence of SEQ ID NO:4.

195. The kit of claim 188, wherein the second vector comprises the polynucleotide sequence of SEQ ID NO:10.

196. The kit of claim 189, wherein the third vector comprises the polynucleotide sequence of SEQ ID NO:11.

197. The kit of any one of claims 188-196, further comprising instructions for using the kit to integrate the gene of interest into a chromosome of a host cell.



FIG. 1






FIG. 2

FIG. 3A



(1). Transpose the landing pad randomly into the chromosome

FIG. 3B



(2). Integrate T7 driven pathway into the chromosome by Cre-Lox recombination

FIG. 4A




FIG. 4B




FIG. 4C





FIG. 4D






FIG. 5



FIG. 6






FIG. 7

FIG. 8A



(1). Transpose the landing pad carrying T7 RNA polymerase and Cre-lox sites randomly into the chromosome

FIG. 8B



(2). Integrate T7 driven pathway into the chromosome by Cre-Lox recombination for expression




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D




FIG. 9E






FIG. 10

FIG. 11A



(1). Transpose the landing pad carrying T7 RNA polymerase and Cre-lox sites randomly into the chromosome

FIG. 11B



(2). Integrate T7 driven pathway into the chromosome by Cre-Lox recombination for expression




FIG. 12A




FIG. 12B

FIG. 13A




FIG. 13B




FIG. 14A




FIG. 14B




FIG. 14C




FIG. 14D




FIG. 14E




FIG. 14F




FIG. 14G




FIG. 14H




FIG. 14I




FIG. 14J




FIG. 14K




FIG. 14L




FIG. 14M




FIG. 14N




FIG. 14O




FIG. 14P




FIG. 14Q




FIG. 14R




FIG. 14S




FIG. 14T




FIG. 14U




FIG. 14V




FIG. 14W




FIG. 14X




FIG. 14Y




FIG. 14Z




FIG. 14AA






FIG. 14BB





Integrate T7 driven pathway into the chromosome by Cre-Lox recombination for expression

FIG. 15




FIG. 16




FIG. 17

	Engineered strain (IPTG)				Control(IPTG)			
	0mM	0.01mM	0.1mM	1.0mM	0mM	0.01mM	0.1mM	1.0mM
1_SB094_Pseudomonas fluorescens Q8r1								
2_SB119_Pseudomonas simiae WCS417								
3_SB203_Photorhabdus luminescens subsp. laumondii TTO1								
4_SB212_Photorhabdus luminescens subsp. luminescens								
5_SB213_Photorhabdus temperata subsp. kharii								
6_SB214_Xenorhabdus doucetiae								
7_SB217_Serratia odorifera								
8_SB218_Erwinia oleae								
9_SB220_Erwinia pyrifoliae								
10_SB222_Yersinia bercovieri								
11_SB223_Yersinia mollaretii								
12_SB226_Dickeya dadantii subsp. dadantii								
13_SB227_Dickeya dadantii subsp. dieffenbachiae								
14_SB228_Dickeya solani								
15_SB229_Dickeya zeae								
16_SB235_Aeromonas encheleia								
17_SB237_Aeromonas piscicola								
18_SB238_Aeromonas salmonicida subsp. pectinolytica								
19_SB239_Aeromonas salmonicida subsp. salmonicida								
20_SB396_Pantoea agglomerans								
21_SB098_Pseudomonas putida KT2440								
22_SB233_Pectobacterium carotovorum subsp. odoriferum								
23_SB236_Aeromonas molluscorum								

FIG. 18A




FIG. 18B






FIG. 18C

FIG. 19A



m/z 586.41, 6.42 min



luminimide A

FIG. 19B

m/z 552.41, 6.35 min



luminimide B




FIG. 19C




FIG. 19D




FIG. 20

FIG. 21A




FIG. 21B

	P1_377				P0_377			
	Engineered strain (PTG)				Control (PTG)			
	0mM	0.01mM	0.1mM	1.0mM	0mM	0.01mM	0.1mM	1.0mM
1_SB094_Pseudomonas fluorescens Q8r1								
2_SB119_Pseudomonas simiae WCS417								
3_SB203_Photorhabdus luminescens subsp. laumondii TTO1								
5_SB213_Photorhabdus temperata subsp. kharii								
6_SB214_Xenorhabdus doucetiae								
7_SB217_Serratia odorifera								
8_SB218_Erwinia oleae								
9_SB220_Erwinia pyrifoliae								
10_SB222_Yersinia bercovieri								
11_SB223_Yersinia mollaretii								
12_SB226_Dickeya dadantii subsp. dadantii								
13_SB227_Dickeya dadantii subsp. dieffenbachiae								
14_SB228_Dickeya solani								
15_SB229_Dickeya zeae								
16_SB235_Aeromonas encheleia								
17_SB237_Aeromonas piscicola								
18_SB238_Aeromonas salmonicida subsp. pectinolytica								
19_SB239_Aeromonas salmonicida subsp. salmonicida								
20_SB396_Pantoea agglomerans								
21_SB098_Pseudomonas putida KT2440								
24_SB26_E.coli BL21 sfp+								




FIG. 21C




FIG. 22A




FIG. 22B




FIG. 22C




FIG. 23




FIG. 24




FIG. 25A




FIG. 25B




FIG. 25C




FIG. 25D